U.S. patent application number 13/770407 was filed with the patent office on 2014-03-13 for biaryl heterocyclic compounds and methods of making and using the same.
This patent application is currently assigned to RIB-X PHARMACEUTICALS, INC.. The applicant listed for this patent is Rib-X Pharmaceuticals, Inc.. Invention is credited to Ashoke Bhattacharjee, Shili Chen, Yi Chen, Jay J. Farmer, Joel A. Goldberg, Roger Hanselmann, Rongliang Lou, Alia Orbin, Adegboyega K. Oyelere, Joseph M. Salvino, Dane M. Springer, Jennifer Tran, Deping Wang, Yusheng Wu, Jiacheng Zhou.
Application Number | 20140073624 13/770407 |
Document ID | / |
Family ID | 34222657 |
Filed Date | 2014-03-13 |
United States Patent
Application |
20140073624 |
Kind Code |
A1 |
Zhou; Jiacheng ; et
al. |
March 13, 2014 |
Biaryl Heterocyclic Compounds and Methods of Making and Using the
Same
Abstract
The present invention relates generally to the field of
anti-infective, anti-proliferative, anti-inflammatory, and
prokinetic agents. More particularly, the invention relates to a
family of compounds having both a biaryl moiety and at least one
heterocylic moiety that are useful as such agents.
Inventors: |
Zhou; Jiacheng; (Newark,
DE) ; Bhattacharjee; Ashoke; (Cheshire, CT) ;
Chen; Shili; (Cheshire, CT) ; Chen; Yi; (West
Roxbury, MA) ; Farmer; Jay J.; (Ithaca, NY) ;
Goldberg; Joel A.; (New Orleans, LA) ; Hanselmann;
Roger; (Branford, CT) ; Lou; Rongliang;
(Cheshire, CT) ; Orbin; Alia; (Macungie, PA)
; Oyelere; Adegboyega K.; (Marietta, GA) ;
Salvino; Joseph M.; (Chester Springs, PA) ; Springer;
Dane M.; (Yardley, PA) ; Tran; Jennifer;
(Guilford, CT) ; Wang; Deping; (Furlong, PA)
; Wu; Yusheng; (New Haven, CT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Rib-X Pharmaceuticals, Inc.; |
|
|
US |
|
|
Assignee: |
RIB-X PHARMACEUTICALS, INC.
New Haven
CT
|
Family ID: |
34222657 |
Appl. No.: |
13/770407 |
Filed: |
February 19, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13240297 |
Sep 22, 2011 |
|
|
|
13770407 |
|
|
|
|
12767380 |
Apr 26, 2010 |
|
|
|
13240297 |
|
|
|
|
12275941 |
Nov 21, 2008 |
7705026 |
|
|
12767380 |
|
|
|
|
11486769 |
Jul 14, 2006 |
7456206 |
|
|
12275941 |
|
|
|
|
11118808 |
Apr 29, 2005 |
7148219 |
|
|
11486769 |
|
|
|
|
10859476 |
Jun 2, 2004 |
6969726 |
|
|
11118808 |
|
|
|
|
60475430 |
Jun 3, 2003 |
|
|
|
60475453 |
Jun 3, 2003 |
|
|
|
60490855 |
Jul 29, 2003 |
|
|
|
60529731 |
Dec 15, 2003 |
|
|
|
60531584 |
Dec 19, 2003 |
|
|
|
Current U.S.
Class: |
514/210.18 ;
514/210.2; 514/227.8; 514/236.8; 514/253.1; 514/254.02; 514/261.1;
514/263.2; 514/364; 514/370; 514/376; 544/137; 544/254; 544/277;
544/364; 544/369; 544/58.2; 548/132; 548/195; 548/231 |
Current CPC
Class: |
A61P 31/10 20180101;
C07D 263/24 20130101; C07D 473/34 20130101; C07D 417/12 20130101;
A61P 11/00 20180101; C07D 263/20 20130101; A61P 13/02 20180101;
A61P 1/04 20180101; A61P 17/00 20180101; A61P 19/02 20180101; A61P
31/02 20180101; A61P 35/00 20180101; C07D 413/14 20130101; C07D
453/02 20130101; A61P 31/00 20180101; C07D 417/14 20130101; A61P
31/12 20180101; A61P 29/00 20180101; C07D 263/26 20130101; C07D
417/10 20130101; C07D 263/32 20130101; C07D 413/12 20130101; A61P
33/00 20180101; A61P 9/00 20180101; C07D 473/00 20130101; A61P
19/08 20180101; A61P 31/04 20180101; C07D 487/04 20130101; C07D
413/10 20130101; A61P 1/00 20180101; A61P 41/00 20180101; C07D
471/04 20130101 |
Class at
Publication: |
514/210.18 ;
548/231; 514/376; 544/369; 514/254.02; 548/132; 514/364; 548/195;
514/370; 514/210.2; 544/254; 514/261.1; 544/364; 514/253.1;
544/58.2; 514/227.8; 544/277; 514/263.2; 544/137; 514/236.8 |
International
Class: |
C07D 413/10 20060101
C07D413/10; C07D 473/34 20060101 C07D473/34; C07D 417/10 20060101
C07D417/10; C07D 487/04 20060101 C07D487/04; C07D 263/24 20060101
C07D263/24; C07D 417/14 20060101 C07D417/14 |
Claims
1. A compound having the formula: ##STR00664## or a
pharmaceutically acceptable salt, ester or prodrug thereof,
wherein: A is selected from the group consisting of: phenyl,
pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl; B is selected
from the group consisting of: phenyl, pyridyl, pyrazinyl,
pyrimidinyl, and pyridazinyl; Het-CH.sub.2--R.sup.3 is selected
from the group consisting of: ##STR00665## M is selected from the
group consisting of: a) saturated, unsaturated, or aromatic
C.sub.3-14 carbocycle, and b) saturated, unsaturated, or aromatic
3-14 membered heterocycle containing one or more heteroatoms
selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein a) or b) optionally is substituted with one or more R.sup.5
groups; M-L is selected from the group consisting of: a) M-X, b)
M-L.sup.1, c) M-L.sup.1-X, d) M-X-L.sup.2, e) M-L.sup.1-X-L.sup.2,
f) M-X-L.sup.1-X-L.sup.2, g) M-L.sup.1-X-L.sup.2-X, h) M-X--X--, i)
M-L.sup.1-X--X--, j) M-X--X-L.sup.2, and k) M-L-X--X-L.sup.2,
wherein X, at each occurrence, independently is selected from the
group consisting of: a) --O--, b) --NR.sup.4--, c) --N(O)--, d)
--N(OR.sup.4)--, e) --S(O).sub.p--, f) --SO.sub.2NR.sup.4--, g)
--NR.sup.4SO.sub.2--, h) --NR.sup.4--N.dbd., i) .dbd.N--NR.sup.4--,
j) --O--N.dbd., k) .dbd.N--O--, l) --N.dbd., m) .dbd.N--, n)
--NR.sup.4--NR.sup.4--, o) --NR.sup.4C(O)O--, p) --OC(O)NR.sup.4--,
q) --NR.sup.4C(O)NR.sup.4-- r) --NR.sup.4C(NR.sup.4)NR.sup.4--, and
s) ##STR00666## L.sup.1 is selected from the group consisting of:
a) C.sub.1-6 alkyl, b) C.sub.2-6 alkenyl, and c) C.sub.2-6 alkynyl,
wherein any of a)-c) optionally is substituted with one or more
R.sup.5 groups; and L.sup.2 is selected from the group consisting
of: a) C.sub.1-6 alkyl, b) C.sub.2-6 alkenyl, and c) C.sub.2-6
alkynyl, wherein any of a)-c) optionally is substituted with one or
more R.sup.5 groups; R.sup.1, at each occurrence, independently is
selected from the group consisting of: a) F, b) Cl, c) Br, d) I, e)
--CF.sub.3, f) --OR.sup.4, g) --CN, h) --NO.sub.2, i)
--NR.sup.4R.sup.4, j) --C(O)R.sup.4, k) --C(O)OR.sup.4, l)
--OC(O)R.sup.4, m) --C(O)NR.sup.4R.sup.4, n) --NR.sup.4C(O)R.sup.4,
o) --OC(O)NR.sup.4R.sup.4, p) --NR.sup.4C(O)OR.sup.4, q)
--NR.sup.4C(O)NR.sup.4R.sup.4, r) --C(S)R.sup.4, s) --C(S)OR.sup.4,
t) --OC(S)R.sup.4, u) --C(S)NR.sup.4R.sup.4, v)
--NR.sup.4C(S)R.sup.4, w) --OC(S)NR.sup.4R.sup.4, x)
--NR.sup.4C(S)OR.sup.4, y) --NR.sup.4C(S)NR.sup.4R.sup.4, z)
--NR.sup.4C(NR.sup.4)NR.sup.4R.sup.4, aa) --S(O).sub.pR.sup.4, bb)
--SO.sub.2NR.sup.4R.sup.4, and cc) R.sup.4; R.sup.2, at each
occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) --CF.sub.3, f) --OR.sup.4, g) --CN, h)
--NO.sub.2, i) --NR.sup.4R.sup.4, j) --C(O)R.sup.4, k)
--C(O)OR.sup.4, l) --OC(O)R.sup.4, m) --C(O)NR.sup.4R.sup.4, n)
--NR.sup.4C(O)R.sup.4, o) --OC(O)NR.sup.4R.sup.4, p)
--NR.sup.4C(O)OR.sup.4, q) --NR.sup.4C(O)NR.sup.4R.sup.4, r)
--C(S)R.sup.4, s) --C(S)OR.sup.4, t) --OC(S)R.sup.4, u)
--C(S)NR.sup.4R.sup.4, v) --NR.sup.4C(S)R.sup.4, w)
--OC(S)NR.sup.4R.sup.4, x) --NR.sup.4C(S)OR.sup.4, y)
--NR.sup.4C(S)NR.sup.4R.sup.4, z)
--NR.sup.4C(NR.sup.4)NR.sup.4R.sup.4, aa) --S(O).sub.pR.sup.4, bb)
--SO.sub.2NR.sup.4R.sup.4, and cc) R.sup.4; R.sup.3 is selected
from the group consisting of: a) --OR.sup.4, b) --NR.sup.4R.sup.4,
c) --C(O)R.sup.4, d) --C(O)OR.sup.4, e) --OC(O)R.sup.4, f)
--C(O)NR.sup.4R.sup.4, g) --NR.sup.4C(O)R.sup.4, h)
--OC(O)NR.sup.4R.sup.4, i) --NR.sup.4C(O)OR.sup.4, j)
--NR.sup.4C(O)NR.sup.4R.sup.4, k) --C(S)R.sup.4, l) --C(S)OR.sup.4,
m) --OC(S)R.sup.4, n) --C(S)NR.sup.4R.sup.4, o)
--NR.sup.4C(S)R.sup.4, p) --OC(S)NR.sup.4R.sup.4, q)
--NR.sup.4C(S)OR.sup.4, r) --NR.sup.4C(S)NR.sup.4R.sup.4, s)
--NR.sup.4C(NR.sup.4)NR.sup.4R.sup.4, t) --S(O).sub.pR.sup.4, u)
--SO.sub.2NR.sup.4R.sup.4, and v) R.sup.4; R.sup.4, at each
occurrence, independently is selected from the group consisting of:
a) H, b) C.sub.1-6 alkyl, c) C.sub.2-6 alkenyl, d) C.sub.2-6
alkynyl, e) C.sub.3-14 saturated, unsaturated, or aromatic
carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic
heterocycle comprising one or more heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur, g)
--C(O)--C.sub.1-6 alkyl, h) --C(O)--C.sub.2-6 alkenyl, i)
--C(O)--C.sub.2-6 alkynyl, j) --C(O)--C.sub.3-14 saturated,
unsaturated, or aromatic carbocycle, k) --C(O)-3-14 membered
saturated, unsaturated, or aromatic heterocycle comprising one or
more heteroatoms selected from the group consisting of nitrogen,
oxygen, and sulfur, l) --C(O)O--C.sub.1-6 alkyl, m)
--C(O)O--C.sub.2-6 alkenyl, n) --C(O)O--C.sub.2-6 alkynyl, o)
--C(O)O--C.sub.3-14 saturated, unsaturated, or aromatic carbocycle,
and p) --C(O)O-3-14 membered saturated, unsaturated, or aromatic
heterocycle comprising one or more heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur, wherein any of
b)-p) optionally is substituted with one or more R.sup.5 groups;
R.sup.1, at each occurrence, is independently selected from the
group consisting of: a) F, b) Cl, c) Br, d) I, e) .dbd.O, f)
.dbd.S, g) .dbd.NR.sup.6, h) .dbd.NOR.sup.6, i)
.dbd.N--NR.sup.6R.sup.6, j) --CF.sub.3, k) --OR.sup.6, l) --CN, m)
--NO.sub.2, n) --NR.sup.6R.sup.6, o) --C(O)R.sup.6, p)
--C(O)OR.sup.6, q) --OC(O)R.sup.6, r) --C(O)NR.sup.6R.sup.6, s)
--NR.sup.6C(O)R.sup.6, t) --OC(O)NR.sup.6R.sup.6, u)
--NR.sup.6C(O)OR.sup.6, v) --NR.sup.6C(O)NR.sup.6R.sup.6, w)
--C(S)R.sup.6, x) --C(S)OR.sup.6, y) --OC(S)R.sup.6, z)
--C(S)NR.sup.6R.sup.6, aa) --NR.sup.6C(S)R.sup.6, bb)
--OC(S)NR.sup.6R.sup.6, cc) --NR.sup.6C(S)OR.sup.6, dd)
--NR.sup.6C(S)NR.sup.6R.sup.6, ee)
--NR.sup.6C(NR.sup.6)NR.sup.6R.sup.6, ff) --S(O).sub.pR.sup.6, gg)
--SO.sub.2NR.sup.6R.sup.6, and hh) R.sup.6; R.sup.6, at each
occurrence, independently is selected from the group consisting of:
a) H, b) C.sub.1-6 alkyl, c) C.sub.2-6 alkenyl, d) C.sub.2-6
alkynyl, e) C.sub.3-14 saturated, unsaturated, or aromatic
carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic
heterocycle comprising one or more heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur, g)
--C(O)--C.sub.1-6 alkyl, h) --C(O)--C.sub.2-6 alkenyl, i)
--C(O)--C.sub.2-6 alkynyl, j) --C(O)--C.sub.3-14 saturated,
unsaturated, or aromatic carbocycle, k) --C(O)-3-14 membered
saturated, unsaturated, or aromatic heterocycle comprising one or
more heteroatoms selected from the group consisting of nitrogen,
oxygen, and sulfur, l) --C(O)O--C.sub.1-6 alkyl, m)
--C(O)O--C.sub.2-6 alkenyl, n) --C(O)O--C.sub.2-6 alkynyl, o)
--C(O)O--C.sub.3-14 saturated, unsaturated, or aromatic carbocycle,
and p) --C(O)O-3-14 membered saturated, unsaturated, or aromatic
heterocycle comprising one or more heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur, wherein any of
b)-p) optionally is substituted with one or more R.sup.7 groups;
R.sup.7, at each occurrence, independently is selected from the
group consisting of: a) F, b) Cl, c) Br, d) I, e) .dbd.O, f)
.dbd.S, g) .dbd.NR.sup.8, h) .dbd.NOR.sup.8, i)
.dbd.N--NR.sup.8R.sup.8, j) --CF.sub.3, k) --OR.sup.8, l) --CN, m)
--NO.sub.2, n) --NR.sup.8R.sup.8, o) --C(O)R.sup.8, p)
--C(O)OR.sup.8, q) --OC(O)R.sup.8, r) --C(O)NR.sup.8R.sup.8, s)
--NR.sup.8C(O)R.sup.8, t) --OC(O)NR.sup.8R.sup.8, u)
--NR.sup.8C(O)OR.sup.8, v) --NR.sup.8C(O)NR.sup.8R.sup.8, w)
--C(S)R.sup.8, x) --C(S)OR.sup.8, y) --OC(S)R.sup.8, z)
--C(S)NR.sup.8R.sup.8, aa) --NR.sup.8C(S)R.sup.8, bb)
--OC(S)NR.sup.8R.sup.8, cc) --NR.sup.8C(S)OR.sup.8, dd)
--NR.sup.8C(S)NR.sup.8R.sup.8, ee)
--NR.sup.8C(NR.sup.8)NR.sup.8R.sup.8, ff) --S(O).sub.pR.sup.8, gg)
--SO.sub.2NR.sup.8R.sup.8, hh) C.sub.1-6 alkyl, ii) C.sub.2-6
alkenyl, jj) C.sub.2-6 alkynyl, kk) C.sub.3-14 saturated,
unsaturated, or aromatic carbocycle, and ll) 3-14 membered
saturated, unsaturated, or aromatic heterocycle comprising one or
more heteroatoms selected from the group consisting of nitrogen,
oxygen, and sulfur, wherein any of hh)-ll) optionally is
substituted with one or more moieties selected from the group
consisting of R.sup.8, F, Cl, Br, I, --CF.sub.3, --OR.sup.8,
--SR.sup.8, --CN, --NO.sub.2, --NR.sup.8R.sup.8, --C(O)R.sup.8,
--C(O)OR.sup.8, --OC(O)R.sup.8, --C(O)NR.sup.8R.sup.8,
--NR.sup.8C(O)R.sup.8, --OC(O)NR.sup.8R.sup.8,
--NR.sup.8C(O)OR.sup.8, --NR.sup.8C(O)NR.sup.8R.sup.8,
--C(S)R.sup.8, --C(S)OR.sup.8, --OC(S)R.sup.8,
--C(S)NR.sup.8R.sup.8, --NR.sup.8C(S)R.sup.8,
--OC(S)NR.sup.8R.sup.8, --NR.sup.8C(S)OR.sup.8,
--NR.sup.8C(S)NR.sup.8R.sup.8,
--NR.sup.8C(NR.sup.8)NR.sup.8R.sup.8, --SO.sub.2NR.sup.8R.sup.8,
and --S(O).sub.pR.sup.8; R.sup.8, at each occurrence, independently
is selected from the group consisting of: a) H, b) C.sub.1-6 alkyl,
c) C.sub.2-6 alkenyl, d) C.sub.2-6 alkynyl, e) C.sub.3-14
saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered
saturated, unsaturated, or aromatic heterocycle comprising one or
more heteroatoms selected from the group consisting of nitrogen,
oxygen, and sulfur, g) --C(O)--C.sub.1-6 alkyl, h)
--C(O)--C.sub.2-6 alkenyl, i) --C(O)--C.sub.2-6 alkynyl, j)
--C(O)--C.sub.3-14 saturated, unsaturated, or aromatic carbocycle,
k) --C(O)-3-14 membered saturated, unsaturated, or aromatic
heterocycle comprising one or more heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur, l)
--C(O)O--C.sub.1-6 alkyl, m) --C(O)O--C.sub.2-6 alkenyl, n)
--C(O)O--C.sub.2-6 alkynyl, o) --C(O)O--C.sub.3-14 saturated,
unsaturated, or aromatic carbocycle, and p) --C(O)O-3-14 membered
saturated, unsaturated, or aromatic heterocycle comprising one or
more heteroatoms selected from the group consisting of nitrogen,
oxygen, and sulfur, wherein any of b)-p) optionally is substituted
with one or more moieties selected from the group consisting of F,
Cl, Br, I, --CF.sub.3, --OH, --OCH.sub.3, --SH, --SCH.sub.3, --CN,
--NO.sub.2, --NH.sub.2, --NHCH.sub.3, --N(CH.sub.3).sub.2,
--C(O)CH.sub.3, --C(O)OCH.sub.3, --C(O)NH.sub.2, --NHC(O)CH.sub.3,
--SO.sub.2NH.sub.2, --SO.sub.2NHCH.sub.3,
--SO.sub.2N(CH.sub.3).sub.2, and --S(O).sub.pCH.sub.3; m is 0, 1,
2, 3, or 4; n is 0, 1, 2, 3, or 4; and p, at each occurrence,
independently is 0, 1, or 2, and wherein the compound does not have
the formula corresponding to any of the structures listed in Table
1.
2. The compound according to claim 1, having the formula:
##STR00667## or a pharmaceutically acceptable salt, ester or
prodrug thereof, wherein A, B, L, M, R.sup.1, R.sup.2, R.sup.3, m,
and n are defined as described in claim 1.
3. The compound according to claim 2, having the formula:
##STR00668## or a pharmaceutically acceptable salt, ester or
prodrug thereof, wherein A, B, L, M, R.sup.1, R.sup.2, R.sup.3, m,
and n are defined as described in claim 1.
4. The compound according to claim 1, wherein A is selected from
the group consisting of phenyl and pyridyl; B is selected from the
group consisting of phenyl and pyridyl; m is 0, 1, or 2; and n is
0, 1, or 2.
5. The compound according to claim 1, wherein A-B is: ##STR00669##
wherein A, R.sup.2, and n are defined as described in claim 1.
6. The compound according to claim 5, wherein A-B is: ##STR00670##
wherein A is defined as described in claim 1.
7. The compound according to claim 5, wherein A-B is: ##STR00671##
wherein A is defined as described in claim 1.
8. The compound according to claim 1, wherein A-B is: ##STR00672##
wherein B is defined as described in claim 1.
9. The compound according to claim 1, wherein A-B is: ##STR00673##
wherein B is defined as described in claim 1.
10. The compound according to claim 1, wherein R.sup.3 is
--NHC(O)R.sup.4.
11. The compound according to claim 10, wherein R.sup.4 is
--CH.sub.3.
12. The compound according to claim 1, wherein R.sup.3 is:
##STR00674##
13. The compound according to claim 1, having the formula:
##STR00675## or a pharmaceutically acceptable salt, ester or
prodrug thereof, wherein A, B, L, M, R.sup.1, R.sup.2, m, and n are
defined as described in claim 1.
14. The compound according to claim 1, having the formula:
##STR00676## or a pharmaceutically acceptable salt, ester or
prodrug thereof, wherein A, L, M, R.sup.1, R.sup.3, and m are
defined as described in claim 1.
15. A pharmaceutical composition comprising one or more compounds
according to claim 1 and a pharmaceutically acceptable carrier.
16. A method of treating an infection, disease, or disorder in a
mammal comprising the step of administering to the mammal an
effective amount of one or more compounds according to claim 1,
wherein the infection, disease, or disorder is selected from
microbial infection, fungal infection, parasitic infection,
proliferative disease, viral infection, inflammatory disease and
gastrointestinal motility disorder.
17. A method of treating a disorder in a mammal comprising the step
of administering to the mammal an effective amount of one or more
compounds according to claim 1 thereby to ameliorate a symptom of
the disorder, wherein the disorder is selected from the group
consisting of: a skin infection, nosocomial pneumonia, post-viral
pneumonia, an abdominal infection, a urinary tract infection,
bacteremia, septicemia, endocarditis, an atrio-ventricular shunt
infection, a vascular access infection, meningitis, surgical
prophylaxis, a peritoneal infection, a bone infection, a joint
infection, a methicillin-resistant Staphylococcus aureus infection,
a vancomycin-resistant Enterococci infection, a linezolid-resistant
organism infection, and tuberculosis.
18. A medical devise containing one or more compounds according to
claim 1.
19. A process for preparing a compound according to claim 1,
comprising the step of reacting a compound of formula (I):
##STR00677## with a compound of formula (II): ##STR00678## in a
solvent in the presence of a base and a palladium catalyst, wherein
Q is a boronate having the formula --BY.sub.2, wherein Y, at each
occurrence, independently is selected from the group consisting of:
a) --OH, and b) --O--C.sub.1-4 alkyl, alternatively, two Y groups
taken together are selected from the group consisting of: a)
--OC(R.sup.4)(R.sup.4)C(R.sup.4)(R.sup.4)O--, and b)
--OC(R.sup.4)(R.sup.4)CH.sub.2C(R.sup.4)(R.sup.4)O--,
alternatively, two Y groups taken together with the boron to which
they are bound comprise a BF.sub.3 alkali metal salt; Z is selected
from the group consisting of: a) I, b) Br, c) Cl, and d)
R.sup.4OSO.sub.3--; and A, B, L, M, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, m, and n are defined as described in claim 1.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 13/240,297, filed Sep. 22, 2011, which is a
continuation of U.S. patent application Ser. No. 12/767,380, filed
Apr. 26, 2010, which is a continuation of U.S. patent application
Ser. No. 12/275,941, filed Nov. 21, 2008, which issued as U.S. Pat.
No. 7,705,026 on Apr. 27, 2010, which is a continuation of U.S.
patent application Ser. No. 11/486,769, filed Jul. 14, 2006, which
issued as U.S. Pat. No. 7,456,206 on Nov. 25, 2008, which is a
continuation of U.S. patent application Ser. No. 11/118,808, filed
Apr. 29, 2005, which issued as U.S. Pat. No. 7,148,219 on Dec. 12,
2006, which is a continuation of U.S. patent application Ser. No.
10/859,476, filed Jun. 2, 2004, which issued as U.S. Pat. No.
6,969,726 on Nov. 29, 2005, which claims the benefit of and
priority to U.S. Patent Application Nos. 60/475,430, filed Jun. 3,
2003; 60/475,453, filed Jun. 3, 2003; 60/490,855, filed Jul. 29,
2003; 60/529,731, filed Dec. 15, 2003; and 60/531,584, filed Dec.
19, 2003, the disclosures of which are incorporated by reference
herein.
FIELD OF THE INVENTION
[0002] The present invention relates generally to the field of
anti-infective, anti-proliferative, anti-inflammatory, and
prokinetic agents. More particularly, the invention relates to a
family of biaryl heterocyclic compounds, comprising both a biaryl
moiety and at least one heterocyclic moiety, that are useful as
therapeutic agents.
BACKGROUND
[0003] Since the discovery of penicillin in the 1920s and
streptomycin in the 1940s, many new compounds have been discovered
or specifically designed for use as antibiotic agents. It was once
believed that infectious diseases could be completely controlled or
eradicated with the use of such therapeutic agents. However, such
beliefs have been shaken by the fact that strains of cells or
microorganisms resistant to currently effective therapeutic agents
continue to evolve. In fact, virtually every antibiotic agent
developed for clinical use has ultimately encountered problems with
the emergence of resistant bacteria. For example, resistant strains
of Gram-positive bacteria such as methicillin-resistant
staphylocci, penicillin-resistant streptococci, and
vancomycin-resistant enterococci have developed, which can cause
serious and even fatal results for patients infected with such
resistant bacteria. Bacteria that are resistant to macrolide
antibiotics, i.e., antibiotics based on a 14- to 16-membered
lactone ring, have developed. Also, resistant strains of
Gram-negative bacteria such as H. influenzae and M. catarrhalis
have been identified. See, e.g., F. D. Lowry, "Antimicrobial
Resistance: The Example of Staphylococcus aureus," J. Clin.
Invest., 2003, 111(9), 1265-1273; and Gold, H. S. and Moellering,
R. C., Jr., "Antimicrobial-Drug Resistance," N. Engl. J. Med.,
1996, 335, 1445-53.
[0004] The problem of resistance is not limited to the area of
anti-infective agents, because resistance has also been encountered
with anti-proliferative agents used in cancer chemotherapy.
Therefore, there exists a need for new anti-infective and
anti-proliferative agents that are both effective against resistant
bacteria and resistant strains of cancer cells.
[0005] In the antibiotic area, despite the problem of increasing
antibiotic resistance, no new major classes of antibiotics have
been developed for clinical use since the approval in the United
States in 2000 of the oxazolidinone ring-containing antibiotic,
N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl
acetamide, which is known as linezolid and is sold under the
tradename Zyvox.RTM. (see compound A). See, R. C. Moellering, Jr.,
"Linezolid: The First Oxazolidinone Antimicrobial," Annals of
Internal Medicine, 2003, 138(2), 135-142.
##STR00001##
[0006] Linezolid was approved for use as an anti-bacterial agent
active against Gram-positive organisms. Unfortunately,
linezolid-resistant strains of organisms are already being
reported. See, Tsiodras et al., Lancet, 2001, 358, 207; Gonzales et
al., Lancet, 2001, 357, 1179; Zurenko et al., Proceedings Of The
39.sup.th Annual Interscience Conference On Antibacterial Agents
And Chemotherapy (ICAAC); San Francisco, Calif., USA, (Sep. 26-29,
1999). Because linezolid is both a clinically effective and
commercially significant anti-microbial agent, investigators have
been working to develop other effective linezolid derivatives.
[0007] Notwithstanding the foregoing, there is an ongoing need for
new anti-infective and anti-proliferative agents. Furthermore,
because many anti-infective and anti-proliferative agents have
utility as anti-inflammatory agents and prokinetic agents, there is
also an ongoing need for new compounds useful as anti-inflammatory
and prokinetic agents.
SUMMARY OF THE INVENTION
[0008] The invention provides a family of compounds useful as
anti-infective agents and/or anti-proliferative agents, for
example, chemotherapeutic agents, anti-microbial agents,
anti-bacterial agents, anti-fungal agents, anti-parasitic agents,
anti-viral agents, anti-inflammatory agents, and/or prokinetic
(gastrointestinal modulatory) agents. The compounds have the
formula:
##STR00002##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein Het-CH.sub.2--R.sup.4 is selected from the group consisting
of:
##STR00003##
A and B independently are selected from the group consisting of
phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl; M-L is
selected from the group consisting of M-X, M-L.sup.1, M-L.sup.1-X,
M-X-L.sup.2, M-L.sup.1-X-L.sup.2, M-X-L.sup.1-X-L.sup.2,
M-L.sup.1-X-L.sup.2-X, M-X--X--, M-L.sup.1-X--X--, M-X--X-L.sup.2,
and M-L.sup.1-X--X-L.sup.2; M is an optionally substituted
saturated, unsaturated, or aromatic C.sub.3-14 carbocycle, or an
optionally substituted saturated, unsaturated, or aromatic 3-14
membered heterocycle containing one or more heteroatoms selected
from the group consisting of nitrogen, oxygen, and sulfur; and the
variables L.sup.1, L.sup.2, M, R.sup.1, R.sup.2, R.sup.3, X, m, and
n are selected from the respective groups of chemical moieties or
integers later defined in the detailed description.
[0009] Particular embodiments of compounds of the invention include
those having the formula:
##STR00004##
wherein the variables A, L, M, R.sup.1, R.sup.3, and m are selected
from the respective groups of chemical moieties or integers later
defined in the detailed description.
[0010] In addition, the invention provides methods of synthesizing
the foregoing compounds. Following synthesis, an effective amount
of one or more of the compounds may be formulated with a
pharmaceutically acceptable carrier for administration to a mammal
for use as an anti-cancer, anti-microbial, anti-biotic,
anti-fungal, anti-parasitic or anti-viral agent, or to treat a
proliferative disease, an inflammatory disease or a
gastrointestinal motility disorder. The compounds or formulations
may be administered, for example, via oral, parenteral, or topical
routes, to provide an effective amount of the compound to the
mammal.
[0011] The foregoing and other aspects and embodiments of the
invention may be more fully understood by reference to the
following detailed description and claims.
DETAILED DESCRIPTION OF THE INVENTION
[0012] The present invention provides a family of compounds that
can be used as anti-proliferative agents and/or anti-infective
agents. The compounds may be used without limitation, for example,
as anti-cancer, anti-microbial, anti-bacterial, anti-fungal,
anti-parasitic and/or anti-viral agents. Further, the present
invention provides a family of compounds that can be used without
limitation as anti-inflammatory agents, for example, for use in
treating chronic inflammatory airway diseases, and/or as prokinetic
agents, for example, for use in treating gastrointestinal motility
disorders such as gastroesophageal reflux disease, gastroparesis
(diabetic and post surgical), irritable bowel syndrome, and
constipation.
1. Definitions
[0013] The term "substituted," as used herein, means that any one
or more hydrogens on the designated atom is replaced with a
selection from the indicated group, provided that the designated
atom's normal valency is not exceeded, and that the substitution
results in a stable compound. When a substituent is keto (i.e.,
.dbd.O), then 2 hydrogens on the atom are replaced. Keto
substituents are not present on aromatic moieties. Ring double
bonds, as used herein, are double bonds that are formed between two
adjacent ring atoms (e.g., C.dbd.C, C.dbd.N, or N.dbd.N).
[0014] The present invention is intended to include all isotopes of
atoms occurring in the present compounds. Isotopes include those
atoms having the same atomic number but different mass numbers. By
way of general example and without limitation, isotopes of hydrogen
include tritium and deuterium, and isotopes of carbon include C-13
and C-14.
[0015] The compounds described herein may have asymmetric centers.
Compounds of the present invention containing an asymmetrically
substituted atom may be isolated in optically active or racemic
forms. It is well known in the art how to prepare optically active
forms, such as by resolution of racemic forms or by synthesis from
optically active starting materials. Many geometric isomers of
olefins, C.dbd.N double bonds, and the like can also be present in
the compounds described herein, and all such stable isomers are
contemplated in the present invention. Cis and trans geometric
isomers of the compounds of the present invention are described and
may be isolated as a mixture of isomers or as separated isomeric
forms. All chiral, diastereomeric, racemic, and geometric isomeric
forms of a structure are intended, unless the specific
stereochemistry or isomeric form is specifically indicated. All
processes used to prepare compounds of the present invention and
intermediates made therein are considered to be part of the present
invention. All tautomers of shown or described compounds are also
considered to be part of the present invention.
[0016] When any variable (e.g., R.sup.1) occurs more than one time
in any constituent or formula for a compound, its definition at
each occurrence is independent of its definition at every other
occurrence. Thus, for example, if a group is shown to be
substituted with 0-2 R.sup.1 moieties, then the group may
optionally be substituted with up to two R.sup.1 moieties and
R.sup.1 at each occurrence is selected independently from the
definition of R.sup.1. Also, combinations of substituents and/or
variables are permissible, but only if such combinations result in
stable compounds.
[0017] When a bond to a substituent is shown to cross a bond
connecting two atoms in a ring, then such substituent may be bonded
to any atom in the ring. When a substituent is listed without
indicating the atom via which such substituent is bonded to the
rest of the compound of a given formula, then such substituent may
be bonded via any atom in such substituent. Combinations of
substituents and/or variables are permissible, but only if such
combinations result in stable compounds.
[0018] Compounds of the present invention that contain nitrogens
can be converted to N-oxides by treatment with an oxidizing agent
(e.g., MCPBA and/or hydrogen peroxides) to afford other compounds
of the present invention. Thus, all shown and claimed
nitrogen-containing compounds are considered, when allowed by
valency and structure, to include both the compound as shown and
its N-oxide derivative (which can be designated as N.fwdarw.O or
N.sup.+--O.sup.-). Furthermore, in other instances, the nitrogens
in the compounds of the present invention can be converted to
N-hydroxy or N-alkoxy compounds. For example, N-hydroxy compounds
can be prepared by oxidation of the parent amine by an oxidizing
agent such as MCPBA. All shown and claimed nitrogen-containing
compounds are also considered, when allowed by valency and
structure, to cover both the compound as shown and its N-hydroxy
(i.e., N--OH) and N-alkoxy (i.e., N--OR, wherein R is substituted
or unsubstituted C.sub.1-6 alkyl, alkenyl, alkynyl, C.sub.3-14
carbocycle, or 3-14-membered heterocycle) derivatives.
[0019] When an atom or chemical moiety is followed by a subscripted
numeric range (e.g., C.sub.1-6), the invention is meant to
encompass each number within the range as well as all intermediate
ranges. For example, "C.sub.1-6 alkyl" is meant to include alkyl
groups with 1, 2, 3, 4, 5, 6, 1-6, 1-5, 1-4, 1-3, 1-2, 2-6, 2-5,
2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, and 5-6 carbons.
[0020] As used herein, "alkyl" is intended to include both branched
and straight-chain saturated aliphatic hydrocarbon groups having
the specified number of carbon atoms. For example, C.sub.1-6 alkyl
is intended to include C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5,
and C.sub.6 alkyl groups. Examples of alkyl include, but are not
limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl,
t-butyl, n-pentyl, s-pentyl, and n-hexyl.
[0021] As used herein, "alkenyl" is intended to include hydrocarbon
chains of either straight or branched configuration having one or
more carbon-carbon double bonds occurring at any stable point along
the chain. For example, C.sub.2-6 alkenyl is intended to include
C.sub.2, C.sub.3, C.sub.4, C.sub.5, and C.sub.6 alkenyl groups.
Examples of alkenyl include, but are not limited to, ethenyl and
propenyl.
[0022] As used herein, "alkynyl" is intended to include hydrocarbon
chains of either straight or branched configuration having one or
more carbon-carbon triple bonds occurring at any stable point along
the chain. For example, C.sub.2-6 alkynyl is intended to include
C.sub.2, C.sub.3, C.sub.4, C.sub.5, and C.sub.6 alkynyl groups.
Examples of alkynyl include, but are not limited to, ethynyl and
propynyl.
[0023] As used herein, "halo" or "halogen" refers to fluoro,
chloro, bromo, and iodo. "Counterion" is used to represent a small,
negatively charged species such as chloride, bromide, hydroxide,
acetate, and sulfate.
[0024] As used herein, "carbocycle" or "carbocyclic ring" is
intended to mean any stable monocyclic, bicyclic, or tricyclic ring
having the specified number of carbons, any of which may be
saturated, unsaturated, or aromatic. For example a C.sub.3-14
carbocycle is intended to mean a mono-, bi-, or tricyclic ring
having 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon atoms.
Examples of carbocycles include, but are not limited to,
cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl,
cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl,
cyclooctyl, cyclooctenyl, cyclooctadienyl, fluorenyl, phenyl,
naphthyl, indanyl, adamantyl, and tetrahydronaphthyl. Bridged rings
are also included in the definition of carbocycle, including, for
example, [3.3.0]bicyclooctane, [4.3.0]bicyclononane,
[4.4.0]bicyclodecane, and [2.2.2]bicyclooctane. A bridged ring
occurs when one or more carbon atoms link two non-adjacent carbon
atoms. Preferred bridges are one or two carbon atoms. It is noted
that a bridge always converts a monocyclic ring into a tricyclic
ring. When a ring is bridged, the substituents recited for the ring
may also be present on the bridge. Fused (e.g., naphthyl and
tetrahydronaphthyl) and spiro rings are also included.
[0025] As used herein, the term "heterocycle" or "heterocyclic" is
intended to mean any stable monocyclic, bicyclic, or tricyclic ring
which is saturated, unsaturated, or aromatic and comprises carbon
atoms and one or more ring heteroatoms, e.g., 1 or 1-2 or 1-3 or
1-4 or 1-5 or 1-6 heteroatoms, independently selected from the
group consisting of nitrogen, oxygen, and sulfur. A bicyclic or
tricyclic heterocycle may have one or more heteroatoms located in
one ring, or the heteroatoms may be located in more than one ring.
The nitrogen and sulfur heteroatoms may optionally be oxidized
(i.e., N.fwdarw.O and S(O).sub.p, where p=1 or 2). When a nitrogen
atom is included in the ring it is either N or NH, depending on
whether or not it is attached to a double bond in the ring (i.e., a
hydrogen is present if needed to maintain the tri-valency of the
nitrogen atom). The nitrogen atom may be substituted or
unsubstituted (i.e., N or NR wherein R is H or another substituent,
as defined). The heterocyclic ring may be attached to its pendant
group at any heteroatom or carbon atom that results in a stable
structure. The heterocyclic rings described herein may be
substituted on carbon or on a nitrogen atom if the resulting
compound is stable. A nitrogen in the heterocycle may optionally be
quaternized. It is preferred that when the total number of S and O
atoms in the heterocycle exceeds 1, then these heteroatoms are not
adjacent to one another. Bridged rings are also included in the
definition of heterocycle. A bridged ring occurs when one or more
atoms (i.e., C, O, N, or S) link two non-adjacent carbon or
nitrogen atoms. Preferred bridges include, but are not limited to,
one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen
atoms, and a carbon-nitrogen group. It is noted that a bridge
always converts a monocyclic ring into a tricyclic ring. When a
ring is bridged, the substituents recited for the ring may also be
present on the bridge. Spiro and fused rings are also included.
[0026] As used herein, the term "aromatic heterocycle" or
"heteroaryl" is intended to mean a stable 5, 6, or 7-membered
monocyclic or bicyclic aromatic heterocyclic ring or 7, 8, 9, 10,
11, or 12-membered bicyclic aromatic heterocyclic ring which
consists of carbon atoms and one or more heteroatoms, e.g., 1 or
1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, independently selected
from the group consisting of nitrogen, oxygen, and sulfur. In the
case of bicyclic heterocyclic aromatic rings, only one of the two
rings needs to be aromatic (e.g., 2,3-dihydroindole), though both
may be (e.g., quinoline). The second ring can also be fused or
bridged as defined above for heterocycles. The nitrogen atom may be
substituted or unsubstituted (i.e., N or NR wherein R is H or
another substituent, as defined). The nitrogen and sulfur
heteroatoms may optionally be oxidized (i.e., N.fwdarw.O and
S(O).sub.p, where p=1 or 2). It is to be noted that total number of
S and O atoms in the aromatic heterocycle is not more than 1.
[0027] Examples of heterocycles include, but are not limited to,
acridinyl, azocinyl, benzimidazolyl, benzofuranyl,
benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl,
benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl,
benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl,
carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran,
furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl,
1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl,
3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl,
isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl,
methylenedioxyphenyl, morpholinyl, naphthyridinyl,
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl,
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl,
phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl,
4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole,
pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl,
pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl,
quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl,
tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl,
tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl,
1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,
thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl,
thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl,
1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and
xanthenyl.
[0028] As used herein, the phrase "pharmaceutically acceptable"
refers to those compounds, materials, compositions, carriers,
and/or dosage forms which are, within the scope of sound medical
judgment, suitable for use in contact with the tissues of human
beings and animals without excessive toxicity, irritation, allergic
response, or other problem or complication, commensurate with a
reasonable benefit/risk ratio.
[0029] As used herein, "pharmaceutically acceptable salts" refer to
derivatives of the disclosed compounds wherein the parent compound
is modified by making acid or base salts thereof. Examples of
pharmaceutically acceptable salts include, but are not limited to,
mineral or organic acid salts of basic residues such as amines,
alkali or organic salts of acidic residues such as carboxylic
acids, and the like. The pharmaceutically acceptable salts include
the conventional non-toxic salts or the quaternary ammonium salts
of the parent compound formed, for example, from non-toxic
inorganic or organic acids. For example, such conventional
non-toxic salts include, but are not limited to, those derived from
inorganic and organic acids selected from 2-acetoxybenzoic,
2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic,
benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic,
ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic,
glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic,
hydrobromic, hydrochloric, hydroiodic, hydroxymaleic,
hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic,
maleic, malic, mandelic, methane sulfonic, napsylic, nitric,
oxalic, pamoic, pantothenic, phenylacetic, phosphoric,
polygalacturonic, propionic, salicyclic, stearic, subacetic,
succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, and
toluene sulfonic.
[0030] The pharmaceutically acceptable salts of the present
invention can be synthesized from a parent compound that contains a
basic or acidic moiety by conventional chemical methods. Generally,
such salts can be prepared by reacting the free acid or base forms
of these compounds with a stoichiometric amount of the appropriate
base or acid in water or in an organic solvent, or in a mixture of
the two; generally, non-aqueous media like ether, ethyl acetate,
ethanol, isopropanol, or acetonitrile are preferred. Lists of
suitable salts are found in Remington's Pharmaceutical Sciences,
18th ed. (Mack Publishing Company, 1990).
[0031] Since prodrugs are known to enhance numerous desirable
qualities of pharmaceuticals (e.g., solubility, bioavailability,
manufacturing, etc.) the compounds of the present invention may be
delivered in prodrug form. Thus, the present invention is intended
to cover prodrugs of the presently claimed compounds, methods of
delivering the same and compositions containing the same.
"Prodrugs" are intended to include any covalently bonded carriers
that release an active parent drug of the present invention in vivo
when such prodrug is administered to a mammalian subject. Prodrugs
the present invention are prepared by modifying functional groups
present in the compound in such a way that the modifications are
cleaved, either in routine manipulation or in vivo, to the parent
compound. Prodrugs include compounds of the present invention
wherein a hydroxy, amino, or sulfhydryl group is bonded to any
group that, when the prodrug of the present invention is
administered to a mammalian subject, cleaves to form a free
hydroxyl, free amino, or free sulfhydryl group, respectively.
Examples of prodrugs include, but are not limited to, acetate,
formate, and benzoate derivatives of alcohol and amine functional
groups in the compounds of the present invention.
[0032] "Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent.
[0033] As used herein, "treating" or "treatment" means the
treatment of a disease-state in a mammal, particularly in a human,
and include: (a) preventing the disease-state from occurring in a
mammal, in particular, when such mammal is predisposed to the
disease-state but has not yet been diagnosed as having it; (b)
inhibiting the disease-state, i.e., arresting its development;
and/or (c) relieving the disease-state, i.e., causing regression of
the disease state.
[0034] As used herein, "mammal" refers to human and non-human
patients.
[0035] As used herein, the term "effective amount" refers to an
amount of a compound, or a combination of compounds, of the present
invention effective when administered alone or in combination as an
anti-proliferative and/or anti-infective agent. The combination of
compounds is preferably a synergistic combination. Synergy, as
described, for example, by Chou and Talalay, Adv. Enzyme Regul.
1984, 22:27-55, occurs when the effect of the compounds when
administered in combination is greater than the additive effect of
the compounds when administered alone as a single agent. In
general, a synergistic effect is most clearly demonstrated at
sub-optimal concentrations of the compounds. Synergy can be in
terms of lower cytotoxicity, increased anti-proliferative and/or
anti-infective effect, or some other beneficial effect of the
combination compared with the individual components.
[0036] All percentages and ratios used herein, unless otherwise
indicated, are by weight.
[0037] Throughout the description, where compositions are described
as having, including, or comprising specific components, it is
contemplated that compositions also consist essentially of, or
consist of, the recited components. Similarly, where processes are
described as having, including, or comprising specific process
steps, the processes also consist essentially of, or consist of,
the recited processing steps. Further, it should be understood that
the order of steps or order for performing certain actions are
immaterial so long as the invention remains operable. Moreover, two
or more steps or actions may be conducted simultaneously.
2. Compounds of the Invention
[0038] In one aspect, the invention provides compounds having the
formula:
##STR00005##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein:
[0039] A is selected from the group consisting of: [0040] phenyl,
pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;
[0041] B is selected from the group consisting of: [0042] phenyl,
pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;
[0043] Het-CH.sub.2--R.sup.3 is selected from the group consisting
of:
##STR00006##
[0044] M is selected from the group consisting of: [0045] a)
saturated, unsaturated, or aromatic C.sub.3-14 carbocycle, and b)
saturated, unsaturated, or aromatic 3-14 membered heterocycle
containing one or more heteroatoms selected from the group
consisting of nitrogen, oxygen, and sulfur, [0046] wherein a) or b)
optionally is substituted with one or more R.sup.5 groups;
[0047] M-L is selected from the group consisting of: [0048] a) M-X,
b) M-L.sup.1, c) M-L.sup.1-X, d) M-X-L.sup.2, e)
M-L.sup.1-X-L.sup.2, f) M-X-L.sup.1-X-L.sup.2, g)
M-L.sup.1-X-L.sup.2-X, h) M-X--X--, i) M-L.sup.1-X--X--, j)
M-X--X-L.sup.2, and k) M-L.sup.1-X--X-L.sup.2, wherein [0049] X, at
each occurrence, independently is selected from the group
consisting of: [0050] a) --O--, b) --NR.sup.4--, c) --N(O)--, d)
--N(OR.sup.4)--, e) --S(O).sub.p--, f) --SO.sub.2NR.sup.4--, g)
--NR.sup.4SO.sub.2--, h) --NR.sup.4--N.dbd., i) .dbd.N--NR.sup.4--,
j) --O--N.dbd., k) .dbd.N--O--, l) --N.dbd., m) .dbd.N--, n)
--NR.sup.4--NR.sup.4--, o) --NR.sup.4C(O)O--, p) --OC(O)NR.sup.4--,
q) --NR.sup.4C(O)NR.sup.4-- r) --NR.sup.4C(NR.sup.4)NR.sup.4--, and
s)
[0050] ##STR00007## [0051] L.sup.1 is selected from the group
consisting of: [0052] a) C.sub.1-6 alkyl, b) C.sub.2-6 alkenyl, and
c) C.sub.2-6 alkynyl, wherein any of a)-c) optionally is
substituted with one or more R.sup.5 groups; and
[0053] L.sup.2 is selected from the group consisting of: [0054] a)
C.sub.1-6 alkyl, b) C.sub.2-6 alkenyl, and c) C.sub.2-6 alkynyl,
[0055] wherein any of a)-c) optionally is substituted with one or
more R.sup.5 groups;
[0056] R.sup.1, at each occurrence, independently is selected from
the group consisting of: [0057] a) F, b) Cl, c) Br, d) I, e)
--CF.sub.3, f) --OR.sup.4, g) --CN, h) --NO.sub.2, i)
--NR.sup.4R.sup.4, j) --C(O)R.sup.4, k) --C(O)OR.sup.4, l)
--OC(O)R.sup.4, m) --C(O)NR.sup.4R.sup.4, n) --NR.sup.4C(O)R.sup.4,
o) --OC(O)NR.sup.4R.sup.4, p) --NR.sup.4C(O)OR.sup.4, q)
--NR.sup.4C(O)NR.sup.4R.sup.4, r) --C(S)R.sup.4, s) --C(S)OR.sup.4,
t) --OC(S)R.sup.4, u) --C(S)NR.sup.4R.sup.4, v)
--NR.sup.4C(S)R.sup.4, w) --OC(S)NR.sup.4R.sup.4, x)
--NR.sup.4C(S)OR.sup.4, y) --NR.sup.4C(S)NR.sup.4R.sup.4, z)
--NR.sup.4C(NR.sup.4)NR.sup.4R.sup.4, aa) --S(O).sub.pR.sup.4, bb)
--SO.sub.2NR.sup.4R.sup.4, and cc) R.sup.4;
[0058] R.sup.2, at each occurrence, independently is selected from
the group consisting of: [0059] a) F, b) Cl, c) Br, d) I, e)
--CF.sub.3, f) --OR.sup.4, g) --CN, h) --NO.sub.2, i)
--NR.sup.4R.sup.4, j) --C(O)R.sup.4, k) --C(O)OR.sup.4, l)
--OC(O)R.sup.4, m) --C(O)NR.sup.4R.sup.4, n) --NR.sup.4C(O)R.sup.4,
o) --OC(O)NR.sup.4R.sup.4, p) --NR.sup.4C(O)OR.sup.4, q)
--NR.sup.4C(O)NR.sup.4R.sup.4, r) --C(S)R.sup.4, s) --C(S)OR.sup.4,
t) --OC(S)R.sup.4, u) --C(S)NR.sup.4R.sup.4, v)
--NR.sup.4C(S)R.sup.4, w) --OC(S)NR.sup.4R.sup.4, x)
--NR.sup.4C(S)OR.sup.4, y) --NR.sup.4C(S)NR.sup.4R.sup.4, z)
--NR.sup.4C(NR.sup.4)NR.sup.4R.sup.4, aa) --S(O).sub.pR.sup.4, bb)
--SO.sub.2NR.sup.4R.sup.4, and cc) R.sup.4;
[0060] R.sup.3 is selected from the group consisting of: [0061] a)
--OR.sup.4, b) --NR.sup.4R.sup.4, c) --C(O)R.sup.4, d)
--C(O)OR.sup.4, e) --OC(O)R.sup.4, f) --C(O)NR.sup.4R.sup.4, g)
--NR.sup.4C(O)R.sup.4, h) --OC(O)NR.sup.4R.sup.4, i)
--NR.sup.4C(O)OR.sup.4, j) --NR.sup.4C(O)NR.sup.4R.sup.4, k)
--C(S)R.sup.4, l) --C(S)OR.sup.4, m) --OC(S)R.sup.4, n)
--C(S)NR.sup.4R.sup.4, o) --NR.sup.4C(S)R.sup.4, p)
--OC(S)NR.sup.4R.sup.4, q) --NR.sup.4C(S)OR.sup.4, r)
--NR.sup.4C(S)NR.sup.4R.sup.4, s)
--NR.sup.4C(NR.sup.4)NR.sup.4R.sup.4, t) --S(O).sub.pR.sup.4, u)
--SO.sub.2NR.sup.4R.sup.4, and v) R.sup.4;
[0062] R.sup.4, at each occurrence, independently is selected from
the group consisting of: [0063] a) H, b) C.sub.1-6 alkyl, c)
C.sub.2-6 alkenyl, d) C.sub.2-6 alkynyl, e) C.sub.3-14 saturated,
unsaturated, or aromatic carbocycle, f) 3-14 membered saturated,
unsaturated, or aromatic heterocycle comprising one or more
heteroatoms selected from the group consisting of nitrogen, oxygen,
and sulfur, g) --C(O)--C.sub.1-6 alkyl, h) --C(O)--C.sub.2-6
alkenyl, i) --C(O)--C.sub.2-6 alkynyl, j) --C(O)--C.sub.3-14
saturated, unsaturated, or aromatic carbocycle, k) --C(O)-3-14
membered saturated, unsaturated, or aromatic heterocycle comprising
one or more heteroatoms selected from the group consisting of
nitrogen, oxygen, and sulfur, l) --C(O)O--C.sub.1-6 alkyl, m)
--C(O)O--C.sub.2-6 alkenyl, n) --C(O)O--C.sub.2-6 alkynyl, o)
--C(O)O--C.sub.3-14 saturated, unsaturated, or aromatic carbocycle,
and p) --C(O)O-3-14 membered saturated, unsaturated, or aromatic
heterocycle comprising one or more heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur, [0064] wherein
any of b)-p) optionally is substituted with one or more R.sup.5
groups;
[0065] R.sup.5, at each occurrence, is independently selected from
the group consisting of: [0066] a) F, b) Cl, c) Br, d) I, e)
.dbd.O, f) .dbd.S, g) .dbd.NR.sup.6, h) .dbd.NOR.sup.6, i)
.dbd.N--NR.sup.6R.sup.6, j) --CF.sub.3, k) --OR.sup.6, l) --CN, m)
--NO.sub.2, n) --NR.sup.6R.sup.6, o) --C(O)R.sup.6, p)
--C(O)OR.sup.6, q) --OC(O)R.sup.6, r) --C(O)NR.sup.6R.sup.6, s)
--NR.sup.6C(O)R.sup.6, t) --OC(O)NR.sup.6R.sup.6, u)
--NR.sup.6C(O)OR.sup.6, v) --NR.sup.6C(O)NR.sup.6R.sup.6, w)
--C(S)R.sup.6, x) --C(S)OR.sup.6, y) --OC(S)R.sup.6, z)
--C(S)NR.sup.6R.sup.6, aa) --NR.sup.6C(S)R.sup.6, bb)
--OC(S)NR.sup.6R.sup.6, cc) --NR.sup.6C(S)OR.sup.6, dd)
--NR.sup.6C(S)NR.sup.6R.sup.6, ee)
--NR.sup.6C(NR.sup.6)NR.sup.6R.sup.6, ff) --S(O).sub.pR.sup.6, gg)
--SO.sub.2NR.sup.6R.sup.6, and hh) R.sup.6;
[0067] R.sup.6, at each occurrence, independently is selected from
the group consisting of: [0068] a) H, b) C.sub.1-6 alkyl, c)
C.sub.2-6 alkenyl, d) C.sub.2-6 alkynyl, e) C.sub.3-14 saturated,
unsaturated, or aromatic carbocycle, f) 3-14 membered saturated,
unsaturated, or aromatic heterocycle comprising one or more
heteroatoms selected from the group consisting of nitrogen, oxygen,
and sulfur, g) --C(O)--C.sub.1-6 alkyl, h) --C(O)--C.sub.2-6
alkenyl, i) --C(O)--C.sub.2-6 alkynyl, j) --C(O)--C.sub.3-14
saturated, unsaturated, or aromatic carbocycle, k) --C(O)-3-14
membered saturated, unsaturated, or aromatic heterocycle comprising
one or more heteroatoms selected from the group consisting of
nitrogen, oxygen, and sulfur, l) --C(O)O--C.sub.1-6 alkyl, m)
--C(O)O--C.sub.2-6 alkenyl, n) --C(O)O--C.sub.2-6 alkynyl, o)
--C(O)O--C.sub.3-14 saturated, unsaturated, or aromatic carbocycle,
and p) --C(O)O-3-14 membered saturated, unsaturated, or aromatic
heterocycle comprising one or more heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur, [0069] wherein
any of b)-p) optionally is substituted with one or more R.sup.7
groups;
[0070] R.sup.7, at each occurrence, independently is selected from
the group consisting of: [0071] a) F, b) Cl, c) Br, d) I, e)
.dbd.O, f) .dbd.S, g) .dbd.NR.sup.8, h) .dbd.NOR.sup.8, i)
.dbd.N--NR.sup.8R.sup.8, j) --CF.sub.3, k) --OR.sup.8, l) --CN, m)
--NO.sub.2, n) --NR.sup.8R.sup.8, o) --C(O)R.sup.8, p)
--C(O)OR.sup.8, q) --OC(O)R.sup.8, r) --C(O)NR.sup.8R.sup.8, s)
--NR.sup.8C(O)R.sup.8, t) --OC(O)NR.sup.8R.sup.8, u)
--NR.sup.8C(O)OR.sup.8, v) --NR.sup.8C(O)NR.sup.8R.sup.8, w)
--C(S)R.sup.8, x) --C(S)OR.sup.8, y) --OC(S)R.sup.8, z)
--C(S)NR.sup.8R.sup.8, aa) --NR.sup.8C(S)R.sup.8, bb)
--OC(S)NR.sup.8R.sup.8, cc) --NR.sup.8C(S)OR.sup.8, dd)
--NR.sup.8C(S)NR.sup.8R.sup.8, ee)
--NR.sup.8C(NR.sup.8)NR.sup.8R.sup.8, ff) --S(O).sub.pR.sup.8, gg)
--SO.sub.2NR.sup.8R.sup.8, hh) C.sub.1-6 alkyl, ii) C.sub.2-6
alkenyl, jj) C.sub.2-6 alkynyl, kk) C.sub.3-14 saturated,
unsaturated, or aromatic carbocycle, and ll) 3-14 membered
saturated, unsaturated, or aromatic heterocycle comprising one or
more heteroatoms selected from the group consisting of nitrogen,
oxygen, and sulfur, [0072] wherein any of hh)-ll) optionally is
substituted with one or more moieties selected from the group
consisting of R.sup.8, F, Cl, Br, I, --CF.sub.3, --OR.sup.8,
--SR.sup.8, --CN, --NO.sub.2, --NR.sup.8R.sup.8, --C(O)R.sup.8,
--C(O)OR.sup.8, --OC(O)R.sup.8, --C(O)NR.sup.8R.sup.8,
--NR.sup.8C(O)R.sup.8, --OC(O)NR.sup.8R.sup.8,
--NR.sup.8C(O)OR.sup.8, --NR.sup.8C(O)NR.sup.8R.sup.8,
--C(S)R.sup.8, --C(S)OR.sup.8, --OC(S)R.sup.8,
--C(S)NR.sup.8R.sup.8, --NR.sup.8C(S)R.sup.8,
--OC(S)NR.sup.8R.sup.8, --NR.sup.8C(S)OR.sup.8,
--NR.sup.8C(S)NR.sup.8R.sup.8,
--NR.sup.8C(NR.sup.8)NR.sup.8R.sup.8, --SO.sub.2NR.sup.8R.sup.8,
and --S(O).sub.pR.sup.8;
[0073] R.sup.8, at each occurrence, independently is selected from
the group consisting of: [0074] a) H, b) C.sub.1-6 alkyl, c)
C.sub.2-6 alkenyl, d) C.sub.2-6 alkynyl, e) C.sub.3-14 saturated,
unsaturated, or aromatic carbocycle, f) 3-14 membered saturated,
unsaturated, or aromatic heterocycle comprising one or more
heteroatoms selected from the group consisting of nitrogen, oxygen,
and sulfur, g) --C(O)--C.sub.1-6 alkyl, h) --C(O)--C.sub.2-6
alkenyl, i) --C(O)--C.sub.2-6 alkynyl, j) --C(O)--C.sub.3-14
saturated, unsaturated, or aromatic carbocycle, k) --C(O)-3-14
membered saturated, unsaturated, or aromatic heterocycle comprising
one or more heteroatoms selected from the group consisting of
nitrogen, oxygen, and sulfur, l) --C(O)O--C.sub.1-6 alkyl, m)
--C(O)O--C.sub.2-6 alkenyl, n) --C(O)O--C.sub.2-6 alkynyl, o)
--C(O)O--C.sub.3-14 saturated, unsaturated, or aromatic carbocycle,
and p) --C(O)O-3-14 membered saturated, unsaturated, or aromatic
heterocycle comprising one or more heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur, [0075] wherein
any of b)-p) optionally is substituted with one or more moieties
selected from the group consisting of F, Cl, Br, I, --CF.sub.3,
--OH, --OCH.sub.3, --SH, --SCH.sub.3, --CN, --NO.sub.2, --NH.sub.2,
--NHCH.sub.3, --N(CH.sub.3).sub.2, --C(O)CH.sub.3, --C(O)OCH.sub.3,
--C(O)NH.sub.2, --NHC(O)CH.sub.3, --SO.sub.2NH.sub.2,
--SO.sub.2NHCH.sub.3, --SO.sub.2N(CH.sub.3).sub.2, and
--S(O).sub.pCH.sub.3;
[0076] m is 0, 1, 2, 3, or 4;
[0077] n is 0, 1, 2, 3, or 4; and
[0078] p, at each occurrence, independently is 0, 1, or 2,
[0079] and wherein the compound does not have the formula
corresponding to any of the structures listed in Table 1.
TABLE-US-00001 TABLE 1 ##STR00008## ##STR00009## ##STR00010##
##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015##
##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020##
##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025##
##STR00026## ##STR00027## ##STR00028## ##STR00029## ##STR00030##
##STR00031## ##STR00032## ##STR00033## ##STR00034##
##STR00035##
[0080] Particular embodiments of the invention include compounds
having the formula:
##STR00036##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, B, L, M, R.sup.1, R.sup.2, R.sup.3, m, and n are defined
above.
[0081] Other embodiments include compounds having the formula:
##STR00037##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, B, L, M, R.sup.1, R.sup.2, R.sup.3, m, and n are defined
as described above.
[0082] Particular compounds include those where A is selected from
the group consisting of phenyl and pyridyl; B is selected from the
group consisting of phenyl and pyridyl; m is 0, 1, or 2; and n is
0, 1, or 2.
[0083] In some embodiments, A-B is:
##STR00038##
wherein A, R.sup.2, and n are defined as described above. In
particular embodiments, A-B is:
##STR00039##
wherein A is defined as described above.
[0084] In various embodiments, A-B is:
##STR00040##
wherein B is defined as described in above.
[0085] In some embodiments, R.sup.3 is --NHC(O)R.sup.4. Particular
compounds according to these embodiments include those where
R.sup.4 is --CH.sub.3 or
##STR00041##
[0086] Particular embodiments of the invention include compounds
having the formula:
##STR00042##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, B, L, M, R.sup.1, R.sup.2, m, and n are defined as
described above.
[0087] Other embodiments of the invention include compounds having
the formula:
##STR00043##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, L, M, R.sup.1, R.sup.3, and m are defined as described
above.
[0088] Still other embodiments of the invention include compounds
having the formula:
##STR00044##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, L, M, R.sup.1, and m are defined as described above.
[0089] Some embodiments of the invention include compounds having
the formula:
##STR00045##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein L, M, and R.sup.3 are defined as described above.
Particular compounds according to these embodiments include those
wherein R.sup.3 is --NHC(O)CH.sub.3.
[0090] Other embodiments of the invention include compounds having
the formula:
##STR00046##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, L, M, R.sup.1, R.sup.3, and m are defined as described
above.
[0091] Still other embodiments of the invention include compounds
having the formula:
##STR00047##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, L, M, R.sup.1, and m are defined as described above.
[0092] Some embodiments of the invention include compounds having
the formula:
##STR00048##
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein L, M, and R.sup.3 are defined as described above.
Particular compounds according to these embodiments include those
wherein R.sup.3 is --NHC(O)CH.sub.3.
[0093] In some embodiments, M-L is M-L.sup.1, and L.sup.1 is
C.sub.1-6 alkyl. In particular embodiments, M-L.sup.1 is
M-CH.sub.2--.
[0094] In other embodiments, M-L is M-L.sup.1-X-L.sup.2, and X is
--NR.sup.4--. In particular compounds according to these
embodiments, X is --NH--, --N(O)--, or --N(OR.sup.4)--, where
R.sup.4 is H or C.sub.1-6 alkyl. Other compounds include those
where X is
##STR00049##
In certain compounds according to these embodiments, L.sup.1 is
C.sub.1-6 alkyl, and L.sup.2 is C.sub.1-6 alkyl. In some
embodiments, L.sup.1 is --CH.sub.2-- and L.sup.2 is --CH.sub.2--.
Particular examples of compounds according to these embodiments
include those where M-L is M-CH.sub.2--NH--CH.sub.2-- or
##STR00050##
[0095] In still other embodiments, M-L is
M-S-L.sup.1-NR.sup.4-L.sup.2, wherein L.sup.1 is C.sub.1-6 alkyl,
and L.sup.2 is C.sub.1-6 alkyl. In particular compounds according
to these embodiments, M-L is
M-S--CH.sub.2CH.sub.2--NH--CH.sub.2--.
[0096] In particular embodiments, M is selected from the group
consisting of: [0097] a) phenyl, b) pyridyl, c) pyrazinyl, d)
pyrimidinyl, e) pyridazinyl, f) oxiranyl, g) aziridinyl, h)
furanyl, i) thiophenyl, j) pyrrolyl, k) oxazolyl, l) isoxazolyl, m)
imidazolyl, n) pyrazolyl, o) isothiazolyl, p) thiazolyl, q)
triazolyl, r) tetrazolyl, s) indolyl, t) purinyl, u) benzofuranyl,
v) benzoxazolyl, w) benzisoxazolyl, x) quinolinyl, y)
isoquinolinyl, z) quinoxalinyl, aa) quinazolinyl, bb) cinnolinyl,
cc) cyclopropyl, dd) cyclobutyl, ee) cyclopentyl, ff) cyclohexyl,
gg) cycloheptyl, hh) oxetanyl, ii) tetrahydrofuranyl, jj)
tetrahydropyranyl, kk) azetidinyl, ll) pyrrolidinyl, mm)
piperidinyl, nn) thietanyl, oo) tetrahydrothiophenyl, pp)
tetrahydrothiopyranyl, qq) piperazinyl, rr) quinuclidinyl, ss)
1-azabicyclo[2.2.1]hyeptanyl, tt) morpholinyl, uu) thiomorpholinyl,
vv) thiooxomorpholinyl, ww) thiodioxomorpholinyl, and xx)
benzothiophenyl wherein any of a)-xx) optionally is substituted
with one or more R.sup.5 groups. In particular embodiments, M is
4-isoxazolyl, [1,2,3]triazol-1-yl, 3H-[1,2,3]triazol-4-yl,
1H-tetrazol-5-yl, piperidin-1-yl, or pyrrolidin-1-yl.
[0098] In preferred embodiments, A is phenyl, substituted phenyl,
pyridyl, or substituted pyridyl. Under certain circumstances, when
A is pyridin-4-yl substituted with M-L at the 2 position, M-L is
not (imidazol-1-yl)methyl or (morpholin-4-yl)methyl.
[0099] In preferred embodiments, B is phenyl or substituted phenyl.
More preferably, B is substituted phenyl. Preferred substituents
include halogens, and in particular, fluorine.
[0100] Under certain circumstances, when B is unsubstituted phenyl,
M-L is selected from the group consisting of M-X, M-L.sup.1-X,
M-L.sup.1-X-L.sup.2, M-X-L.sup.1-X-L.sup.2, M-X--X--,
M-L.sup.1-X--X--, M-X--X-L.sup.2, and M-L.sup.1-X--X-L.sup.2. Under
certain circumstances, when B is pyridin-2-yl substituted with A at
the 5 position, M-L is selected from the group consisting of M-X,
M-L.sup.1-X, M-L.sup.1-X-L.sup.2, M-L.sup.1-X-L.sup.2-X, M-X--X--,
M-X--X-L.sup.2, and M-L.sup.1-X--X-L.sup.2.
[0101] In another aspect, the invention provides a pharmaceutical
composition comprising an effective amount of one or more of the
foregoing compounds and a pharmaceutically acceptable carrier.
Suitable formulating agents are described in detail in section 5
hereinbelow.
[0102] One or more of the foregoing compounds may also be
incorporated into a medical device. For example, a medical device,
such as a medical stent, can contain or be coated with one or more
of the compounds of the invention.
[0103] In another aspect, the invention provides a method for
treating a microbial infection, a fungal infection, a viral
infection, a parasitic disease, a proliferative disease, an
inflammatory disease, or a gastrointestinal motility disorder in a
mammal. The method involves administering an effective amount of
one or more compounds or pharmaceutical compositions of the
invention, for example, via oral, parenteral or topical routes.
[0104] The invention provides a method of treating a disorder in a
mammal comprising the step of administering to the mammal an
effective amount of one or more compounds of the invention thereby
to ameliorate a symptom of a particular disorder. Such a disorder
can be selected from the group consisting of a skin infection,
nosocomial pneumonia, post-viral pneumonia, an abdominal infection,
a urinary tract infection, bacteremia, septicemia, endocarditis, an
atrio-ventricular shunt infection, a vascular access infection,
meningitis, surgical prophylaxis, a peritoneal infection, a bone
infection, a joint infection, a methicillin-resistant
Staphylococcus aureus infection, a vancomycin-resistant Enterococci
infection, a linezolid-resistant organism infection, and
tuberculosis.
3. Synthesis of the Compounds of the Invention
[0105] The invention provides methods and intermediates for making
compounds of the present invention. The following schemes depict
some exemplary chemistries available for synthesizing the compounds
of the invention. It will be appreciated, however, that the desired
compounds may be synthesized using other alternative chemistries
known in the art.
[0106] The following examples illustrate some of the compounds of
the present invention. Compounds of general structures Ia through
IVb (wherein X is CH or N) can be synthesized by the chemistries
exemplified below in the following schemes.
##STR00051## ##STR00052##
[0107] Scheme A exemplifies the synthesis of biaryl amine
intermediate 5, which is useful in producing certain compounds of
the present invention. Known iodoaryl oxazolidinone intermediate 1
(see U.S. Pat. Nos. 5,523,403 and 5,565,571) is coupled to a
substituted aryl boronic acid (the Suzuki reaction) to produce
biaryl alcohol 2. Other coupling reactions (for example, the Stille
reaction) using alternate coupling intermediates easily obtained or
synthesized by those skilled in the art could also be employed to
synthesize target biaryl intermediates similar to 2. These
alternate coupling reactions are within the scope of the present
invention. Alcohol 2 is then converted to amine 5 by chemistry well
known to those skilled in the art.
##STR00053##
[0108] Scheme B illustrates the synthesis of intermediates 7 and 8
of the present invention using Suzuki coupling chemistry between
boronic acids and aryl triflates. Boronic ester 6 is treated with
an appropriate aryl triflate to yield the BOC-protected biaryl 7.
The BOC group of 7 is removed to provide amine 8, an intermediate
useful in the synthesis of certain compounds of the present
invention.
##STR00054##
[0109] Scheme C depicts the synthesis of intermediates 9-13, which
are useful in producing certain methoxy-substituted biaryl
derivatives of the present invention. Suzuki coupling of boronic
ester 6 produces biaryl aldehyde 9, which can be reduced to alcohol
10. Mesylation of 10 yields 11 that can be converted to azide 12.
Reduction of azide 12 yields amine 13.
##STR00055##
[0110] Scheme D depicts the synthesis of pyridyl intermediates,
which are useful for the synthesis of compounds of the present
invention, via similar chemistry to that shown in Scheme C.
Coupling of boronic ester 6 to a halopyridine aldehyde produces
biaryl aldehyde 14. Aldehyde 14 serves as the precursor to
intermediates 15-18 via chemistry described above.
##STR00056##
[0111] Biaryl aldehyde 19 (Scheme E) can be synthesized from a
Suzuki coupling of iodide 1 and 4-formylphenylboronic acid. Scheme
E illustrates how intermediate aldehydes of type 19, 9, and 14 can
be converted via reductive amination chemistry to other amines,
such as amines 20-22, which are useful as intermediates for the
synthesis of certain compounds of the invention.
##STR00057##
[0112] Scheme F depicts the general synthesis of compounds of type
Ia and Ib from amines of type 5, 13, 18, and 20-22. Compounds of
type Ia and Ib are synthesized via acylation of amines 5, 13 and 18
and 20-22 with the appropriate acids using, for example,
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI)
as the coupling agent. Compounds 4001-4007 were specifically
synthesized from amine 5 and the appropriate carboxylic acids.
##STR00058##
[0113] Scheme G highlights the synthesis of compounds of general
structure II from amines of type 5 and 18. The amine can be
acylated with carboxylic acids using EDCI (or other commonly
employed peptide coupling reagents known in the art) to afford
amides II. Acid chlorides can be purchased or synthesized and
allowed to react with amines 5 and 18, in the presence of bases
such as triethylamine, to also produce amides II. Alternatively,
carboxylic acids can be pre-loaded onto a solid polymeric support,
such as a tetrafluorophenol containing resin (TFP resin), and
reacted with amines to yield amide products of general structure II
(such as compounds 4008-4015).
##STR00059##
[0114] Scheme H illustrates the synthesis of compounds of general
structure IIIa from amines of type 5, 13, and 18 using reductive
amination chemistry. For example, biaryl amine compounds 4016-4028
are synthesized in this manner.
##STR00060##
[0115] Scheme I depicts the synthesis of general structure IIIb of
the present invention from amine intermediate 8. For example,
compounds 4029-4031 are synthesized using this reductive amination
chemistry.
##STR00061##
[0116] Scheme J shows the synthesis of compounds of general
structure IVa and IVb. Amines 20, 21, and 22 can be converted to
tertiary amines IVa, such as compounds 4032-4034 and 4036, using
standard reductive amination chemistry employed earlier for other
derivatives. This reductive amination chemistry can be employed on
biaryl aldehyde intermediates such as 19, 9, and 14 to yield
optionally substituted amines of general structure IVb, illustrated
by compound 4037.
##STR00062##
[0117] It should be noted that, when X is N, any of the synthetic
routes described above may be used to produce compounds having any
regioisomer of pyridine (e.g., pyridin-2-yl or pyridin-3-yl).
[0118] In addition, the invention provides alternative approaches
for synthesizing compounds of the invention. In one approach, the
method includes the step of combining a compound of formula
(I):
##STR00063##
with a compound of formula (II):
##STR00064##
in a solvent in the presence of a base and a palladium catalyst,
wherein
[0119] Q is a boronate having the formula --BY.sub.2, wherein
[0120] Y, at each occurrence, independently is selected from the
group consisting of: [0121] a) --OH, and b) --O--C.sub.1-4 alkyl,
[0122] alternatively, two Y groups taken together are selected from
the group consisting of: [0123] a)
--OC(R.sup.4)(R.sup.4)C(R.sup.4)(R.sup.4)O--, and b)
--OC(R.sup.4)(R.sup.4)CH.sub.2C(R.sup.4)(R.sup.4)O--,
alternatively, two Y groups taken together with the boron to which
they are bound comprise a BF.sub.3 alkali metal salt;
[0124] Z is selected from the group consisting of: [0125] a) I, b)
Br, c) Cl, and d) R.sup.4OSO.sub.3--; and [0126] A, B, Het, L, M,
R.sup.1, R.sup.2, R.sup.3, R.sup.4, m, and n are defined as
described above.
[0127] In another approach, the method includes the step of
combining a compound of formula (III):
##STR00065##
with a compound of formula (IV):
##STR00066##
in a solvent in the presence of a base and a palladium catalyst,
wherein A, B, Het, L, M, R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, Z,
m, and n are defined as described above.
[0128] In either approach, Z can be I. Furthermore, Q can be
--BF.sub.2.KF or
##STR00067##
[0129] In some embodiments, the base is selected from the group
consisting of an alkali metal hydroxide, an alkali metal carbonate,
an alkali metal fluoride, a trialkyl amine, and mixtures thereof.
Examples of suitable bases include potassium carbonate, sodium
carbonate, potassium fluoride, triethylamine,
diisopropylethylamine, and mixtures thereof. In particular
embodiments, the ratio of equivalents of base to equivalents of
compound (I) or compound (III) is about 3:1.
[0130] In some embodiments, the palladium catalyst is a ligand
coordinated palladium (0) catalyst, such as a
tetrakis(trialkylphosphine)palladium (0) or a
tetrakis(triarylphosphine)palladium (0) catalyst. An example of a
suitable palladium catalyst is
tetrakis(triphenylphosphine)palladium (0). In particular
embodiments, the ratio of the equivalents of
tetrakis(triphenylphosphine)palladium (0) to the equivalents of
compound (I) or compound (III) is about 1:20.
[0131] In some embodiments, the solvent comprises an aqueous
solvent. In other embodiments, the solvent comprises a mixture of
water and an organic solvent, wherein the organic solvent is
selected from the group consisting of methanol, ethanol, propanol,
isopropanol, butanol, isobutanol, secondary butanol, tertiary
butanol, benzene, toluene, tetrahydrofuran, dimethylformamide,
1,2-diethyl ether, dimethoxyethane, diisopropyl ether,
methyltertiarybutyl ether, methoxymethyl ether, 2-methoxyethyl
ether, 1,4-dioxane, 1,3-dioxolane, and mixtures thereof. In a
particular embodiment, the solvent is a mixture of water, toluene,
and ethanol in a ratio, for example, of about 1:3:1 by volume.
[0132] In some embodiments, the method is carried out at a
temperature between about 20.degree. C. and about 100.degree. C. In
other embodiments, the process is carried out at the reflux
temperature of the solvent.
4. Characterization of Compounds of the Invention
[0133] Compounds designed, selected and/or optimized by methods
described above, once produced, may be characterized using a
variety of assays known to those skilled in the art to determine
whether the compounds have biological activity. For example, the
molecules may be characterized by conventional assays, including
but not limited to those assays described below, to determine
whether they have a predicted activity, binding activity and/or
binding specificity.
[0134] Furthermore, high-throughput screening may be used to speed
up analysis using such assays. As a result, it may be possible to
rapidly screen the molecules described herein for activity, for
example, as anti-cancer, anti-bacterial, anti-fungal,
anti-parasitic or anti-viral agents. Also, it may be possible to
assay how the compounds interact with a ribosome or ribosomal
subunit and/or are effective as modulators (for example,
inhibitors) of protein synthesis using techniques known in the art.
General methodologies for performing high-throughput screening are
described, for example, in Devlin, High Throughput Screening,
(Marcel Dekker, 1998); and U.S. Pat. No. 5,763,263. High-throughput
assays can use one or more different assay techniques including,
but not limited to, those described below.
[0135] (1) Surface Binding Studies.
[0136] A variety of binding assays may be useful in screening new
molecules for their binding activity. One approach includes surface
plasmon resonance (SPR) that can be used to evaluate the binding
properties of molecules of interest with respect to a ribosome,
ribosomal subunit or a fragment thereof.
[0137] SPR methodologies measure the interaction between two or
more macromolecules in real-time through the generation of a
quantum-mechanical surface plasmon. One device, (BIAcore
Biosensor.TM. from Pharmacia Biosensor, Piscatawy, N.J.) provides a
focused beam of polychromatic light to the interface between a gold
film (provided as a disposable biosensor "chip") and a buffer
compartment that can be regulated by the user. A 100 nm thick
"hydrogel" composed of carboxylated dextran that provides a matrix
for the covalent immobilization of analytes of interest is attached
to the gold film. When the focused light interacts with the free
electron cloud of the gold film, plasmon resonance is enhanced. The
resulting reflected light is spectrally depleted in wavelengths
that optimally evolved the resonance. By separating the reflected
polychromatic light into its component wavelengths (by means of a
prism), and determining the frequencies that are depleted, the
BIAcore establishes an optical interface which accurately reports
the behavior of the generated surface plasmon resonance. When
designed as above, the plasmon resonance (and thus the depletion
spectrum) is sensitive to mass in the evanescent field (which
corresponds roughly to the thickness of the hydrogel). If one
component of an interacting pair is immobilized to the hydrogel,
and the interacting partner is provided through the buffer
compartment, the interaction between the two components can be
measured in real time based on the accumulation of mass in the
evanescent field and its corresponding effects of the plasmon
resonance as measured by the depletion spectrum. This system
permits rapid and sensitive real-time measurement of the molecular
interactions without the need to label either component.
[0138] (2) Fluorescence Polarization.
[0139] Fluorescence polarization (FP) is a measurement technique
that can readily be applied to protein-protein, protein-ligand, or
RNA-ligand interactions in order to derive IC.sub.50s and Kds of
the association reaction between two molecules. In this technique
one of the molecules of interest is conjugated with a fluorophore.
This is generally the smaller molecule in the system (in this case,
the compound of interest). The sample mixture, containing both the
ligand-probe conjugate and the ribosome, ribosomal subunit or
fragment thereof, is excited with vertically polarized light. Light
is absorbed by the probe fluorophores, and re-emitted a short time
later. The degree of polarization of the emitted light is measured.
Polarization of the emitted light is dependent on several factors,
but most importantly on viscosity of the solution and on the
apparent molecular weight of the fluorophore. With proper controls,
changes in the degree of polarization of the emitted light depends
only on changes in the apparent molecular weight of the
fluorophore, which in-turn depends on whether the probe-ligand
conjugate is free in solution, or is bound to a receptor. Binding
assays based on FP have a number of important advantages, including
the measurement of IC.sub.50s and Kds under true homogenous
equilibrium conditions, speed of analysis and amenity to
automation, and ability to screen in cloudy suspensions and colored
solutions.
[0140] (3) Protein Synthesis.
[0141] It is contemplated that, in addition to characterization by
the foregoing biochemical assays, the compound of interest may also
be characterized as a modulator (for example, an inhibitor of
protein synthesis) of the functional activity of the ribosome or
ribosomal subunit.
[0142] Furthermore, more specific protein synthesis inhibition
assays may be performed by administering the compound to a whole
organism, tissue, organ, organelle, cell, a cellular or subcellular
extract, or a purified ribosome preparation and observing its
pharmacological and inhibitory properties by determining, for
example, its inhibition constant (IC.sub.50) for inhibiting protein
synthesis. Incorporation of .sup.3H leucine or .sup.35S methionine,
or similar experiments can be performed to investigate protein
synthesis activity. A change in the amount or the rate of protein
synthesis in the cell in the presence of a molecule of interest
indicates that the molecule is a modulator of protein synthesis. A
decrease in the rate or the amount of protein synthesis indicates
that the molecule is a inhibitor of protein synthesis.
[0143] Furthermore, the compounds may be assayed for
anti-proliferative or anti-infective properties on a cellular
level. For example, where the target organism is a microorganism,
the activity of compounds of interest may be assayed by growing the
microorganisms of interest in media either containing or lacking
the compound. Growth inhibition may be indicative that the molecule
may be acting as a protein synthesis inhibitor. More specifically,
the activity of the compounds of interest against bacterial
pathogens may be demonstrated by the ability of the compound to
inhibit growth of defined strains of human pathogens. For this
purpose, a panel of bacterial strains can be assembled to include a
variety of target pathogenic species, some containing resistance
mechanisms that have been characterized. Use of such a panel of
organisms permits the determination of structure-activity
relationships not only in regards to potency and spectrum, but also
with a view to obviating resistance mechanisms. The assays may be
performed in microtiter trays according to conventional
methodologies as published by The National Committee for Clinical
Laboratory Standards (NCCLS) guidelines (NCCLS. M7-A5-Methods for
Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow
Aerobically; Approved Standard-Fifth Edition. NCCLS Document
M100-S12/M7 (ISBN 1-56238-394-9)).
5. Formulation and Administration
[0144] The compounds of the invention may be useful in the
prevention or treatment of a variety of human or other animal
disorders, including for example, bacterial infection, fungal
infections, viral infections, parasitic diseases, and cancer. It is
contemplated that, once identified, the active molecules of the
invention may be incorporated into any suitable carrier prior to
use. The dose of active molecule, mode of administration and use of
suitable carrier will depend upon the intended recipient and target
organism. The formulations, both for veterinary and for human
medical use, of compounds according to the present invention
typically include such compounds in association with a
pharmaceutically acceptable carrier.
[0145] The carrier(s) should be "acceptable" in the sense of being
compatible with the other ingredients of the formulations and not
deleterious to the recipient. Pharmaceutically acceptable carriers,
in this regard, are intended to include any and all solvents,
dispersion media, coatings, anti-bacterial and anti-fungal agents,
isotonic and absorption delaying agents, and the like, compatible
with pharmaceutical administration. The use of such media and
agents for pharmaceutically active substances is known in the art.
Except insofar as any conventional media or agent is incompatible
with the active compound, use thereof in the compositions is
contemplated. Supplementary active compounds (identified or
designed according to the invention and/or known in the art) also
can be incorporated into the compositions. The formulations may
conveniently be presented in dosage unit form and may be prepared
by any of the methods well known in the art of
pharmacy/microbiology. In general, some formulations are prepared
by bringing the compound into association with a liquid carrier or
a finely divided solid carrier or both, and then, if necessary,
shaping the product into the desired formulation.
[0146] A pharmaceutical composition of the invention should be
formulated to be compatible with its intended route of
administration. Examples of routes of administration include oral
or parenteral, for example, intravenous, intradermal, inhalation,
transdermal (topical), transmucosal, and rectal administration.
Solutions or suspensions used for parenteral, intradermal, or
subcutaneous application can include the following components: a
sterile diluent such as water for injection, saline solution, fixed
oils, polyethylene glycols, glycerine, propylene glycol or other
synthetic solvents; antibacterial agents such as benzyl alcohol or
methyl parabens; antioxidants such as ascorbic acid or sodium
bisulfite; chelating agents such as ethylenediaminetetraacetic
acid; buffers such as acetates, citrates or phosphates and agents
for the adjustment of tonicity such as sodium chloride or dextrose.
pH can be adjusted with acids or bases, such as hydrochloric acid
or sodium hydroxide.
[0147] Useful solutions for oral or parenteral administration can
be prepared by any of the methods well known in the pharmaceutical
art, described, for example, in Remington's Pharmaceutical
Sciences, 18th ed. (Mack Publishing Company, 1990). Formulations
for parenteral administration can also include glycocholate for
buccal administration, methoxysalicylate for rectal administration,
or citric acid for vaginal administration. The parenteral
preparation can be enclosed in ampoules, disposable syringes or
multiple dose vials made of glass or plastic. Suppositories for
rectal administration also can be prepared by mixing the drug with
a non-irritating excipient such as cocoa butter, other glycerides,
or other compositions which are solid at room temperature and
liquid at body temperatures. Formulations also can include, for
example, polyalkylene glycols such as polyethylene glycol, oils of
vegetable origin, and hydrogenated naphthalenes. Formulations for
direct administration can include glycerol and other compositions
of high viscosity. Other potentially useful parenteral carriers for
these drugs include ethylene-vinyl acetate copolymer particles,
osmotic pumps, implantable infusion systems, and liposomes.
Formulations for inhalation administration can contain as
excipients, for example, lactose, or can be aqueous solutions
containing, for example, polyoxyethylene-9-lauryl ether,
glycocholate and deoxycholate, or oily solutions for administration
in the form of nasal drops, or as a gel to be applied intranasally.
Retention enemas also can be used for rectal delivery.
[0148] Formulations of the present invention suitable for oral
administration may be in the form of: discrete units such as
capsules, gelatin capsules, sachets, tablets, troches, or lozenges,
each containing a predetermined amount of the drug; a powder or
granular composition; a solution or a suspension in an aqueous
liquid or non-aqueous liquid; or an oil-in-water emulsion or a
water-in-oil emulsion. The drug may also be administered in the
form of a bolus, electuary or paste. A tablet may be made by
compressing or molding the drug optionally with one or more
accessory ingredients. Compressed tablets may be prepared by
compressing, in a suitable machine, the drug in a free-flowing form
such as a powder or granules, optionally mixed by a binder,
lubricant, inert diluent, surface active or dispersing agent.
Molded tablets may be made by molding, in a suitable machine, a
mixture of the powdered drug and suitable carrier moistened with an
inert liquid diluent.
[0149] Oral compositions generally include an inert diluent or an
edible carrier. For the purpose of oral therapeutic administration,
the active compound can be incorporated with excipients. Oral
compositions prepared using a fluid carrier for use as a mouthwash
include the compound in the fluid carrier and are applied orally
and swished and expectorated or swallowed. Pharmaceutically
compatible binding agents, and/or adjuvant materials can be
included as part of the composition. The tablets, pills, capsules,
troches and the like can contain any of the following ingredients,
or compounds of a similar nature: a binder such as microcrystalline
cellulose, gum tragacanth or gelatin; an excipient such as starch
or lactose; a disintegrating agent such as alginic acid, Primogel,
or corn starch; a lubricant such as magnesium stearate or Sterotes;
a glidant such as colloidal silicon dioxide; a sweetening agent
such as sucrose or saccharin; or a flavoring agent such as
peppermint, methyl salicylate, or orange flavoring.
[0150] Pharmaceutical compositions suitable for injectable use
include sterile aqueous solutions (where water soluble) or
dispersions and sterile powders for the extemporaneous preparation
of sterile injectable solutions or dispersion. For intravenous
administration, suitable carriers include physiological saline,
bacteriostatic water, Cremophor EL.TM. (BASF, Parsippany, N.J.) or
phosphate buffered saline (PBS). It should be stable under the
conditions of manufacture and storage and should be preserved
against the contaminating action of microorganisms such as bacteria
and fungi. The carrier can be a solvent or dispersion medium
containing, for example, water, ethanol, polyol (for example,
glycerol, propylene glycol, and liquid polyetheylene glycol), and
suitable mixtures thereof. The proper fluidity can be maintained,
for example, by the use of a coating such as lecithin, by the
maintenance of the required particle size in the case of dispersion
and by the use of surfactants. In many cases, it will be preferable
to include isotonic agents, for example, sugars, polyalcohols such
as manitol, sorbitol, sodium chloride in the composition. Prolonged
absorption of the injectable compositions can be brought about by
including in the composition an agent which delays absorption, for
example, aluminum monostearate and gelatin.
[0151] Sterile injectable solutions can be prepared by
incorporating the active compound in the required amount in an
appropriate solvent with one or a combination of ingredients
enumerated above, as required, followed by filter sterilization.
Generally, dispersions are prepared by incorporating the active
compound into a sterile vehicle which contains a basic dispersion
medium and the required other ingredients from those enumerated
above. In the case of sterile powders for the preparation of
sterile injectable solutions, methods of preparation include vacuum
drying and freeze-drying which yields a powder of the active
ingredient plus any additional desired ingredient from a previously
sterile-filtered solution thereof.
[0152] Formulations suitable for intra-articular administration may
be in the form of a sterile aqueous preparation of the drug that
may be in microcrystalline form, for example, in the form of an
aqueous microcrystalline suspension. Liposomal formulations or
biodegradable polymer systems may also be used to present the drug
for both intra-articular and ophthalmic administration.
[0153] Formulations suitable for topical administration, including
eye treatment, include liquid or semi-liquid preparations such as
liniments, lotions, gels, applicants, oil-in-water or water-in-oil
emulsions such as creams, ointments or pastes; or solutions or
suspensions such as drops. Formulations for topical administration
to the skin surface can be prepared by dispersing the drug with a
dermatologically acceptable carrier such as a lotion, cream,
ointment or soap. Particularly useful are carriers capable of
forming a film or layer over the skin to localize application and
inhibit removal. For topical administration to internal tissue
surfaces, the agent can be dispersed in a liquid tissue adhesive or
other substance known to enhance adsorption to a tissue surface.
For example, hydroxypropylcellulose or fibrinogen/thrombin
solutions can be used to advantage. Alternatively, tissue-coating
solutions, such as pectin-containing formulations can be used.
[0154] For inhalation treatments, inhalation of powder
(self-propelling or spray formulations) dispensed with a spray can,
a nebulizer, or an atomizer can be used. Such formulations can be
in the form of a fine powder for pulmonary administration from a
powder inhalation device or self-propelling powder-dispensing
formulations. In the case of self-propelling solution and spray
formulations, the effect may be achieved either by choice of a
valve having the desired spray characteristics (i.e., being capable
of producing a spray having the desired particle size) or by
incorporating the active ingredient as a suspended powder in
controlled particle size. For administration by inhalation, the
compounds also can be delivered in the form of an aerosol spray
from pressured container or dispenser which contains a suitable
propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
[0155] Systemic administration also can be by transmucosal or
transdermal means. For transmucosal or transdermal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants generally are known in the art,
and include, for example, for transmucosal administration,
detergents and bile salts. Transmucosal administration can be
accomplished through the use of nasal sprays or suppositories. For
transdermal administration, the active compounds typically are
formulated into ointments, salves, gels, or creams as generally
known in the art.
[0156] The active compounds may be prepared with carriers that will
protect the compound against rapid elimination from the body, such
as a controlled release formulation, including implants and
microencapsulated delivery systems. Biodegradable, biocompatible
polymers can be used, such as ethylene vinyl acetate,
polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and
polylactic acid. Methods for preparation of such formulations will
be apparent to those skilled in the art. Liposomal suspensions can
also be used as pharmaceutically acceptable carriers. These can be
prepared according to methods known to those skilled in the art,
for example, as described in U.S. Pat. No. 4,522,811.
[0157] Oral or parenteral compositions can be formulated in dosage
unit form for ease of administration and uniformity of dosage.
Dosage unit form refers to physically discrete units suited as
unitary dosages for the subject to be treated; each unit containing
a predetermined quantity of active compound calculated to produce
the desired therapeutic effect in association with the required
pharmaceutical carrier. The specification for the dosage unit forms
of the invention are dictated by and directly dependent on the
unique characteristics of the active compound and the particular
therapeutic effect to be achieved, and the limitations inherent in
the art of compounding such an active compound for the treatment of
individuals. Furthermore, administration can be by periodic
injections of a bolus, or can be made more continuous by
intravenous, intramuscular or intraperitoneal administration from
an external reservoir (e.g., an intravenous bag).
[0158] Where adhesion to a tissue surface is desired the
composition can include the drug dispersed in a fibrinogen-thrombin
composition or other bioadhesive. The compound then can be painted,
sprayed or otherwise applied to the desired tissue surface.
Alternatively, the drugs can be formulated for parenteral or oral
administration to humans or other mammals, for example, in
effective amounts, e.g., amounts that provide appropriate
concentrations of the drug to target tissue for a time sufficient
to induce the desired effect.
[0159] Where the active compound is to be used as part of a
transplant procedure, it can be provided to the living tissue or
organ to be transplanted prior to removal of tissue or organ from
the donor. The compound can be provided to the donor host.
Alternatively or, in addition, once removed from the donor, the
organ or living tissue can be placed in a preservation solution
containing the active compound. In all cases, the active compound
can be administered directly to the desired tissue, as by injection
to the tissue, or it can be provided systemically, either by oral
or parenteral administration, using any of the methods and
formulations described herein and/or known in the art. Where the
drug comprises part of a tissue or organ preservation solution, any
commercially available preservation solution can be used to
advantage. For example, useful solutions known in the art include
Collins solution, Wisconsin solution, Belzer solution, Eurocollins
solution and lactated Ringer's solution.
[0160] Active compound as identified or designed by the methods
described herein can be administered to individuals to treat
disorders (prophylactically or therapeutically). In conjunction
with such treatment, pharmacogenomics (i.e., the study of the
relationship between an individual's genotype and that individual's
response to a foreign compound or drug) may be considered.
Differences in metabolism of therapeutics can lead to severe
toxicity or therapeutic failure by altering the relation between
dose and blood concentration of the pharmacologically active drug.
Thus, a physician or clinician may consider applying knowledge
obtained in relevant pharmacogenomics studies in determining
whether to administer a drug as well as tailoring the dosage and/or
therapeutic regimen of treatment with the drug.
[0161] In therapeutic use for treating, or combating, bacterial
infections in mammals, the compounds or pharmaceutical compositions
thereof will be administered orally, parenterally and/or topically
at a dosage to obtain and maintain a concentration, that is, an
amount, or blood-level or tissue level of active component in the
animal undergoing treatment which will be anti-microbially
effective. The term "effective amount" is understood to mean that
the compound of the invention is present in or on the recipient in
an amount sufficient to elicit biological activity, for example,
anti-microbial activity, anti-fungal activity, anti-viral activity,
anti-parasitic activity, and/or anti-proliferative activity.
Generally, an effective amount of dosage of active component will
be in the range of from about 0.1 to about 100, more preferably
from about 1.0 to about 50 mg/kg of body weight/day. The amount
administered will also likely depend on such variables as the type
and extent of disease or indication to be treated, the overall
health status of the particular patient, the relative biological
efficacy of the compound delivered, the formulation of the drug,
the presence and types of excipients in the formulation, and the
route of administration. Also, it is to be understood that the
initial dosage administered may be increased beyond the above upper
level in order to rapidly achieve the desired blood-level or tissue
level, or the initial dosage may be smaller than the optimum and
the daily dosage may be progressively increased during the course
of treatment depending on the particular situation. If desired, the
daily dose may also be divided into multiple doses for
administration, for example, two to four times per day.
6. Examples
[0162] Exemplary compounds synthesized in accordance with the
invention are listed in Table 2.
TABLE-US-00002 TABLE 2 Compound Number Structure 1001 ##STR00068##
N-{3-[2-Fluoro-4'-(2-[1,2,3]triazol-1-yl-ethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1002 ##STR00069##
N-{3-[2-Fluoro-4'-(2-imidazol-1-yl-ethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1003 ##STR00070##
2-(4-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-piperazin-1-yl)-acetamide 1004 ##STR00071##
N-{3-[4'-(4-Cyanomethyl-piperazin-1-ylmethyl)-2-fluoro-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1005 ##STR00072##
N-{3-[4'-(4-Cyanomethyl-piperazin-1-ylmethyl)-2,3'-difluoro-biphenyl-
4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1006 ##STR00073##
N-{3-[2-Fluoro-4'-(4-formyl-piperazin-1-ylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1007 ##STR00074##
N-{3-[2-Fluoro-4'-(1H-tetrazol-5-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1008 ##STR00075##
N-[3-(2-Fluoro-4'-imidazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1009 ##STR00076##
N-[3-(2,3'-Difluoro-4'-[1,2,3]triazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1010 ##STR00077##
N-[3-(2,3'-Difluoro-4'-imidazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1011 ##STR00078##
N-{3-[4'-(4-Aminomethyl-[1,2,3]triazol-1-ylmethyl)-2-fluoro-biphenyl-
4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1012 ##STR00079##
N-{3-[2-Fluoro-4'-(4-methylaminomethyl-[1,2,3]triazol-1-ylmethy)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1013
##STR00080##
N-{3-[4'-(4-Dimethylaminomethyl-[1,2,3]triazol-1-ylmethyl)-2-fluoro-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1014
##STR00081##
N-(1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-1H-[1,2,3]triazol-4-ylmethyl)-2-amino-acetamide
1015 ##STR00082##
N-[3-(2-Fluoro-4'-[1,2,3]triazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1016 ##STR00083##
N-{3-[2-Fluoro-4'-(5-(S)-oxo-2,5-(S)-dihydro-[1,2,4]oxadiazol-3-
ylmethyl)-biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
1017 ##STR00084##
N-{3-[2-Fluoro-4'-(5-(S)-methyl-[1,2,4]oxadiazol-3-ylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1018
##STR00085##
N-{3-[2,6-Difluoro-4'-(4-hydroxymethyl-[1,2,3]triazol-1-ylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1019
##STR00086##
N-{3-[4'-(4-Dimethylaminomethyl-[1,2,3]triazol-1-ylmethyl)-2,6-
difluoro-biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
1020 ##STR00087##
N-[3-(2-Fluoro-4'-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-thiazol-4-
ylmethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
1021 ##STR00088##
N-(3-{2-Fluoro-4'-[2-(3-methoxy-benzylamino)-thiazol-4-ylmethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1022
##STR00089##
N-{3-[4'-(3-Cyano-azetidin-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1023 ##STR00090##
N-[3-(2-Fluoro-4-[1,2,3]triazol-2-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1024 ##STR00091##
N-{3-[4'-(5-Amino-tetrazol-2-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1025 ##STR00092##
N-{3-[4'-(5-Amino-tetrazol-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1026 ##STR00093##
1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-5-amino-1H-[1,2,3]triazole-4-carboxylic acid
amide 1027 ##STR00094##
N-{3-[2-Fluoro-4'-(7-oxo-6,7-dihydro-[1,2,3]triazolo[4,5-d]pyrimidin-
3-ylmethyl)-biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-
acetamide 1028 ##STR00095##
N-{3-[2-Fluoro-4'-(4-hydroxymethyl-[1,2,3]triazol-1-ylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1029
##STR00096##
N-(3-{2-Fluoro-4'-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1030
##STR00097##
N-(3-{2-Fluoro-4'-[4-(2-hydroxy-ethyl)-piperidin-1-ylmethyl]-biphenyl-
4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1031 ##STR00098##
N-{3-[4'-(R)-(1-Amino-2-imidazol-1-yl-ethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1032 ##STR00099##
5-(S)-Aminomethyl-3-(2-fluoro-4'-tetrazol-1-ylmethyl-biphenyl-4-yl)-
oxazolidin-2-one 1033 ##STR00100##
2-Chloro-N-[3-(2-fluoro-4'-tetrazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1034 ##STR00101##
2,2-Dichloro-N-[3-(2-fluoro-4'-tetrazol-1-ylmethyl-biphenyl-4-yl)-2-
oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 1035 ##STR00102##
N-{3-[3-Fluoro-4-(6-tetrazol-1-ylmethyl-pyridin-3-yl)-phenyl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1036 ##STR00103##
N-{3-[3-Fluoro-4-(6-[1,2,3]triazol-1-ylmethyl-pyridin-3-yl)-phenyl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1037 ##STR00104##
N-[3-(2-Fluoro-4'-[1,2,4]triazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1038 ##STR00105##
N-(3-{4'-[4-(3-Chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-
ylmethyl]-2-fluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-
acetamide 1039 ##STR00106##
[{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-yl}-(2H-tetrazol-5-(R/S)-yl)-methyl]-carbamic acid
benzyl ester 1040 ##STR00107##
N-(3-{4'-[Amino-(2H-tetrazol-5-(R/S)-yl)-methyl]-2-fluoro-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1041 ##STR00108##
[{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-yl}-(2-methyl-2H-tetrazol-5-(R/S)-yl)-methyl]-carbamic
acid benzyl ester 1042 ##STR00109##
N-(3-{4'-[Amino-(2-methyl-2H-tetrazol-5-(R/S)-yl)-methyl]-2-fluoro-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1043
##STR00110##
N-[3-(2-Fluoro-4'-pyrazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-oxazolidin-
5-(S)-ylmethyl]-acetamide 1044 ##STR00111##
N-(3-{2-Fluoro-4'-[2-(4-formyl-piperazin-1-yl)-1-(S)-hydroxy-ethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1045
##STR00112##
N-(3-{2-Fluoro-4'-[1-(R)-(4-formyl-piperazin-1-yl)-2-hydroxy-ethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1046
##STR00113##
N-{3-[2-Fluoro-4'-(1-(S)-hydroxy-2-imidazol-1-yl-ethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1047 ##STR00114##
N-[3-(2-Fluoro-4'-tetrazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-oxazolidin-
5-(S)-ylmethyl]-acetamide 1048 ##STR00115##
N-[3-(2,6-Difluoro-4'-tetrazol-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide
1049 ##STR00116##
1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-1H-pyrazole-4-carboxylic acid ethyl ester 1050
##STR00117##
N-{3-[2-Fluoro-4'-(4-hydroxymethyl-imidazol-1-ylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1051 ##STR00118##
1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-1H-pyrazole-4-carboxylic acid 1052
##STR00119##
N-{3-[2-Fluoro-4'-(4-methyl-pyrazol-1-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1053 ##STR00120##
N-{3-[4'-(3-Amino-pyrazol-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1054 ##STR00121##
N-[3-(2-Fluoro-4'-pyrrol-1-ylmethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-
(S)-ylmethyl]-acetamide 1055 ##STR00122##
N-{3-[2-Fluoro-4'-(3-formyl-pyrrol-1-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1056 ##STR00123##
N-[3-(2-Fluoro-4'-tetrazol-2-ylmethyl-biphenyl-4-yl)-2-oxo-oxazolidin-
5-(S)-ylmethyl]-acetamide 1057 ##STR00124##
3-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-5-amino-3H-imidazole-4-carboxylic acid amide
1058 ##STR00125##
N-{3-[2-Fluoro-4'-(5-methyl-tetrazol-1-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1059 ##STR00126##
N-{3-[2-Fluoro-4'-(5-methyl-tetrazol-2-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1060 ##STR00127##
N-(3-{2-Fluoro-4'-[1-(R)-hydroxy-2-(1H-tetrazol-5-yl)-ethyl]-biphenyl-
4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1061 ##STR00128##
N-{3-[2-Fluoro-4'-(1-(S)-hydroxy-2-[1,2,3]triazol-1-yl-ethyl)-biphenyl-
4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1062 ##STR00129##
N-{3-[4'-(2-Azetidin-1-yl-1-(S)-hydroxy-ethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1063 ##STR00130##
N-{3-[4'-[1-(R)-Azetidin-1-yl-2-hydroxy-ethyl)-2-fluoro-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1064 ##STR00131##
N-[3-(2-Fluoro-4'-thiomorpholin-4-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1065 ##STR00132##
N-{3-[2-Fluoro-4'-(1-oxo-1lambda*4*-thiomorpholin-4-ylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1066
##STR00133##
N-{3-[2-Fluoro-4'-(2-methyl-imidazol-1-ylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1067 ##STR00134##
N-{3-[2-Fluoro-4'-(5-methyl-imidazol-1-ylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1068 ##STR00135##
N-{3-[4'-(2,4-Dimethyl-imidazol-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1069 ##STR00136##
N-{3-[4'-(3-Amino-[1,2,4]triazol-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1070 ##STR00137##
N-[3-(2-Fluoro-4'-thiazolidin-3-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1071 ##STR00138##
N-{3-[3-Fluoro-4-(6-pyrrol-1-ylmethyl-pyridin-3-yl)-phenyl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1072 ##STR00139##
N-{3-[3-Fluoro-4-(6-[1,2,4]triazol-1-ylmethyl-pyridin-3-yl)-phenyl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1073 ##STR00140##
N-{3-[2-Fluoro-4'-(2-hydroxy-1-(R)-[1,2,3]triazol-1-yl-ethyl)-biphenyl-
4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1074 ##STR00141##
N-(3-{4'-[1-(R)-(3,3-Difluoro-piperidin-1-yl)-2-hydroxy-ethyl]-2-
fluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
1075 ##STR00142##
N-(3-{4'-[2-(3,3-Difluoro-piperidin-1-yl)-1-(S)-hydroxy-ethyl]-2-
fluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
1076 ##STR00143##
N-{3-[3-Fluoro-4-(6-pyrazol-1-ylmethyl-pyridin-3-yl)-phenyl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1077 ##STR00144##
N-{3-[3-Fluoro-4-(6-imidazol-1-ylmethyl-pyridin-3-yl)-phenyl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1078 ##STR00145##
N-{3-[2-Fluoro-4'-(2-methylsulfanyl-4,5-dihydro-imidazol-1-ylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1079
##STR00146##
N-{3-[2-Fluoro-4'-(5-methylsulfanyl-tetrazol-1-ylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1080 ##STR00147##
N-{3-[2-Fluoro-4'-(5-methylsulfanyl-tetrazol-2-ylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1081 ##STR00148##
N-{3-[4'-(5-Ethylsulfanyl-tetrazol-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1082 ##STR00149##
N-{3-[4'-(5-Ethylsulfanyl-tetrazol-2-ylmethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1083 ##STR00150##
N-{3-[4'-(5-Chloro-tetrazol-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1084 ##STR00151##
3-(2-Fluoro-4'-imidazol-1-ylmethyl-biphenyl-4-yl)-5-(R)-[1,2,3]triazol-
1-ylmethyl-oxazolidin-2-one 1085 ##STR00152##
3-(2-Fluoro-4'-pyrazol-1-ylmethyl-biphenyl-4-yl)-5-(R)-[1,2,3]triazol-1-
ylmethyl-oxazolidin-2-one 1086 ##STR00153##
N-{3-[2-Fluoro-4'-(1H-imidazol-4-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1087 ##STR00154##
N-{3-[2-Fluoro-4'-(3-(S)-hydroxy-pyrrolidin-1-ylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1088 ##STR00155##
N-{3-[2-Fluoro-4'-(3-(R)-hydroxy-pyrrolidin-1-ylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1089 ##STR00156##
N-{3-[2,6-Difluoro-4'-(4-hydroxymethyl-[1,2,3]triazol-1-ylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1090
##STR00157##
N-[3-(4'-Azetidin-1-ylmethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-
5-(S)-ylmethyl]-acetamide 1091 ##STR00158##
N-{3-[4'-(3-(R)-Amino-pyrrolidin-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1092 ##STR00159##
N-{3-[4'-(3-(S)-Amino-pyrrolidin-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1093 ##STR00160##
1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-pyrrolidine-3-(R/S)-carboxylic acid amide 1094
##STR00161##
N-{3-[2-Fluoro-4'-(4-fluoro-piperidin-1-ylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1095 ##STR00162##
N-{3-[2-Fluoro-4'-(5-fluoromethyl-2-oxo-oxazolidin-3-(R/S)ylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1096
##STR00163##
N-{3-[2-Fluoro-4'-(3-(R/S)-fluoro-piperidin-1-ylmethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1097 ##STR00164##
N-{3-[4'-(3,3-Difluoro-piperidin-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1098 ##STR00165##
N-(3-{2-Fluoro-4'-[6-(3-fluoro-propylamino)-purin-9-ylmethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
1099 ##STR00166##
N-(3-{2-Fluoro-4'-[6-(2-hydroxy-ethylamino)-purin-9-ylmethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1100
##STR00167##
N-{3-[4'-(6-Chloro-purin-9-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1101 ##STR00168##
N-{3-[2-Fluoro-4'-(2-oxo-oxazolidin-3-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1102 ##STR00169##
N-(3-{2-Fluoro-4'-[6-(2-fluoro-ethylamino)-purin-9-ylmethyl]-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1103
##STR00170##
N-(3-{4'-[6-(2,2-Difluoro-ethylamino)-purin-9-ylmethyl]-2-fluoro-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1104
##STR00171##
N-(3-{2-Fluoro-4'-[6-(2,2,2-trifluoro-ethylamino)-purin-9-ylmethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1105
##STR00172##
N-{3-[4'-(6-Dimethylamino-purin-9-ylmethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1106 ##STR00173##
N-{3-[2-Fluoro-4'-(6-methylamino-purin-9-ylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1107 ##STR00174##
N-(3-{2-Fluoro-4'-[6-(3-hydroxy-propylamino)-purin-9-ylmethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1108
##STR00175##
N-(3-{2-Fluoro-4'-[6-(2-methylsulfanyl-ethylamino)-purin-9-ylmethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1109
##STR00176##
N-(3-{2-Fluoro-4'-[6-(4-hydroxy-butylamino)-purin-9-ylmethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 1110
##STR00177##
N-{3-[4'-(6-Amino-purin-9-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1111 ##STR00178##
N-{3-[2-Fluoro-4'-(6-oxo-1,6-dihydro-purin-9-ylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1112 ##STR00179##
N-[3-(2-Fluoro-4'-isoxazolidin-2-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1113 ##STR00180##
N-{3-[4'-(2-Amino-imidazol-1-ylmethyl)-2-fluoro-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1114 ##STR00181##
N-{3-[2-Fluoro-4'-(7-oxo-4,5-dihydro-[1,2,3]triazolo[1,5-c]pyrimidin-6-
ylmethyl)-biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
1115 ##STR00182##
N-[3-(2-Fluoro-4'-pyrrolidin-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1116 ##STR00183##
N-[3-(2-Fluoro-4'-piperidin-1-ylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 1117 ##STR00184##
N-{3-[2-Fluoro-4'-(1-(S)-hydroxy-2-morpholin-4-yl-ethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1118 ##STR00185##
N-{3-[2-Fluoro-4'-(2-hydroxy-1-(R)-morpholin-4-yl-ethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1119 ##STR00186##
(1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-pyrrolidin-3-(R)-yl)-carbamic acid tert-butyl
ester 1120 ##STR00187##
(1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-pyrrolidin-3-(S)-yl)-carbamic acid tert-butyl
ester 1121 ##STR00188##
1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-piperidine-3-(R/S)-carboxylic acid amide 1122
##STR00189##
1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-pyrrolidine-2-(S)-carboxylic acid amide 1123
##STR00190##
N-{3-[2-Fluoro-4'-(3-oxo-piperazin-1-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1124 ##STR00191##
N-{3-[4'-(2,2-Dimethyl-4-oxo-imidazolidin-1-ylmethyl)-2-fluoro-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1125
##STR00192##
1-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-azetidine-3-(R/S)-carboxylic acid amide 1126
##STR00193##
1-{4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-azetidine-2-carboxylic acid amide 1127
##STR00194##
N-{3-[2-Fluoro-4'-(2-oxo-piperazin-1-ylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 1128 ##STR00195##
2-(4-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-oxo-piperazin-1-yl)-acetamide 1129
##STR00196##
N-{3-[4'-(4-Cyanomethyl-2-oxo-piperazin-1-ylmethyl)-2-fluoro-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 1130
##STR00197##
N-{3-[2-Fluoro-4'-(2-oxo-4-[1,2,3]thiadiazol-4-ylmethyl-piperazin-1-
ylmethyl)-biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
2001 ##STR00198##
N-{3-[2-Fluoro-4'-(5-methyl-isoxazol-3-yloxymethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2002 ##STR00199##
N-{3-[2-Fluoro-4'-([1,2,4]triazol-4-ylaminomethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2003 ##STR00200##
N-(3-{2-Fluoro-4'-[(3-methyl-isoxazol-5-ylamino)-methyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2004 ##STR00201##
N-(3-{2-Fluoro-4'-[(5-methyl-isoxazol-3-ylamino)-methyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2005 ##STR00202##
4-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-piperidine-1-carboxylic acid ethyl
ester 2006 ##STR00203##
N-(3-{4'-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-2-fluoro-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2007
##STR00204##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-benzamide 2008 ##STR00205##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-thiophene-3-carboxylic acid amide 2009
##STR00206##
N-(3-{2-Fluoro-4'-[(3-oxo-isoxazolidin-4-(R)-ylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2010
##STR00207##
N-(3-{2-Fluoro-4'-[(3-oxo-isoxazolidin-4-(S)-ylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2011
##STR00208##
N-{3-[4'-(Azetidin-3-(R/S)-ylaminomethyl)-2-fluoro-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2012 ##STR00209##
N-(3-{4'-[(3-Aminomethyl-[1,2,4]thiadiazol-5-ylamino)-methyl]-2-
fluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
2013 ##STR00210##
N-[5-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-
fluoro-biphenyl-4-ylmethyl}-amino)-[1,2,4]thiadiazol-3-ylmethyl]-2-
(S)-amino-propionamide 2014 ##STR00211## 2,6-Diamino-hexanoic
acid[5-({4'-[5-(acetylamino-methyl)-2-oxo-
oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amino)-
[1,2,4]thiadiazol-3-ylmethyl]-amide 2015 ##STR00212##
N-{3-[2-Fluoro-4'-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-biphenyl-
4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2016 ##STR00213##
N-{3-[2-Fluoro-4'-(3H-[1,2,3]triazol-4-ylsulfanylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2017 ##STR00214##
N-{3-[4'-(4,6-Dioxo-1,4,5,6-tetrahydro-pyrimidin-2-ylsulfanylmethyl)-
2-fluoro-biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
2018 ##STR00215##
N-{3-[2-Fluoro-4'-(pyridin-2-ylsulfanylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2019 ##STR00216##
N-{3-[2-Fluoro-4'-(pyridin-4-ylsulfanylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2020 ##STR00217##
N-{3-[2-Fluoro-4'-(1-methyl-1H-tetrazole-5-sulfinylmethyl)-biphenyl-
4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2021 ##STR00218##
N-{3-[2-Fluoro-4'-(3H-[1,2,3]triazole-4-sulfinylmethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2022 ##STR00219##
N-{3-[2-Fluoro-4'-(pyridine-4-sulfinylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2023 ##STR00220##
N-{3-[2-Fluoro-4'-(pyridine-2-sulfinylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2024 ##STR00221##
N-{3-[2-Fluoro-4'-(1-methyl-1H-tetrazole-5-sulfonylmethyl)-biphenyl-
4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2025 ##STR00222##
N-{3-[2-Fluoro-4'-(3H-[1,2,3]triazole-4-sulfonylmethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2026 ##STR00223##
N-(3-{2-Fluoro-4'-[2-(3H-[1,2,3]triazol-4-ylsulfanyl)-ethyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2027 ##STR00224##
N-(3-{4'-[1-(2-Dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-
2-fluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
2028 ##STR00225##
N-{3-[4'-(5-Amino-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-2-fluoro-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2029
##STR00226##
N-{3-[2-Fluoro-4'-([1,3,4]thiadiazol-2-ylsulfanylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2030 ##STR00227##
N-{3-[2-Fluoro-4'-(thiazol-2-ylsulfanylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2031 ##STR00228##
N-{3-[2-Fluoro-4'-(4-methyl-thiazol-2-ylsulfanylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2032 ##STR00229##
N-{3-[2-Fluoro-4'-(1H-imidazol-2-ylsulfanylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2033 ##STR00230##
N-{3-[2-Fluoro-4'-(2-methyl-2H-[1,2,4]triazol-3-ylsulfanylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2034
##STR00231##
N-{3-[2-Fluoro-4'-(2-methyl-2H-[1,2,4]triazol-3-ylsulfanylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2035
##STR00232##
N-{3-[2-Fluoro-4'-([1,3,4]thiadiazole-2-sulfinylmethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2036 ##STR00233##
N-{3-[2-Fluoro-4'-(thiazole-2-sulfinylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2037 ##STR00234##
N-{3-[2-Fluoro-4'-(4-methyl-thiazole-2-sulfinylmethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2038 ##STR00235##
N-{3-[2-Fluoro-4'-(1H-imidazole-2-sulfinylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2039 ##STR00236##
N-{3-[2-Fluoro-4'-(2-methyl-2H-[1,2,4]triazole-3-sulfinylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2040
##STR00237##
N-(3-{3-Fluoro-4-[6-(3H-[1,2,3]triazol-4-ylsulfanylmethyl)-pyridin-3-
yl]-phenyl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2041
##STR00238##
N-{3-[2-Fluoro-4'-(pyridin-2-yl-hydrazonomethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2042 ##STR00239##
N-(3-{2-Fluoro-4'-[(4-trifluoromethyl-pyrimidin-2-yl)-
hydrazonomethyl]-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-
acetamide 2043 ##STR00240##
N-(3-{2-Fluoro-4'-[(1-methyl-1H-imidazole-4-sulfonylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2044
##STR00241##
N-(3-{2-Fluoro-4'-[(6-morpholin-4-yl-pyridine-3-sulfonylamino)-
methyl]-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
2045 ##STR00242##
N-{3-[2-Fluoro-4'-(pyridin-3-ylsulfamoylmethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2046 ##STR00243##
N-{3-[2-Fluoro-4'-([1,2,4]triazol-4-ylaminomethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2047 ##STR00244##
N-{3-[2-Fluoro-4'-(2H-[1,2,4]triazol-3-ylsulfanylmethyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2048 ##STR00245##
N-{3-[2-Fluoro-4'-(N'-pyridin-2-yl-hydrazinomethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 2049 ##STR00246##
N-(3-{4'-[N'-(4,5-Dihydro-1H-imidazol-2-yl)-hydrazinomethyl]-2-
fluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
2050 ##STR00247##
N-{3-[2-Fluoro-4'-(isoxazol-3-ylaminomethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2051 ##STR00248##
N-(3-{2-Fluoro-4'-[(quinoline-8-sulfonylamino)-methyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2052 ##STR00249##
N-(3-{2-Fluoro-4'-[(1-methyl-1H-imidazole-4-sulfonylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2053
##STR00250##
N-(3-{2-Fluoro-4'-[(6-morpholin-4-yl-pyridine-3-sulfonylamino)-
methyl]-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
2054 ##STR00251## N-{3-[2-Fluoro-4
'-pyridin-3-ylsulfamoylmethyl)-biphenyl-4-yl]2-oxo-
oxazolidin-5-(S)-ylmethyl}acetamide 2055 ##STR00252##
5-({4'[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-3H-imidazole-4-carboxylic acid amide
2056 ##STR00253##
N-{3-[2-Fluoro-4'-(morpholin-4-yliminomethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 2057 ##STR00254##
N-(3-{2-Fluoro-4'-[(4-methyl-piperazin-1-ylamino)-methyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2058 ##STR00255##
N-(3-{2-Fluoro-4'-[(4-trifluoromethyl-benzenesulfonylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 2059
##STR00256##
N-(3-{2-Fluoro-4'-[(2-oxo-piperidin-3-(S)-ylamino)-methyl]-biphenyl-
4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 3001 ##STR00257##
N-{3-[2-Fluoro-4'-(pyridin-4-ylmethylsulfanyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 3002 ##STR00258##
N-{3-[2-Fluoro-4'-(pyridin-4-ylmethanesulfinyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 3003 ##STR00259##
N-{3-[2-Fluoro-4'-(pyridin-4-ylmethanesulfonyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 3004 ##STR00260##
N-{3-[2-Fluoro-4'-(1-oxy-pyridin-4-ylmethanesulfonyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 3005 ##STR00261##
N-(3-{2-Fluoro-4'-[(pyridin-4-ylmethyl)-sulfamoyl]-biphenyl-4-yl}-2-
oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 3006 ##STR00262##
N-(3-{2-Fluoro-4'-[(pyridin-2-ylmethyl)-sulfamoyl]-biphenyl-4-yl}-2-
oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 3007 ##STR00263##
N-{3-[2-Fluoro-4'-(2-pyridin-2-yl-ethylsulfamoyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4001 ##STR00264##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-(6-methyl-2,4-dioxo-1,2,3,4-tetrahydro-
pyrimidin-5-yl)-acrylamide
4002 ##STR00265##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-pyridin-3-yl-acrylamide 4003 ##STR00266##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-(2,4-dimethoxy-6-methyl-pyrimidin-5-yl)-
acrylamide 4004 ##STR00267##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-(4-hydroxy-2-methoxy-6-methyl-pyrimidin-5-
yl)-acrylamide 4005 ##STR00268##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-
pyrimidin-5-yl)-acrylamide 4006 ##STR00269##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-pyrimidin-5-yl-acrylamide 4007 ##STR00270##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-(1-methyl-6-oxo-1,6-dihydro-pyrimidin-5-yl)-
acrylamide 4008 ##STR00271## Quinoline-4-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-oxo-
oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4009
##STR00272## Quinoline-3-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-oxo-
oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4010
##STR00273## 1-Methyl-1H-pyrrole-2-carboxylic acid
{4'-[5-(S)-(acetylamino-
methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide
4011 ##STR00274## 1H-Indole-6-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-oxo-
oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4012
##STR00275##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-methanesulfonyl-benzamide 4013 ##STR00276##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-4-fluoro-benzamide 4014 ##STR00277##
Benzo[1,3]dioxole-5-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-
oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4015
##STR00278## 5-Methoxy-1H-indole-2-carboxylic acid
{4'-[5-(S)-(acetylamino-
methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide
4016 ##STR00279##
N-[3-(2-Fluoro-4'-{[(quinolin-4-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}- acetamide 4017 ##STR00280##
N-(3-{2-Fluoro-4'-[(4-pyridin-2-yl-benzylamino)-methyl}-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4018 ##STR00281##
N-[3-(2-Fluoro-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4019 ##STR00282##
N-[3-(2-Fluoro-4'-{[(quinolin-2-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4020 ##STR00283##
N-[3-(4'-{[(Benzofuran-2-ylmethyl)-amino]-methyl}-2-fluoro-biphenyl-
4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4021 ##STR00284##
N-[3-(2-Fluoro-4'-{[(quinolin-3-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4022 ##STR00285##
N-[3-(2-Fluoro-4'-{[(naphthalen-1-ylmethyl)-amino]-methyl}-biphenyl-
4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4023 ##STR00286##
N-[3-(2-Fluoro-4'-{[(furan-3-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-
2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4024 ##STR00287##
N-[3-(2-Fluoro-4'-{[(pyridin-2-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4025 ##STR00288##
N-[3-(2-Fluoro-4'-{[(pyridin-3-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4026 ##STR00289##
N-{3-(2-Fluoro-4'-{[(furan-2-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-
2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4027 ##STR00290##
N-[3-(2-Fluoro-2'-methoxy-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4028
##STR00291##
N-[3-(2-Fluoro-4'-{[(furan-3-ylmethyl)-amino]-methyl}-2'-methoxy-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4029
##STR00292##
N-[3-(2-Fluoro-4'-{2-hydroxy-1-(R)-[(pyridin-4-ylmethyl)-amino]-
ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4030 ##STR00293##
N-[3-(4'-{1-(R)-[(2,4-Dihydroxy-6-methyl-pyrimidin-5-ylmethyl)-
amino]-2-hydroxy-ethyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-
(S)-ylmethyl]-acetamide 4031 ##STR00294##
N-[3-(2-Fluoro-4'-{2-hydroxy-1-(R)-[(quinolin-4-ylmethyl)-amino]-
ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4032 ##STR00295##
N-(3-{2-Fluoro-4'-[(methyl-quinolin-4-ylmethyl-amino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)- acetamide 4033
##STR00296##
N-(3-{2-Fluoro-2'-methoxy-4'-[(methyl-pyridin-4-ylmethyl-amino)-
methyl]-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
4034 ##STR00297##
N-(3-{2-Fluoro-4'-[(furan-3-ylmethyl-methyl-amino)-methyl]-2'-
methoxy-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
4035 ##STR00298##
N-(3-{4'-[(Ethyl-pyridin-4-ylmethyl-amino)-methyl]-2-fluoro-biphenyl-
4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4036 ##STR00299##
N-[3-(4'-{[(2,4-Dihydroxy-6-methyl-pyrimidin-5-ylmethyl)-methyl-
amino]-methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 4037 ##STR00300##
N-[3-(4'-{[Bis-(4-hydroxy-3-methoxy-benzyl)-amino]-methyl}-2-
fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
4038 ##STR00301##
N-[3-(2-Fluoro-4'-{[(isoxazol-4-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4039 ##STR00302##
N-(3-{2-Fluoro-2'-methoxy-4'-[(methyl-pyridin-4-ylmethyl-amino)-
methyl]-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
4040 ##STR00303##
N-[3-(2-Fluoro-2'-methoxy-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4041
##STR00304##
N-(3-{2-Fluoro-2'-methoxy-4'-[(methyl-pyridin-4-ylmethyl-amino)-
methyl]-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
4042 ##STR00305##
N-[3-(2-Fluoro-4'-{[(furan-3-ylmethyl)-amino]-methyl}-2'-methoxy-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4043
##STR00306##
N-(3-{2-Fluoro-4'-[(furan-3-ylmethyl-methyl-amino)-methyl]-2'-
methoxy-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
4044 ##STR00307##
N-(3-{2-Fluoro-4'-[(methyl-pyridin-4-ylmethyl-amino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4045
##STR00308##
N-(3-{2-Fluoro-4'-[(methyl-pyridin-2-ylmethyl-amino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4046
##STR00309##
N-[3-(4'-{[(3,5-Dichloro-benzyl)-methyl-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4047
##STR00310##
N-(3-{2-Fluoro-4'-[(methyl-pyridin-3-ylmethyl-amino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4048
##STR00311##
N-[3-(2-Fluoro-4'-{[(1H-pyrrol-2-ylmethyl)-amino]-methyl}-biphenyl-
4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4049 ##STR00312##
N-[3-(2-Fluoro-4'-{[(1-methyl-1H-indol-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4050
##STR00313## 1H-Indole-6-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-oxo-
oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-methyl-amide 4051
##STR00314## 1-Methyl-1H-pyrrole-2-carboxylic acid
{4'-[5-(S)-(acetylamino-
methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-methyl-
amide 4052 ##STR00315##
N-{3-[3-Fluoro-4-(5-{[(pyridin-4-ylmethyl)-amino]-methyl}-pyridin-2-
yl)-phenyl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4053
##STR00316##
N-{3-[3-Fluoro-4-(5-{[(furan-3-ylmethyl)-amino]-methyl}-pyridin-2-
yl)-phenyl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4054
##STR00317##
N-[3-(2-Fluoro-4'-{[(6-methoxy-pyridin-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4055
##STR00318##
N-[3-(2-Fluoro-4'-{[(6-methoxy-pyridin-3-ylmethyl)-methyl-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4056 ##STR00319##
N-(3-{4'-[(2,5-Bis-trifluoromethyl-benzylamino)-methyl]-2-fluoro-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4057
##STR00320##
N-[3-(2-Fluoro-4'-{[(6-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-
5-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 4058 ##STR00321##
N-[3-(2-Fluoro-4'-{[(furan-3-ylmethyl)-amino]-methyl]-2'-methoxy-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4059
##STR00322##
N-[3-(2-Fluoro-4'-{[(1-methyl-1H-pyrrol-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4060
##STR00323##
N-[3-(2-Fluoro-4'-{[(isoquinolin-4-ylmethyl)-amino]-methyl}-biphenyl-
4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4061 ##STR00324##
N-(3-{2-Fluoro-4'-[(furan-3-ylmethyl-methyl-amino)-methyl]-biphenyl-
4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4062 ##STR00325##
N-(3-{4'-[(4-Dimethylamino-benzylamino)-methyl]-2-fluoro-biphenyl-
4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4063 ##STR00326##
N-(3-{4'-[(4-Chloro-benzylamino)-methyl]-2-fluoro-biphenyl-4-yl}-2-
oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4064 ##STR00327##
N-(3-{4'-[(2,4-Dichloro-benzylamino)-methyl]-2-fluoro-biphenyl-4-yl}-
2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4065 ##STR00328##
N-[3-(2-Fluoro-4'-{[(isoquinolin-5-ylmethyl)-amino]-methyl}-biphenyl-
4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4066 ##STR00329##
N-[3-(2-Fluoro-4'-{[(3H-imidazol-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4067
##STR00330##
N-[3-(2-Fluoro-4'-{[(3H-imidazol-4-ylmethyl)-methyl-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4068
##STR00331##
N-[3-(2-Fluoro-4'-{[(1H-imidazol-4-ylmethyl)-(3H-imidazol-4-
ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 4069 ##STR00332##
N-[3-(2-Fluoro-4'-{[(5-nitro-furan-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4070
##STR00333##
N-(3-{4'-[(3-Cyano-benzylamino)-methyl]-2-fluoro-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4071 ##STR00334##
N-[3-(2-Fluoro-4'-{[(quinolin-6-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4072 ##STR00335##
N-[3-(2-Fluoro-4'-{[(6-methyl-pyridin-2-ylmethyl)-amino]methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4073
##STR00336##
N-{3-[3-Fluoro-4-(6-{[(pyridin-4-ylmethyl)-amino]-methyl}-pyridin-3-
yl)-phenyl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4074
##STR00337##
N-[3-(2-Fluoro-4'-{[(thiazol-2-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4075 ##STR00338##
N-[3-(2-Fluoro-4'-{[(5-hydroxymethyl-furan-2-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
4076 ##STR00339##
N-[3-(2-Fluoro-4'-{[(1-methyl-1H-imidazol-2-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4077 ##STR00340##
N-[3-(4'-{[(Benzo[b]thiophen-3-ylmethyl)-amino)-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4078
##STR00341##
N-[3-(4'-{[(5-Bromo-furan-2-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4079
##STR00342##
N-(3-{2-Fluoro-4'-[(3-imidazol-1-yl-propylamino)-methyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4080 ##STR00343##
N-{3-[2-Fluoro-4'-(N-pyridin-4-ylmethyl-carbamimidoyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4081 ##STR00344##
N-[3-(2-Fluoro-4'-{[(5-methyl-furan-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4082
##STR00345##
N-[3-(2-Fluoro-4'-{[(5-methyl-3H-imidazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4083 ##STR00346##
N-[3-(2-Fluoro-4'-{[(1H-indol-3-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4084 ##STR00347##
N-[3-(2-Fluoro-4'-{[(5-phenyl-thiophen-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4085
##STR00348##
N-[3-(4'-{[(4,5-Dimethyl-furan-2-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4086
##STR00349##
N-[3-(2-Fluoro-4'-{[(thiophen-3-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4087 ##STR00350##
N-(3-{2-Fluoro-4'-[(2-pyridin-2-yl-ethylamino)-methyl]-biphenyl-4-yl}-
2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4088 ##STR00351##
N-[2-Oxo-3-(2,2',3'-trifluoro-4'-{[(furan-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-oxazolidin-5-(S)-ylmethyl]-acetamide 4089
##STR00352##
N-[2-Oxo-3-(2,2',3'-trifluoro-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-oxazolidin-5-(S)-ylmethyl]-acetamide 4090
##STR00353##
N-[2-Oxo-3-(2,2',3'-trifluoro-4'-{[pyridin-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-oxazolidin-5-(S)-ylmethyl]-acetamide 4091
##STR00354##
N-[3-(2-Fluoro-4'-{[(1H-imidazol-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4092
##STR00355##
N-[3-(4'-{[(1H-Benzoimidazol-2-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4093
##STR00356##
N-(3-{2-Fluoro-4'-[(4-sulfamoyl-benzylamino)-methyl]-biphenyl-4-yl}-
2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4094 ##STR00357##
N-[3-(2-Fluoro-4'-{[2-(4-sulfamoyl-phenyl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4095
##STR00358##
N-[3-(2-Fluoro-4'-{[(3-hydroxy-5-hydroxymethyl-2-methyl-pyridin-4-
ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 4096 ##STR00359##
N-[3-(2-Fluoro-4'-{[2-(4-methyl-thiazol-5-yl-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4097
##STR00360##
N-{3-[2-Fluoro-4'-(N-pyridin-2-ylmethyl-carbamimidoyl)-biphenyl-4-
yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4098 ##STR00361##
N-[3-(2-Fluoro-4'-{[(5-methoxy-1H-indol-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4099
##STR00362##
N-[3-(2-Fluoro-4'-{[(3-methyl-thiophen-2-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4100 ##STR00363##
N-[3-(4'-{[(1-Benzenesulfonyl-1H-pyrrol-2-ylmethyl)-amino]-methyl}-
2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4101 ##STR00364##
N-[3-(4'-{[(2,4-Dioxo-1,2,3,4-tetrahydro-pyrimidin-5-ylmethyl)-
amino]-methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 4102 ##STR00365##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid (pyridin-4-ylmethyl)-amide 4103
##STR00366##
N-[3-(4'-{[(2,5-Dimethyl-furan-3-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4104
##STR00367##
N-[3-(2-Fluoro-4'-{[(5-methyl-3-phenyl-isoxazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4105 ##STR00368##
N-[3-(2-Fluoro-4'-{[(5-methyl-2-trifluoromethyl-furan-3-ylmethyl)-
amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4106 ##STR00369##
N-{4'-[5-(R)-(Acetylamino-methyl)-4,5-dihydro-isoxazol-3-yl]-
biphenyl-4-ylmethyl}-phthalamic acid 4107 ##STR00370##
N-(4-{5-[5-(R)-(Acetylamino-methyl)-4,5-(S)-dihydro-isoxazol-3-yl]-
pyridin-2-yl}-benzyl)-phthalamic acid 4108 ##STR00371##
N-[3-(4'-{[(2,4-Dimethyl-thiazol-5-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4109
##STR00372##
N-[3-(4'-{[(3,5-Dimethyl-isoxazol-4-ylmethyl)-amino]-methyl}-2-
fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4110 ##STR00373##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid (pyridin-2-ylmethyl)-amide 4111
##STR00374##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid (furan-2-ylmethyl)-amide 4112
##STR00375##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid[2-(4-methyl-thiazol-5-yl)-ethyl]-amide
4113 ##STR00376##
N-[3-(2-Fluoro-4'-{[(2-thiophen-2-yl-thiazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4114 ##STR00377##
N-[3-(2-Fluoro-4'-{[2-(2-oxo-imidazolidin-1-yl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4115
##STR00378##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid (2-pyridin-2-yl-ethyl)-amide 4116
##STR00379##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid[2-(3H-imidazol-4-yl)-ethyl]-amide 4117
##STR00380##
N-[3-(2-Fluoro-4'-{[(2-morpholin-4-yl-pyridin-3-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4118 ##STR00381##
N-[3-(2-Fluoro-4'-{[(6-morpholin-4-yl-pyridin-3-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4119 ##STR00382##
N-[3-(2-Fluoro-4'-{[(5-pyridin-2-yl-thiophen-2-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4120 ##STR00383##
5-[({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-methyl]-2-methyl-furan-3-carboxylic
acid methyl ester 4121 ##STR00384##
N-[3-(4'-{[(Benzothiazol-2-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4122
##STR00385##
N-[3-(2-Fluoro-4'-{[(2-phenyl-thiazol-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4123
##STR00386##
N-[3-(2-Fluoro-4'-{[(2-phenyl-1H-imidazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4124 ##STR00387##
N-[3-(4'-{[(2-Ethyl-3H-imidazol-4-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4125
##STR00388##
N-[3-(4'-{[(5-Chloro-1-methyl-3-trifluoromethyl-1H-pyrazol-4-
ylmethyl)-amino]-methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-
(S)-ylmethyl]-acetamide 4126 ##STR00389##
N-[3-(4'-{[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-ylmethyl)-amino]-
methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4127 ##STR00390##
N-[3-(2-Fluoro-4'-{[(3-thiophen-2-yl-1H-pyrazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4128 ##STR00391##
N-[3-(4'-{[(5-Cyano-6-methylsulfanyl-pyridin-2-ylmethyl)-amino]-
methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4129 ##STR00392##
N-[3-(4'-{[(2-Amino-4-oxo-4H-chromen-3-ylmethyl)-amino]-methyl}-
2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4130 ##STR00393##
N-[3-(2-Fluoro-4'-{[(2-methyl-5-phenyl-furan-3-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4131 ##STR00394##
N-[3-(4'-{[(3,4-Dihydro-2H-pyran-2-ylmethyl)-amino]-methyl}-2-
fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4132 ##STR00395##
N-[3-(4'-{[(Pyridin-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-4,5-
dihydro-isoxazol-5-(R)-ylmethyl]-acetamide 4133 ##STR00396##
N-{3-[6-(4-{[(Pyridin-4-ylmethyl)-amino]-methyl}-phenyl)-pyridin-3-
yl]-4,5-dihydro-isoxazol-5-(R)-ylmethyl}-acetamide 4134
##STR00397##
N-{2-Oxo-3-[6-(4-{[(pyridin-4-ylmethyl)-amino]-methyl}-phenyl)-
pyridin-3-yl]-oxazolidin-5-(S)-ylmethyl}-acetamide 4135
##STR00398##
N-[3-(4'-{[(4-Amino-pyridin-3-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4136
##STR00399## N-[3-(4'-{[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-
ethanesulfonylamino]-methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 4137 ##STR00400##
N-[3-(2-Fluoro-4'-{[(thiophen-2-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4138 ##STR00401##
N-[3-(2-Fluoro-4'-{[(quinolin-7-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4139 ##STR00402##
N-[3-(4'-{[(4-Chloro-1-methyl-1H-pyrazol-3-ylmethyl)-amino]-
methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4140 ##STR00403##
N-[3-(2-Fluoro-4'-{[(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4141 ##STR00404##
N-[3-(2-Fluoro-4'-{[(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4142 ##STR00405##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-isonicotinamide 4143 ##STR00406##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid (thiazol-2-ylmethyl)-amide 4144
##STR00407##
N-[3-(2-Fluoro-4'-{1-(R/S)-[(furan-3-ylmethyl)-amino]-ethyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4145
##STR00408##
N-[3-(2-Fluoro-4'-{1-(R/S)-[(thiazol-2-ylmethyl)-amino]-ethyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4146
##STR00409##
N-[3-(2-Fluoro-4'-{[(5-methyl-2-phenyl-2H-[1,2,3]triazol-4-ylmethyl)-
amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4147 ##STR00410##
N-(3-{2-Fluoro-4'-[(4-pyrrol-1-yl-benzylamino)-methyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4148
##STR00411##
N-[3-(2-Fluoro-4'-{[3-(5-methyl-1H-pyrazol-4-yl)-propylamino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4149 ##STR00412##
N-[3-(2-Fluoro-4'-{2-[(pyridin-4-ylmethyl)-amino]ethyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4150 ##STR00413##
N-[3-(2-Fluoro-4'-{[2-(R/S)-(1-methyl-pyrrolidin-2-yl)-ethylamino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4151 ##STR00414##
N-[3-(2-Fluoro-4'-{[(2-methoxy-pyridin-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4152
##STR00415##
N-[3-(4'-{[(2-Amino-pyridin-3-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4153
##STR00416##
N-[3-(2-Fluoro-4'-{[(pyrrolidin-3-(R/S)-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4154
##STR00417##
N-[3-(2,3'-Difluoro-4'-{[(thiazol-2-ylmethyl)-amino]-methyl}-biphenyl-
4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4155 ##STR00418##
N-[3-(2,3'-Difluoro-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4156
##STR00419##
N-[3-(2-Fluoro-4'-{[3-(2-oxo-pyrrolidin-1-yl)-propylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4157
##STR00420##
4-[({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-methyl]-1-cyclopropyl-2,5-dimethyl-1H-
pyrrole-3-carboxylic acid ethyl ester 4158 ##STR00421##
N-{3-[2-Fluoro-4'-({[5-(3-sulfamoyl-phenyl)-furan-2-ylmethyl]-
amino}-methyl)-biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-
acetamide 4159 ##STR00422##
N-(3-{2-Fluoro-4'-[(1-pyridin-4-(R/S)-yl-ethylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4160
##STR00423##
N-(3-{2-Fluoro-4'-[1-(R/S)-(1-pyridin-4-(R/S)-yl-ethylamino)-ethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4161
##STR00424##
N-[3-(4'-{[(5-Ethyl-furan-2-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4162
##STR00425##
N-[3-(4'-{[(5-Ethyl-thiophen-2-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4163
##STR00426##
N-[3-(2-Fluoro-4'-{[(1,3,5-trimethyl-1H-pyrazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4164 ##STR00427##
N-[3-(2,3'-Difluoro-4'-{[([1,2,3]thiadiazol-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4165
##STR00428##
N-[3-(2-Fluoro-4'-{[(2-methyl-1H-imidazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4166 ##STR00429##
N-[3-(2-Fluoro-3'-{[([1,2,3]thiadiazol-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4167
##STR00430## N-[3-(2-Fluoro-4'-{[(5-methyl
sulfanyl-thiophen-2-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4168 ##STR00431##
N-[3-(4'-{[(4-Bromo-1-methyl-1H-pyrazol-3-ylmethyl)-amino]-
methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4169 ##STR00432##
N-[3-(4'-{[(4-Bromo-2H-pyrazol-3-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4170
##STR00433##
N-{3-[4'-(Benzylsulfamoyl-methyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 4171 ##STR00434##
N-[3-(2-Fluoro-4'-{2-hydroxy-1-[([1,2,3]thiadiazol-4-(R/S)-ylmethyl)-
amino]-ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4172 ##STR00435##
N-[3-(2-Fluoro-4'-{2-hydroxy-1-[([1,2,3]thiadiazol-4-(R/S)-ylmethyl)-
amino]-ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4173 ##STR00436##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid[1-carbamoyl-2-(S)-(3H-imidazol-4-yl)-
ethyl]-amide 4174 ##STR00437##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-3-(S)-(1H-imidazol-4-yl)-propionamide
4175 ##STR00438##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-3-(S)-(1H-indol-3-yl)-propionamide 4176
##STR00439##
N-[3-(2-Fluoro-2',5'-dimethyl-4'-{[(pyridin-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4177 ##STR00440##
N-(3-{4'-[(2,2-Difluoro-2-pyridin-2-yl-ethylamino)-methyl]-2-fluoro-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4178
##STR00441##
N-[3-(2-Fluoro-4'-{[(5-(S)-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-
ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 4179 ##STR00442##
N-[3-(2-Fluoro-4'-{[(3-fluoro-pyridin-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4180
##STR00443##
N-[3-(2-Fluoro-4'-{[(5-methylamino-[1,2,4]thiadiazol-3-ylmethyl)-
amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4181 ##STR00444##
N-[3-(4'-{[(6-Bromo-pyridin-3-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4182
##STR00445##
N-[3-(4'-{[(5-Bromo-pyridin-2-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4183
##STR00446##
N-(3-(2-Fluoro-4'-{[(isoxazol-3-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4184 ##STR00447##
2-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-yl}-2-(R)-[(pyridin-4-ylmethyl)-amino]-acetamide 4185
##STR00448##
2-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-yl}-2-(R)-[(pyridin-2-ylmethyl)-amino]-acetamide 4186
##STR00449##
N-[3-(2-Fluoro-4'-{[(piperidin-4-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4187 ##STR00450##
5-{4-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-
phenyl}-pyridine-2-carboxylic acid (pyridin-2-ylmethyl)-amide 4188
##STR00451##
5-{4-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-
phenyl}-pyridine-2-carboxylic acid (pyridin-4-ylmethyl)-amide 4189
##STR00452##
5-{4-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-
phenyl}-pyridine-2-carboxylic acid (thiazol-2-ylmethyl)-amide 4190
##STR00453##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-3,2'-difluoro-
biphenyl-4-carboxylic acid (pyridin-2-ylmethyl)-amide 4191
##STR00454##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-3,2'-difluoro-
biphenyl-4-carboxylic acid [2-(3H-imidazol-4-yl)-ethyl]-amide 4192
##STR00455##
N-{3-[2-Fluoro-4'-(pyridin-2-ylmethoxymethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 4193 ##STR00456##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-(1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-
acrylamide 4194 ##STR00457##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-3-(1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-
acrylamide 4195 ##STR00458##
N-(3-{3-Fluoro-4-[6-(pyridin-2-ylmethoxymethyl)-pyridin-3-yl]-
phenyl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4196
##STR00459##
N-{3-[2-Fluoro-4'-(pyridin-4-ylmethoxymethyl)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 4197 ##STR00460##
N-(3-{3-Fluoro-4-[5-(pyridin-2-ylmethoxymethyl)-pyridin-2-yl]-
phenyl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4198
##STR00461##
N-{3-[2-Fluoro-4'-(1-oxy-pyridin-4-ylmethoxymethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4199 ##STR00462##
N-[3-(2-Fluoro-4'-{1-(R)-hydroxy-2-[(oxazol-4-ylmethyl)-amino]-
ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4200 ##STR00463##
N-[3-(2-Fluoro-4'-{2-hydroxy-1-(S)-[(oxazol-4-ylmethyl)-amino]-
ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4201 ##STR00464##
N-[3-(2-Fluoro-4'-{1-(R)-hydroxy-2-[(pyridin-4-ylmethyl)-amino]-
ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4202 ##STR00465##
N-[3-(2-Fluoro-4'-{2-hydroxy-1-(R)-[(pyridin-4-ylmethyl)-amino]-
ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4203 ##STR00466##
N-[3-(2-Fluoro-4'-{[(pyrimidin-5-ylmethyl)-amino]-methyl}-biphenyl-
4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4204 ##STR00467##
N-(3-{4'-[(Acetyl-[1,2,3]thiadiazol-4-ylmethyl-amino)-methyl]-2-
fluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
4205 ##STR00468##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid (oxazol-4-ylmethyl)-amide 4206
##STR00469##
N-[3-(2-Fluoro-4'-{[([1,2,4]thiadiazol-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4207
##STR00470## 2-(4-Chloro-benzylamino)-thiazole-4-carboxylic acid
{4'-[5-(S)-
(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-
ylmethyl}-amide 4208 ##STR00471##
N-[3-(2-Fluoro-4'-{[(oxazol-5-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4209 ##STR00472##
N-[3-(4'-{[([1,3]Dioxolan-2-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4210
##STR00473##
N-(3-{2-Fluoro-4'-[(oxiranylmethyl-amino)-methyl]-biphenyl-4-yl}-2-
oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4211 ##STR00474##
N-{3-[2-Fluoro-4'-(pyridin-4-ylmethylsulfanylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4212 ##STR00475##
N-{3-[2-Fluoro-4'-(pyridin-4-ylmethanesulfinylmethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4213 ##STR00476##
3-(2-Fluoro-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-
5-(R)-hydroxymethyl-oxazolidin-2-one 4214 ##STR00477##
N-{3-[2-Fluoro-4'-(pyridin-4-ylmethanesulfonylmethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4215 ##STR00478##
N-(3-{2-Fluoro-4'-[(methyl-quinolin-3-ylmethyl-amino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4216
##STR00479##
N-{3-[2-Fluoro-4'-(pyridin-2-ylmethylsulfanylmethyl)-biphenyl-4-yl]-2-
oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4217 ##STR00480##
N-{3-[2-Fluoro-4'-(pyridin-2-ylmethanesulfinylmethyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4218 ##STR00481##
N-[3-(2-Fluoro-4'-{[(1-methyl-1H-indol-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4219
##STR00482##
N-[3-(2-Fluoro-4'-{[(tetrahydro-furan-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4220
##STR00483##
N-[3-(2-Fluoro-4'-{[(tetrahydro-furan-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4221
##STR00484##
N-[3-(2-Fluoro-4'-{[(thiophen-2-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4222 ##STR00485##
N-{3-[2-Fluoro-4'-(N-furan-2-ylmethyl-carbamimidoyl)-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4223 ##STR00486##
5-{4-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-
phenyl}-pyridine-2-carboxylic acid
[2-(3H-imidazol-4-yl)-ethyl]-amide 4224 ##STR00487##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid ([1,2,4]oxadiazol-3-ylmethyl)-amide 4225
##STR00488##
4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-carboxylic acid ([1,2,4]thiadiazol-3-ylmethyl)-amide
4226 ##STR00489##
N-[3-(2-Fluoro-4'-oxiranylmethylsulfanylmethyl-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 4227 ##STR00490##
N-[3-(2-Fluoro-4'-{[2-(1H-imidazol-4-yl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4228
##STR00491##
N-[3-(2-Fluoro-4'-{[2-(5-methyl-3H-indol-3-yl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4229
##STR00492##
N-[3-(2-Fluoro-4'-{[(5-methyl-isoxazol-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4230
##STR00493##
3-(2-Fluoro-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-
5-(R)-[1,2,4]triazol-1-ylmethyl-oxazolidin-2-one 4231 ##STR00494##
3-(2-Fluoro-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-
5-(R)-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-oxazolidin-2-one
4232 ##STR00495##
N-[3-(2-Fluoro-4'-{1-(R/S)-[(pyridin-4-ylmethyl)-amino]-ethyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4233
##STR00496##
N-[3-(2-Fluoro-4'-{[([1,2,4]oxadiazol-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4234
##STR00497##
N-[3-(2-Fluoro-4'-{[(oxazol-4-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4235 ##STR00498##
N-{3-[3-Fluoro-4-(6-{[(oxazol-4-ylmethyl)-amino]-methyl}-pyridin-3-
yl)-phenyl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4236
##STR00499##
N-(3-{2-Fluoro-4'-[N'-(pyridine-4-carbonyl)-hydrazinomethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4237
##STR00500##
N-(3-{2-Fluoro-4'-[N'-(pyridine-3-carbonyl)-hydrazinomethyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4238
##STR00501##
N-[3-(2-Fluoro-4'-{[(oxazol-5-ylmethyl)-amino]-methyl}-biphenyl-4-
yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4239 ##STR00502##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl]-2-[1,2,3]triazol-1-yl-acetamide 4240
##STR00503##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-(4-hydroxymethyl-[1,2,3]triazol-1-yl)-
acetamide 4241 ##STR00504##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-[4-(2-hydroxy-butyl)-[1,2,3]triazol-1-yl]-
acetamide 4242 ##STR00505## 2-Methyl-thiazole-4-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-
oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4243
##STR00506## 2-Methyl-thiazole-4-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-
oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4244
##STR00507##
N-{3-[2-Fluoro-4'-([1,2,4]oxadiazol-3-ylmethylsulfanylmethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4245
##STR00508##
N-[3-(2-Fluoro-4'-{[(1-oxy-pyridin-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4246
##STR00509##
N-{3-[4'-(2-Benzylamino-1-(S)-hydroxy-ethyl)-2-fluoro-biphenyl-4-yl]-
2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4247 ##STR00510##
N-{3-(4'-{2-[Benzyl-(3-fluoro-propyl)-amino]-1-(S)-hydroxy-ethyl}-2-
fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4248 ##STR00511##
N-[3-(4'-{2-[Benzyl-(2-methylsulfanyl-ethyl)-amino]-1-(S)-hydroxy-
ethyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4249 ##STR00512##
N-[3-(4'-{2-[Benzyl-(3-chloro-3,3-difluoro-propyl)-amino]-1-(S)-
hydroxy-ethyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 4250 ##STR00513##
N-(2-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-yl}-2-(S)-hydroxy-ethyl)-N-benzyl-acetamide 4251
##STR00514##
N-(3-{4'-[2-(Benzyl-methyl-amino)-1-(S)-hydroxy-ethyl]-2-fluoro-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4252
##STR00515##
N-{3-[3-Fluoro-4-(6-{[(isoxazol-4-ylmethyl)-amino]-methyl}-pyridin-
3-yl)-phenyl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4253
##STR00516##
N-[3-(4'-{[(3-Bromo-isoxazol-5-ylmethyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4254
##STR00517##
N-[3-(2-Fluoro-4'-{2-[(isoxazol-4-ylmethyl)-amino]-1-methoxyimino-
ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4255 ##STR00518##
N-[3-(2-Fluoro-4'-{1-methoxyimino-2-[(oxazol-4-ylmethyl)-amino]-
ethyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4256 ##STR00519##
N-[3-(4'-{[3-(1-Benzyl-1H-[1,2,3]triazol-4-yl)-propylamino]-methyl}-
2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4257 ##STR00520##
N-[3-(2-Fluoro-4'-{[(2-fluoro-pyridin-3-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4258
##STR00521##
N-[3-(2-Fluoro-4'-{[3-(3H-[1,2,3]triazol-4-yl)-propylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4259
##STR00522##
N-(3-{2-Fluoro-4'-[(2-pyrrolidin-1-yl-ethylamino)-methyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4260 ##STR00523##
N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-3-(5-pyrimidin-2-yl-pyridin-2-yl)-propionamide 4261
##STR00524##
N-[3-(2-Fluoro-2'-methoxy-4'-{[(pyridin-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4262
##STR00525##
N-(3-{2-Fluoro-4'-[(2-[1,2,3]triazol-1-yl-ethylamino)-methyl]-biphenyl-
4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4263 ##STR00526##
N-{3-[4'-(Benzyloxyamino-methyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 4264 ##STR00527##
N-(3-{2-Fluoro-4'-[(3-[1,2,3]triazol-1-yl-propylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4265
##STR00528##
N-[3-(4'-{[Benzyloxy-(3-fluoro-propyl)-amino]-methyl}-2-fluoro-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4266
##STR00529##
N-[3-(2-Fluoro-4'-{[2-(3H-[1,2,3]triazol-4-yl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4267
##STR00530##
N-[3-(2-Fluoro-4'-{[(3H-[1,2,3]triazol-4-ylmethyl)-amino]methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4268
##STR00531##
3-(2-Fluoro-4'-{[(3H-[1,2,3]triazol-4-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-5-(R)-[1,2,3]triazol-1-ylmethyl-oxazolidin-2-one
4269 ##STR00532##
N-[3-(2-Fluoro-4'-{[(5-methyl-3H-[1,2,3]triazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4270 ##STR00533##
N-[3-(4'-{[Bis-(5-methyl-3H-[1,2,3]triazol-4-ylmethyl)-amino]-
methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4271 ##STR00534##
N-(3-{2-Fluoro-4'-[N'-(4-methyl-[1,2,3]thiadiazole-carbonyl)-
hydrazinomethyl}-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-
acetamide 4272 ##STR00535##
N-[3-(2-Fluoro-4'-{[(3-methyl-3H-[1,2,3]triazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4273 ##STR00536##
N-[3-(2-Fluoro-4'-{[(2-methyl-2H-[1,2,3]triazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4274 ##STR00537##
N-(3-{2-Fluoro-4'-[(3-fluoro-2-[1,2,3]triazol-1-yl-propylamino)-
methyl]-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
4275 ##STR00538##
N-[3-(2-Fluoro-4'-{[2-(4-fluoro-phenyl)-2-(R/S)-hydroxy-ethylamino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4276 ##STR00539##
N-[3-(2-Fluoro-4'-{[methyl-(3H-[1,2,3]triazol-4-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4277 ##STR00540##
N-{3-[3-Fluoro-4-(6-{[(3H-[1,2,3]triazol-4-ylmethyl)-amino]-methyl}-
pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
4278 ##STR00541##
N-[3-(2-Fluoro-4'-{[1-(R/S)-(3H-[1,2,3]triazol-4-yl)-ethylamino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4279 ##STR00542##
N-[3-(2-Fluoro-4'-{[(pyrrolidin-2-(R/S)-ylmethyl)-amino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4280
##STR00543##
{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro
biphenyl-4-ylmethyl}-(1-methyl-1H-tetrazol-5-ylmethyl)-carbamic
acid tert-butyl ester 4281 ##STR00544##
{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-(2-methyl-2H-tetrazol-5-ylmethyl)-carbamic
acid tert-butyl ester 4282 ##STR00545##
N-[3-(2-Fluoro-4'-{[(1H-tetrazol-5-ylmethyl)-amino]-methyl}-biphenyl-
4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 4283 ##STR00546##
N-[3-(2-Fluoro-4'-{[(1-methyl-1H-tetrazol-5-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
4284 ##STR00547##
N-[3-(2-Fluoro-4'-{[(2-methyl-2H-tetrazol-5-ylmethyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
4285 ##STR00548##
N-[3-(2-Fluoro-4'-{[(N-hydroxy-pyridine-4-carboximidoyl)-amino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide
4286 ##STR00549##
N-[3-(4'-{2-[Benzyl-(2-methanesulfonyl-ethyl)-amino]-1-(S)-hydroxy-
ethyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-
acetamide 4287 ##STR00550##
N-[3-[4'-{[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-
ethanesulfonylamino]-methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-
oxazolidin-5-(S)-ylmethyl]-acetamide 4288 ##STR00551##
N-{3-[4'-(Benzylsulfamoyl-methyl)-2-fluoro-biphenyl-4-yl]-2-oxo-
oxazolidin-5(S)-ylmethyl}-acetamide 4289 ##STR00552##
5-Oxo-pyrrolidine-2-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-
oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4290
##STR00553##
3-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-carbamoyl)-azetidine-1-carboxylic acid
tert-butyl ester 4291 ##STR00554## Azetidine-3-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-oxo-
oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4292
##STR00555##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-(R)-amino-3-(3H-imidazol-4-yl)-propionamide
4293 ##STR00556##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-2-pyridin-3-yl-acetamide 4294
##STR00557##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-amino-2-pyridin-3-yl-acetamide 4295
##STR00558##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-carbamoyl)-azetidine-1-carboxylic acid
tert-butyl ester 4296 ##STR00559## Azetidine-2-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-oxo-
oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4297
##STR00560##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-(R)-amino-2-(4-fluoro-phenyl)-acetamide 4298
##STR00561##
4-[({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-methyl]-piperidine-1-carboxylic acid
tert- butylester 4299 ##STR00562##
N-{3-[2-Fluoro-4'-(1-[1,2,3]thiadiazol-4-ylmethyl-ureidomethyl)-
biphenyl-4-yl]-2-oxo-oxazolidin-5-(S)-ylmethyl}-acetamide 4300
##STR00563##
N-(3-{4'-[(Cyclopropylmethyl-amino)-methyl]-2-fluoro-biphenyl-4-yl}-
2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4301 ##STR00564##
4-(R)-Hydroxy-pyrrolidine-2-(S)-carboxylicacid {4-[5-(S)-
(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-
ylmethyl}-amide 4302 ##STR00565##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-(S)-amino-3-pyridin-2-yl-propionamide 4303
##STR00566##
[1-(S)-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-
fluoro-biphenyl-4-ylmethyl}-carbamoyl)-2-pyridin-2-yl-ethyl]-carbamic
acid tert-butyl ester 4304 ##STR00567##
[1-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-carbamoyl)-cyclopropyl]-carbamic acid
tert-butyl ester 4305 ##STR00568##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-carbamoyl)-2,5-dihydro-pyrrole-1-(S)-carboxylic
acid tert-butylester 4306 ##STR00569##
2,5-Dihydro-1H-pyrrole-2-(S)-carboxylic acid
{4'-[5-(S)-(acetylamino-
methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide
4307 ##STR00570##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-(R)-amino-3-(1H-indol-3-yl)-propionamide
4308 ##STR00571##
[1-(R)-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-
fluoro-biphenyl-4-ylmethyl}-carbamoyl)-2-(1H-indol-3-yl)-ethyl]-
carbamic acid tert-butyl ester 4309 ##STR00572##
Pyrrolidine-2-(S)-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-
oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4310
##STR00573##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-(R)-amino-3-pyridin-3-yl-propionamide 4311
##STR00574##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-carbamoyl)-4-(R)-hydroxy-pyrrolidine-1-(S)-
carboxylic acid tert-butyl ester 4312 ##STR00575##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-3-(S)-(1H-indol-3-yl)-propionamide 4313
##STR00576##
2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-3-(1H-imidazol-4-yl)-propionamide 4314
##STR00577##
N-(3-{2-Fluoro-4'-[(2-oxo-2-piperazin-1-yl-ethylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4315
##STR00578##
4-[2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-
fluoro-biphenyl-4-ylmethyl}-amino)-acetyl]-piperazine-1-carboxylic
acid tert-butyl ester 4316 ##STR00579##
N-(3-{2-Fluoro-4'-[(2-morpholin-4-yl-2-oxo-ethylamino)-methyl]-
biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4317
##STR00580##
3-[({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-amino)-methyl]-pyrrolidine-1-carboxylic acid
tert-butyl ester 4318 ##STR00581##
N-(3-{2-Fluoro-4'-[(2-morpholin-4-yl-ethylamino)-methyl]-biphenyl-4-
yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 4319 ##STR00582##
Cyclopropanecarboxylic acid {4'-[5-(S)-(acetylamino-methyl)-2-oxo-
oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4320
##STR00583##
N-(3-{2-Fluoro-4'-[(furan-3-ylmethyl-methyl-amino)-methyl]-2'-
methoxy-biphenyl-4-yl}-2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide
4321 ##STR00584## 1-Amino-cyclopropanecarboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-
2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 4322
##STR00585## Piperazine-2-(R/S)-carboxylic acid
{4'-[5-(S)-(acetylamino-methyl)-2-
oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-ylmethyl}-amide 5001
##STR00586##
N-[3-(2-Fluoro-4'-{[2-(3H-[1,2,3]triazol-4-ylsulfanyl)-ethylamino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
5002 ##STR00587##
N-[3-(2-Fluoro-4'-{[3-(3H-[1,2,3]triazol-4-ylsulfanyl)-propylamino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
5003 ##STR00588##
N-[3-(2-Fluoro-4'-{[2-([1,3,4]thiadiazol-2-ylsulfanyl)-ethylamino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
5004 ##STR00589##
N-[3-(2-Fluoro-4'-{[2-(pyridin-2-ylsulfanyl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 5005
##STR00590##
N-[3-(2-Fluoro-4'-{[2-(4H-[1,2,4]-triazol-3-ylsulfanyl)-ethylamino]-
methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide
5006 ##STR00591##
N-[3-(2-Fluoro-4'-{[2-(thiazol-2-ylsulfanyl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 5007
##STR00592##
3-(2-Fluoro-4'-{[2-(3H-[1,2,3]triazol-4-ylsulfanyl)-ethylaminol]-
methyl}-biphenyl-4-yl)-5-(R)-[1,2,3]triazol-1-ylmethyl-oxazolidin-2-
one 5008 ##STR00593##
N-[3-(2-Fluoro-4'-{[2-(1H-imidazol-2-ylsulfanyl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 5009
##STR00594##
N-[3-(2-Fluoro-4'-{[2-(pyrimidin-2-ylsulfanyl)-ethylamino]-methyl}-
biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide 5010
##STR00595##
2-[2-({4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-
fluoro-biphenyl-4-ylmethyl}-amino)-ethylsulfanyl]-1H-imidazole-4-
carboxylic acid ethyl ester 5011 ##STR00596##
N-[3-(2-Fluoro-4'-{[2-(S)-(hydroxy-3-(4H-[1,2,4]triazol-3-ylsulfanyl)-
propylamino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 5012 ##STR00597##
N-(3-{2-Fluoro-4'-[(3-pyridin-4-yl-ureido)-methyl]-biphenyl-4-yl}-2-
oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 5013 ##STR00598##
N-(3-{2-Fluoro-4'-[3-(3-fluoro-phenyl)-ureidomethyl]-biphenyl-4-yl}-
2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 5014 ##STR00599##
N-{4'-[5-(S)-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-
biphenyl-4-ylmethyl}-2-(2,4-dichloro-phenoxy)-acetamide 5015
##STR00600##
N-[3-(4'-{[3-(3-Chloro-5-trifluoromethyl-pyridin-2-ylamino)-
propylamino]-methyl}-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-
ylmethyl]-acetamide 6001 ##STR00601##
N-(3-{2-Fluoro-4'-[3-(3-imidazol-1-yl-propyl)-ureido]-biphenyl-4-yl}-
2-oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 6002 ##STR00602##
N-{3-[2-Fluoro-4'-(3-thiazol-2-ylmethyl-ureido)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 6003 ##STR00603##
N-(3-{2-Fluoro-4'-[3-(2-pyridin-2-yl-ethyl)-ureido]-biphenyl-4-yl}-2-
oxo-oxazolidin-5-(S)-ylmethyl)-acetamide 6004 ##STR00604##
N-{3-[2-Fluoro-4'-(3-pyridin-4-ylmethyl-ureido)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide
6005 ##STR00605##
N-{3-[2-Fluoro-4'-(3-pyridin-2-ylmethyl-ureido)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide 6006 ##STR00606##
N-{3-[2-Fluoro-4'-(3-pyridin-4-yl-ureido)-biphenyl-4-yl]-2-oxo-
oxazolidin-5-(S)-ylmethyl}-acetamide
[0163] Nuclear magnetic resonance (NMR) spectra were obtained on a
Bruker Avance 300 or Avance 500 spectrometer, or in some cases a
GE-Nicolet 300 spectrometer. Common reaction solvents were either
high performance liquid chromatography (HPLC) grade or American
Chemical Society (ACS) grade, and anhydrous as obtained from the
manufacturer unless otherwise noted. "Chromatography" or "purified
by silica gel" refers to flash column chromatography using silica
gel (EM Merck, Silica Gel 60, 230-400 mesh) unless otherwise
noted.
Example 1
Synthesis of Biaryl Precursors
[0164] Scheme 1 depicts the synthesis of various biaryl
intermediates useful in producing compounds of the present
invention. Known iodoaryl oxazolidinone intermediate 50 (see U.S.
Pat. Nos. 5,523,403 and 5,565,571) is coupled to a substituted aryl
boronic acid (the Suzuki reaction) to produce biaryl alcohol 51.
Mesylate 52, azide 53, and amine 54 are then synthesized using
chemistry well known to those skilled in the art.
##STR00607##
Synthesis of Alcohol 51
[0165] A suspension of
N-[3-(3-fluoro-4-iodo-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
50 (14.0 g, 37 mmol) in toluene (120 mL) was treated with
4-(hydroxymethyl)phenylboronic acid (7.87 g, 51.8 mmol, 1.4 equiv),
potassium carbonate (K.sub.2CO.sub.3, 15.32 g, 111 mmol, 3.0
equiv), ethanol (EtOH, 40 mL), and H.sub.2O (40 mL) at 25.degree.
C., and the resulting mixture was degassed three times under a
steady stream of argon at 25.degree. C.
Tetrakis(triphenylphosphine)palladium (Pd(PPh.sub.3).sub.4, 2.14 g,
1.85 mmol, 0.05 equiv) was subsequently added to the reaction
mixture, and the resulting reaction mixture was degassed three
times again before being warmed to gentle reflux for 6 h. When thin
layer chromatography (TLC) and HPLC showed the coupling reaction
was complete, the reaction mixture was cooled to room temperature
before being treated with H.sub.2O (240 mL). The resulting mixture
was then stirred at room temperature for 10 min before being cooled
to 0-5.degree. C. for 1 h. The solid precipitates were collected by
filtration, washed with H.sub.2O (2.times.100 mL) and 20% ethyl
acetate (EtOAc)/hexane (2.times.50 mL), and dried in vacuo. The
crude desired
N-[3-(2-Fluoro-4'-hydroxymethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-
-ylmethyl]-acetamide 51 (12.50 g, 94% yield) was obtained as
off-white solids. This material was found to be essentially pure by
HPLC and .sup.1H NMR and was directly used in the subsequent
reaction without further purification. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 1.76 (s, 3H, COCH.sub.3), 3.35 (t, 2H, J=5.4
Hz), 3.69 (dd, 1H, J=6.4, 9.2 Hz), 4.08 (t, 1H, J=9.1 Hz), 4.46 (d,
2H, J=5.7 Hz, CH.sub.2OH), 4.68 (m, 1H), 5.16 (t, 1H, J=5.7 Hz,
OH), 7.25-7.52 (m, 7H, aromatic-H), 8.18 (t, 1H, J=5.8 Hz,
NHCOCH.sub.3). LCMS (ESI) m/e 359 (M+H).sup.+.
Synthesis of Mesylate 52
[0166] A suspension of 51 (12.49 g, 34.90 mmol) in methylene
chloride (CH.sub.2Cl.sub.2, 150 mL) was treated with triethylamine
(Et.sub.3N, 7.07 g, 9.7 mL, 70 mmol, 2.0 equiv) at 25.degree. C.,
and the resulting mixture was cooled to 0-5.degree. C. before being
treated dropwise with methanesulfonyl chloride (4.80 g, 3.24 mL,
41.9 mmol, 1.2 equiv) at 0-5.degree. C. The resulting reaction
mixture was subsequently stirred at 0-5.degree. C. for 2 h. When
TLC and HPLC showed the reaction was complete, the reaction mixture
was treated with H.sub.2O (100 mL) at 0-5.degree. C. The mixture
was then concentrated in vacuo to remove most of the
CH.sub.2Cl.sub.2, and the resulting slurry was treated with
H.sub.2O (150 mL). The mixture was stirred at room temperature for
10 min before being cooled to 0-5.degree. C. for 30 min. The solid
precipitates were collected by filtration, washed with H.sub.2O
(2.times.100 mL) and 20% EtOAc/hexane (2.times.50 mL), and dried in
vacuo. The crude desired methanesulfonic acid
4'-[5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-4-yl-
methyl ester 52 (11.84 g, 78% yield) was obtained as off-white
solids, which by TLC and HPLC was found to be essentially pure and
was directly used in the subsequent reaction without further
purification. LCMS (ESI) m/e 437 (M+H).sup.+.
Synthesis of Azide 53
[0167] A solution of 52 (9.27 g, 21.26 mmol) in anhydrous
N,N-dimethylformamide (DMF, 50 mL) was treated with sodium azide
(NaN.sub.3, 5.53 g, 85.04 mmol, 4.0 equiv) at 25.degree. C., and
the resulting reaction mixture was warmed to 70-80.degree. C. for 4
h. When TLC and HPLC showed the reaction was complete, the reaction
mixture was cooled to room temperature before being treated with
H.sub.2O (150 mL). The resulting mixture was stirred at room
temperature for 10 min before being cooled to 0-5.degree. C. for 1
h. The solid precipitates were collected by filtration, washed with
H.sub.2O (2.times.100 mL) and 20% EtOAc/hexane (2.times.50 mL), and
dried in vacuo. The crude desired
N-[3-(4'-azidomethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-
-acetamide 53 (7.16 g, 88% yield) was obtained as off-white solids.
The material was found to be essentially pure by TLC and HPLC and
was directly used in the subsequent reaction without further
purification. LCMS (ESI) m/e 384 (M+H).sup.+.
Synthesis of Amine 54
[0168] A solution of 53 (7.16 g, 18.69 mmol) in tetrahydrofuran
(THF) (100 mL) was treated with triphenylphosphine (PPh.sub.3, 5.88
g, 22.43 mmol, 1.2 equiv) and H.sub.2O (3.6 g, 3.6 mL, 0.2 mmol,
11.0 equiv) at 25.degree. C., and the resulting reaction mixture
was warmed to 50-55.degree. C. for 12 h. When TLC and HPLC showed
the reduction reaction was complete, the reaction mixture was
cooled to room temperature before the solvents were removed in
vacuo. The residue was directly purified by flash column
chromatography (0-15% MeOH--CH.sub.2Cl.sub.2 gradient elution) to
afford the desired
N-[3-(4'-Aminomethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-
-acetamide 54 (5.82 g, 87% yield) as off-white crystals, which were
of sufficient purity to be directly used in subsequent reactions.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.85 (s, 3H,
COCH.sub.3), 3.04 (br. s, 2H, NH.sub.2), 3.44 (t, 2H, J=5.4 Hz),
3.78 (m, 3H), 4.18 (t, 1H, J=9.1 Hz), 4.77 (m, 1H), 7.25-7.60 (m,
7H, aromatic-H), 8.20 (t, 1H, J=5.8 Hz, NHCOCH.sub.3). LCMS (ESI)
m/e 359 (M+2H).sup.2+.
Example 2
Synthesis of Triazole 1001 and Imidazole 1002
[0169] Scheme 2 illustrates the synthesis of triazole 1001 and
imidazole 1002. Aryl bromide 60 was converted to boronic acid 61
which was used in a Suzuki coupling with aryl iodide 50 to afford
alcohol 63 after desilylation. The alcohol was converted to
mesylate 64 and then to azide 65. The cycloaddition of azide 65
with trimethylsilylacetylene followed by desilylation afforded
triazole 1001. Alkylation of mesylate 64 with imidazole yielded
compound 1002.
##STR00608##
Synthesis of Bromide 60
[0170] To a solution of 4-bromophenethyl alcohol (5.60 g, 27.9
mmol), imidazole (3.80 g, 55.7 mmol) and a catalytic amount of
4-dimethylaminopyridine (DMAP) in DMF (55 mL) was added
t-butyldiphenylchlorosilane (TBDPSCl, 7.20 mL, 27.9 mmol) at
0.degree. C. and the mixture was stirred at ambient temperature for
72 h. The reaction was quenched with ice cold water (50 mL) and
extracted with ether (4.times.50 mL). The combined etheral layer
was washed with water (4.times.100 mL), dried over anhydrous sodium
sulfate (Na.sub.2SO.sub.4), concentrated and purified by flash
chromatography (2% ethyl acetate in hexanes) to yield 10.6 g of
60.
Synthesis of Boronic Acid 61
[0171] To a solution of 60 (10.5 g, 24.0 mmol) in THF (50 mL) was
added n-butyl lithium (n-BuLi, 2.5M in hexane, 11.5 mL, 28.8 mmol)
at -78.degree. C. and the mixture was stirred for 1 h before the
addition of trimethyl borate (3.54 mL, 31.2 mmol). The solution was
then stirred overnight at ambient temperature and quenched with 1M
potassium hydrogen sulfate (KHSO.sub.4, 25 mL). The resulting
mixture was extracted with CH.sub.2Cl.sub.2 (3.times.50 mL), washed
with brine (3.times.100 mL), dried (anhydrous Na.sub.2SO.sub.4),
concentrated and purified by flash chromatography (25% ethyl
acetate in hexanes) to yield 5 g of boronic acid 61 as mixture of
acid and cyclic anhydrides.
Synthesis of Alcohol 63
[0172] To a mixture of boronic acid 61 (4.7 g, 11.7 mmol), known
oxazolidinone 50 (4.00 g, 10.6 mmol; see U.S. Pat. Nos. 5,523,403
and 5,565,571), potassium carbonate (K.sub.2CO.sub.3, 4.40 g, 31.8
mmol) and Pd(PPh.sub.3).sub.4 (0.613 g, 5 mol %) was added toluene
(90 mL), ethanol (30 mL) and H.sub.2O (30 mL). The reaction mixture
was refluxed overnight under argon atmosphere, concentrated and
redissolved in CH.sub.2Cl.sub.2 (100 mL). The organic phase was
washed with brine solution (2.times.100 mL), dried (anhydrous
Na.sub.2SO.sub.4), concentrated and used for the next step without
further purification. To a solution of this crude material in THF
(70 mL) was added tetrabutylammonium fluoride (TBAF, 20 mL, 20
mmol) and the mixture was stirred overnight at ambient temperature.
The reaction mixture was concentrated and washed with water
(4.times.100 mL) to yield 3.5 g of 63. LCMS (ESI) m/z 373
(M+H).
Synthesis of Mesylate 64 and Azide 65
[0173] To a solution of 63 (1.0 g, 2.7 mmol) in CH.sub.2Cl.sub.2
(15 mL), DMF (4 mL) and N,N-diisopropylethylamine (Hunig's base,
0.75 mL, 4.05 mmol) was added methanesulfonyl chloride (0.32 mL,
2.7 mmol) at 0.degree. C. After 2 h the reaction mixture was poured
into CH.sub.2Cl.sub.2 (150 mL) and the organic layer was washed
with water (3.times.100 mL), dried, concentrated to afford 64 as a
solid. The crude solid 64 thus obtained was heated with NaN.sub.3
(0.35 g, 5.4 mmol) at 90.degree. C. overnight. The reaction mixture
was poured into ethyl acetate (100 mL). The ethyl acetate layer was
washed with water (3.times.50 mL), dried and concentrated to yield
1.1 g of pure azide 65. LCMS (ESI) m/z 398 (M+H).
Synthesis of Triazole 1001
[0174] A solution of azide 65 (100 mg, 0.252 mmol) and
trimethylsilylacetylene (0.072 mL, 0.504 mmol) in DMF (3 mL) was
heated at 90.degree. C. until the azide was consumed. The reaction
mixture was concentrated and treated with TBAF (1 mL, 1 mmol) and
acetic acid (0.028 mL, 0.504 mmol) in THF (3 mL). The solution was
stirred for 72 h and concentrated. The crude product was purified
by flash chromatography using 4% methanol (MeOH) in
CH.sub.2Cl.sub.2 to yield 85 mg of 1001. LCMS (ESI) m/z 424
(M+H).
Synthesis of Imidazole 1002
[0175] To a solution of imidazole (70 mg, 1.0 mmol) in DMF (5 mL)
was added sodium hydride (NaH, 60%, 41 mg, 1 mmol) at 0.degree. C.
and the mixture was stirred for 30 minutes before the addition of
mesylate 64 (114 mg, 0.250 mmol). The resulting solution was heated
to 80.degree. C. for 3 h, concentrated and purified by flash
chromatography (5% MeOH in CH.sub.2Cl.sub.2). After trituration
with ether, the residue afforded 40 mg of 1002. LCMS (ESI) m/z 423
(M+H).
Example 3
Synthesis of Piperazines 1003-1006
[0176] Scheme 3 illustrates the synthesis of compounds 1003-1006.
Mesylate 52 served as alkylating agent for piperazine intermediates
68, 69 and 70 to afford compounds 1003, 1004 and 1006 respectively.
Mesylate 67 was employed to alkylate piperazine intermediate 69 to
provide compound 1005.
##STR00609##
Synthesis of Mesylate 67
[0177] Mesylate 67 was synthesized by coupling iodide 50 and
4-formyl-3-fluorophenylboronic acid following the procedure
described above for the synthesis of
N-[3-(2-fluoro-4'-hydroxymethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethy-
l]-acetamide (see Example 1). The biaryl aldehyde obtained (1.0 g,
2.67 mmol) was suspended in 40 mL methanol and the mixture was
cooled to 0.degree. C. Sodium borohydride (0.112 g, 2.943 mmol) was
added, and the mixture was stirred for 50 min. Water was added (20
mL), and after stirring another 20 min the mixture was partitioned
between methylene chloride and brine. The aqueous phase was
extracted twice with methylene chloride. The aqueous phase was
acidified to pH 7, then extracted twice with methylene chloride.
The combined organic phase was washed with brine, dried over
Na.sub.2SO.sub.4, and concentrated. The crude material was
azeotroped with toluene to afford the expected alcohol (900
mg).
[0178] The above alcohol (900 mg) was dissolved in methylene
chloride (20 mL), DMF (13 mL) and Hunig's base (1.23 mL) and the
mixture was cooled to 0.degree. C. Methanesulfonyl chloride (557
uL, 7.20 mmol) was added and the mixture was stirred for 1.5 h at
0.degree. C. LCMS indicated a mixture of desired mesylate and some
of the corresponding benzyl chloride. The mixture was stirred for
another 30 min and then concentrated. The residue was treated with
400 mL water, and the precipitate was filtered and washed with
water. Drying under vacuum overnight yielded 750 mg crude mesylate
67 (as a mixture with some of the corresponding chloride).
Synthesis of Piperazine 68
[0179] A solution of tert-butyl-1-piperazine carboxylate (1 g, 5.4
mmol), bromoacetamide (820 mg, 5.94 mmol) and Hunig's base (1.2 mL,
7.2 mmol) in a mixture of CH.sub.2Cl.sub.2 (10 mL) and MeOH (10 mL)
was heated to reflux for 4 h. The reaction mixture was concentrated
and the crude product thus obtained was purified by flash
chromatography (19:1:0.01 CH.sub.2Cl.sub.2/MeOH/NH.sub.4OH) to
yield 1.3 g of pure BOC-protected piperazinyl acetamide. To a
solution of the acetamide (250 mg, 1 mmol) in CH.sub.2Cl.sub.2 (10
mL) was added trifluoroacetic acid (TFA, 5 mL) at 0.degree. C. and
the mixture was stirred at that temperature for 2 h. The reaction
mixture was concentrated to yield 68 which was used for subsequent
reactions without further purification.
Synthesis of Piperazine 69
[0180] A solution of tert-butyl-1-piperazine carboxylate (1 g, 5.4
mmol), bromoacetonitrile (0.5 mL, 5.94 mmol) and Hunig's base (1.2
mL, 7.2 mmol) in a mixture of CH.sub.2Cl.sub.2 (10 mL) and MeOH (10
mL) was stirred at ambient temperature for 4 h. The reaction
mixture was concentrated and the crude product thus obtained was
purified by flash chromatography (19:1:0.01
CH.sub.2Cl.sub.2/MeOH/NH.sub.4OH) to yield 1.3 g of pure
BOC-protected piperazinyl acetonitrile. To a solution of the
piperazinyl acetonitrile (300 mg, 1.3 mmol) in CH.sub.2Cl.sub.2 (10
mL) was added TFA (5 mL) at 0.degree. C. and the mixture was
stirred at that temperature for 2 h. The reaction mixture was
concentrated to yield 69 which was used for subsequent reactions
without further purification.
Synthesis of Compound 1003
[0181] A solution of mesylate of 52 (138 mg, 0.320 mmol) and 68
(.about.1 mmol) in Hunig's base (2 mL) and DMF (8 mL) was heated to
90.degree. C. for 2 h. Then the solution was concentrated and
purified by flash chromatography over silica gel (20:1:0.01
CH.sub.2Cl.sub.2/MeOH/NH.sub.4OH) to yield 1003. LCMS (ESI) m/z 484
(M+H).sup.+.
Synthesis of Compound 1004
[0182] Compound 1004 was synthesized from mesylate 52 and
piperazine intermediate 69 in the same manner as described above
for the synthesis of compound 1003. LCMS (ESI) m/z 466
(M+H).sup.+.
Synthesis of Compound 1005
[0183] Compound 1005 was synthesized from mesylate 67 and
piperazine intermediate 69 in the same manner as described above
for the synthesis of compound 1003. LCMS (ESI) m/z 484
(M+H).sup.+.
Synthesis of Compound 1006
[0184] Compound 1006 was synthesized from mesylate 52 and available
piperazine intermediate 70 in the same manner as described above
for the synthesis of compound 1003. LCMS (ESI) m/z 455
(M+H).sup.+.
Example 4
Synthesis of Compounds 1007-1010
[0185] Scheme 4 illustrates the synthesis of compounds 1007-1010.
Mesylate 52 was converted to nitrile 71, which was subsequently
transformed to tetrazole 1007. Mesylate 52 served as alkylating
agent for the anion derived from imidazole to afford imidazole
derivative 1008. Mesylate 67 was converted to azide 72, which was
then subsequently converted to triazole 1009. Mesylate 67 served as
alkylating agent for the anion derived from imidazole to afford
imidazole derivative 1010.
##STR00610##
Synthesis of Tetrazole 1007
[0186] To a solution of mesylate 52 (2.0 g, 4.6 mmol) in DMF (30
mL) was added sodium cyanide (NaCN, 0.45 g, 9.2 mmol) and the
mixture was heated to 70.degree. C. for 3 h. The reaction mixture
was cooled to ambient temperature and poured into water (800 mL).
The solid thus obtained was filtered and passed through a small bed
of silica gel (CH.sub.2Cl.sub.2: MeOH=12:1) to yield 1.8 g of
nitrile 71. LCMS (ESI) m/z 368 (M+H).sup.+.
[0187] A mixture of 71 (100 mg, 0.272 mmol), NaN.sub.3 (40 mg,
0.598 mmol) and ammonium chloride (NH.sub.4Cl, 32 mg, 0.598 mmol)
in DMF (2 mL) was heated to 90.degree. C. for 3 days. The reaction
mixture was concentrated and purified by flash chromatography (10%
MeOH in CH.sub.2Cl.sub.2) to yield 35.6 mg of tetrazole 1007. LCMS
(ESI) m/z 411 (M+H).sup.+.
Synthesis of Imidazole 1008
[0188] To a solution of imidazole (37.4 mg, 0.550 mmol) in DMF (5
mL) was added NaH (60%, 20 mg, 0.50 mmol) at 0.degree. C. and the
mixture was stirred for 30 minutes before the addition of mesylate
52 (200 mg, 0.459 mmol). The resulting solution was heated to
60.degree. C. for 2 h and poured into water (75 mL). The aqueous
suspension was extracted with 10% MeOH in CH.sub.2Cl.sub.2
(3.times.75 mL) and the combined organic layer was washed with
saturated NH.sub.4Cl solution (2.times.100 mL). The organic layer
was dried (anhydrous Na.sub.2SO.sub.4), concentrated and triturated
with ether to yield 170 mg of imidazole 1008. LCMS (ESI) m/z 409
(M+H).sup.+.
Synthesis of Azide 72
[0189] Crude mesylate 67 (100 mg, 0.224 mmol; as a mixture with
some corresponding benzyl chloride) was dissolved in DMF (10 mL)
and sodium azide (114.6 mg, 1.762 mmol) was added. The mixture was
stirred at room temperature for 14 h, and then partitioned between
ethyl acetate and water. The organic phase was washed with water,
dried over Na.sub.2SO.sub.4, and concentrated to provide azide 72
as a solid (190 mg).
Synthesis of Triazole 1009
[0190] Compound 1009 was synthesized from azide 72 and
trimethylsilylacetylene in the same manner as described above for
the synthesis of triazole 1001. LCMS (ESI) m/z 428 (M+H).sup.+.
Synthesis of Imidazole 1010
[0191] Compound 1010 was synthesized from mesylate 67 and imidazole
in the same manner as described above for the synthesis of
imidazole derivative 1008. LCMS (ESI) m/z 427 (M+H).sup.+.
Example 5
Synthesis of Compounds 1011-1015
[0192] Scheme 5 illustrates the synthesis of compounds 1011-1015.
The cycloaddition of azide 53 with alkynes 74-76 afforded triazoles
1011-1013 respectively. The cycloaddition of azide 53 with alkyne
77 gave BOC-protected intermediate 78 which was subsequently
cleaved to provide derivative 1014. The cycloaddition of azide 53
with trimethylsilylacetylene, followed by desilylation, yielded
triazole 1015.
##STR00611##
Synthesis of Triazole 1011
[0193] A solution of azide 53 (0.10 g, 0.26 mmol) in propargyl
amine 74 (0.50 mL) was treated with copper iodide (0.05 g, 0.26
mmol) and was stirred at 23.degree. C. for 0.5 h. The reaction
mixture was diluted with CH.sub.2Cl.sub.2 and MeOH and purified by
flash chromatography and preparative TLC to afford 1011 as a brown
solid (0.027 g; 24%). LCMS (ESI) m/z 439 (M+H).sup.+.
Synthesis of Triazole 1012
[0194] A solution of azide 53 (0.10 g, 0.26 mmol) in
N-methylpropargyl amine 75 (0.50 mL) was treated with copper iodide
(5.00 mg, 0.026 mmol) and stirred at 23.degree. C. for 12 h. The
solvent was removed in vacuo, and the crude product was purified by
preparative TLC to afford 1012 as a brown solid (0.038 g; 32%).
LCMS (ESI) m/z 453 (M+H).sup.+.
Synthesis of Triazole 1013
[0195] A solution of azide 53 (0.10 g, 0.26 mmol) in
N,N-dimethylpropargyl amine 76 (0.056 mL, 0.520 mmol) was treated
with copper iodide (5.00 mg, 0.026 mmol) and stirred at 23.degree.
C. for 12 h. The solvent was removed in vacuo, and the crude
product was purified by flash chromatography to afford 1013 as a
yellow film (0.073 g; 60%). LCMS (ESI) m/z 467 (M+H).sup.+.
Synthesis of Alkyne 77
[0196] A solution of propargyl amine 74 (0.34 mL, 5.0 mmol) in
methylene chloride (25 mL) was treated with BOC-glycine (0.96 g,
5.5 mmol) and EDCI (1.1 g, 5.5 mmol) and stirred at 23.degree. C.
for 0.5 h. The reaction mixture was diluted with CH.sub.2Cl.sub.2,
washed with 1.0 M HCl (aqueous), washed with saturated aqueous
sodium bicarbonate (NaHCO.sub.3), dried over Na.sub.2SO.sub.4, and
the solvent evaporated in vacuo to afford alkyne 77 (0.51 g;
48%).
Synthesis of Triazole 1014
[0197] A solution of azide 53 (0.15 g, 0.39 mmol) in THF (2 mL) was
treated with alkyne 77 (0.17 g, 0.78 mmol) and copper iodide (7.00
mg, 0.039 mmol) and stirred at 23.degree. C. for 16 h. The solvent
was removed in vacuo, and the crude product was purified by flash
chromatography to afford 78 as a white powder (0.16 g; 68%). LCMS
(ESI) m/z 618 (M+Na).sup.+.
[0198] A solution of 78 (0.15 g, 0.25 mmol) was treated with HCl
(1.3 mL of 4.0 M solution in dioxane) and was stirred at 23.degree.
C. for 2 h. The solvent was removed in vacuo, and the residue twice
redissolved in methylene chloride and evaporated to afford 1014 as
a white film (0.14 g, 100%). LCMS (ESI) m/z 496 (M+H).sup.+.
Synthesis of Triazole 1015
[0199] A solution of azide 53 (0.75 mg, 2.0 mmol) in DMF (10 mL)
was treated with trimethylacetylene (2.3 mL, 20 mmol) and was
stirred at 90.degree. C. for 12 h. The reaction mixture was cooled
to 23.degree. C. and the solvent was removed in vacuo to afford the
expected silyl-substituted triazole as a brown foam (0.24 mg; 25%).
LCMS (ESI) m/z 482 (M+H).sup.+.
[0200] A solution of the above silyl-substituted triazole (0.050 g,
0.10 mmol) in THF (0.20 mL) was treated with acetic acid (6 .mu.L,
0.10 mmol) and tetrabutylammonium fluoride (0.21 mL of 1.0 M
solution in THF) and was stirred at 23.degree. C. for 16 h. The
reaction mixture was diluted with CH.sub.2Cl.sub.2, washed with
water, dried (Na.sub.2SO.sub.4), and the solvent removed in vacuo.
The crude product was purified to afford 1015 as a white powder
(0.020 g; 47%). LCMS (ESI) m/z 432 (M+Na).sup.+.
Example 6
Synthesis of Compounds 1016-1017
[0201] Scheme 6 illustrates the synthesis of compounds 1016-1017.
Hydroxyamidine 79 was converted to bromide 80 which was
subsequently coupled to boronate 81 to afford compound 1016.
Hydroxyamidine 79 was transformed to oxadiazole 82, which was
coupled to boronate 81 to afford compound 1017.
##STR00612##
Synthesis of Hydroxyamidine 79
[0202] A solution of 4-bromophenylacetonitrile (10 g, 54 mmol) in
methanol (100 mL) was treated with sodium bicarbonate (2.2 g, 57
mmol) and hydroxylamine hydrochloride (4.0 g, 57 mmol) and refluxed
for 1.5 h. Additional sodium bicarbonate (0.21 g, 5.4 mmol) and
hydroxylamine hydrochloride (0.38 g, 5.4 mmol) were added, and the
reaction mixture was refluxed for 12 h. The reaction mixture was
cooled to 23.degree. C. and the solvent removed in vacuo to afford
hydroxyamidine 79 as a blue powder (4.0 g; 34%).
Synthesis of Bromide 80
[0203] A solution of hydroxyamidine 79 (0.20 g, 0.91 mmol) in
1,4-dioxane (1 mL) was treated with 1,1'-carbonyldiimidazole (0.18
g, 1.1 mmol) and diazabicycloundecene (DBU, 0.15 mL, 0.97 mmol) and
stirred at 105.degree. C. for 1 h. The reaction mixture was diluted
with water and extracted with ethyl acetate. The water layer was
treated with 1.0 M HCl (aqueous) until the pH was 2, and then
extracted with ethyl acetate. The organic layer was dried over
Na.sub.2SO.sub.4, and the solvent removed in vacuo to afford
bromide 80 as a yellow powder (0.11 g; 49%).
Synthesis of Boronate 81
[0204] A suspension of
N-[3-(3-fluoro-4-iodo-phenyl)-2-oxo-oxazolidin-5-ylmethyl]acetamide
62 (20.0 g, 52.8 mmol) in anhydrous 1,4-dioxane (130 mL) was
treated with 4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (10.2 g, 11.6
mL, 80.0 mmol) and triethylamine (16.0 g, 22.4 mL, 158.4 mmol) at
room temperature, and the resulting reaction mixture was degassed
three times under a steady stream of argon before being treated
with dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II)
(Pd(dppf).sub.2Cl.sub.2, 1.32 g, 1.6 mmol, 0.03 equiv) at room
temperature. The reaction mixture was then degassed three times
again under a steady stream of argon before being heated to reflux
for 7 h. When TLC and LCMS showed that the reaction was complete,
the reaction mixture was cooled down to room temperature before
being treated with water (100 mL) and ethyl acetate (100 mL). The
two layers were separated, and the aqueous layer was extracted with
ethyl acetate (2.times.50 mL). The combined organic extracts were
washed with water (2.times.50 mL) and saturated aqueous NaCl
solution (50 mL), dried over magnesium sulfate (MgSO.sub.4), and
concentrated in vacuo. The residual brown oil was further dried in
vacuo to afford the crude desired
N-{3-[3-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-2-
-oxo-oxazolidin-5-ylmethyl}acetamide 81 (18.8 g, 20.0 g
theoretical, 94%) as a brown solid which was of sufficient purity
to be used in subsequent reactions.
Synthesis of Compound 1016
[0205] A solution of boronate ester 81 (0.085 g, 0.220 mmol),
bromide 80 (0.055 g, 0.220 mmol), and potassium carbonate (0.12 g,
0.90 mmol) in dioxane (1.4 mL), ethanol (0.46 mL) and water (0.46
mL) was degassed and treated with Pd(dppf)Cl.sub.2 (6.0 mg, 6.7
.mu.mol), degassed again, and heated at 80.degree. C. for 1.5 h.
The reaction mixture was diluted with CH.sub.2Cl.sub.2 and water,
and the precipitate in the water layer was recovered by vacuum
filtration to afford 1016 as a grey powder (0.034 g; 36%). LCMS
(ESI) m/z 427 (M+H).sup.+.
Synthesis of Bromide 82
[0206] A solution of hydroxyamidine 79 (0.25 g, 1.1 mmol) in
pyridine (5 mL) was cooled to 0.degree. C. and treated with a
solution of acetic anhydride (0.11 mL, 1.1 mmol) in pyridine (5 mL)
and then stirred at 120.degree. C. for 1.5 h. The reaction mixture
was diluted with ethyl acetate, washed with 1.0 M HCl (aqueous),
washed with saturated aqueous sodium bicarbonate, dried over
Na.sub.2SO.sub.4, and the solvent evaporated in vacuo. The crude
product was purified by flash chromatography to afford bromide 82
as a clear film (0.10 g; 36%).
Synthesis of Compound 1017
[0207] A solution of boronate ester 81 (0.15 g, 0.40 mmol), bromide
82 (0.10 g, 0.40 mmol), and potassium carbonate (0.22 g, 1.6 mmol)
in dioxane (2.5 mL), ethanol (0.83 mL) and water (0.83 mL) was
degassed and treated with Pd(dppf)Cl.sub.2 (10.0 mg, 0.012 mmol),
degassed again, and stirred at 80.degree. C. for 2 h. The reaction
mixture was diluted with CH.sub.2Cl.sub.2 and washed with water.
The water layer was extracted with 2.times.CH.sub.2Cl.sub.2, dried
over Na.sub.2SO.sub.4, and the solvent evaporated in vacuo. The
crude product was purified by flash chromatography and preparative
TLC to afford 1017 as a white powder (0.054 g; 32%). LCMS (ESI) m/z
425 (M+H).sup.+.
Example 7
Synthesis of Compounds 1018-1019
[0208] Scheme 7 illustrates the synthesis of compounds 1018-1019.
Known aryl iodide 83 was coupled to 4-hydroxymethylboronic acid to
afford biaryl alcohol 84. Alcohol 84 was converted to azide 85,
which was used in alkyne cycloaddition reactions to afford
triazoles 1018 and 1019.
##STR00613##
Synthesis of Azide 85
[0209] Known aryl iodide 83 (Gravestock, M. B., International
Patent Application WO9910342) (1.00 g, 2.52 mmol) was dissolved in
6 mL DMF. 4-Hydroxymethyl-phenylboronic acid (0.461 g, 3.03 mmol)
was added, followed by potassium phosphate (K.sub.3PO.sub.4, 0.804
g, 3.79 mmol) and Pd(PPh.sub.3).sub.4 (0.292 g, 0.253 mmol). The
mixture was degassed by evacuating the air from the flask, and
refilling with argon (3 times), and then heated to 100.degree. C.
for 4 hours. The mixture was allowed to cool and was then
partitioned between ethyl acetate and water. The aqueous phase was
extracted with ethyl acetate, and the combined organic phase was
washed with brine, dried over MgSO.sub.4, and evaporated. The
residue was chromatographed on silica using a gradient mixture of
methanol/methylene chloride (1% to 8%) to afford alcohol 84 (0.315
g, 0.838 mmol; 33%) as an ivory solid. An analytical sample was
obtained by recrystallizing the material from methanol/methylene
chloride/pentane. LCMS (ESI) m/z 377.
[0210] Alcohol 84 (0.889 g, 2.36 mmol) was suspended in 0.3 mL
methylene chloride and 0.3 mL DMF. Triethylamine (0.66 mL, 4.74
mmol) was added, and the mixture was cooled to 0.degree. C.
Methanesulfonyl chloride (0.260 mL, 3.36 mmol) was added dropwise,
and the mixture was stirred for 25 minutes. The mixture was then
partitioned with ethyl acetate and water, and the organic layer was
washed with brine, dried over MgSO.sub.4, and evaporated. The
residue was dissolved in 3 mL DMF, and sodium azide (0.384 g, 5.91
mmol) was added. The mixture was heated to 70.degree. C. for 4
hours. The reaction mixture was partitioned with ethyl acetate and
water, and the organic layer was washed with brine, dried over
MgSO.sub.4, and evaporated. The residue was chromatographed on
silica using a gradient mixture of methanol/methylene chloride (1%
to 4%) to afford azide 85 (0.480 g, 1.20 mmol; 51%) as a tan solid.
LCMS (ESI) m/z 402.
Synthesis of Triazole 1018
[0211] Azide 85 (0.084 g, 0.209 mmol) was dissolved in 0.7 mL THF
and propargyl alcohol (25 .mu.L, 0.400 mmol) was added, followed by
Hunig's base (73 .mu.L, 0.400 mmol) and copper(I) iodide (0.040 g,
0.210 mmol). The mixture was allowed to stir overnight at room
temperature, and then was placed in a -20.degree. C. freezer for 2
days. The mixture was then partitioned with ethyl acetate and
water, and the aqueous layer was extracted with ethyl acetate and
then 2% methanol/methylene chloride. The combined organic layer was
washed with brine, dried over MgSO.sub.4 and evaporated. The
residue was chromatographed on silica using a gradient mixture of
methanol/methylene chloride (1% to 8%) to afford triazole 1018
(0.060 g, 0.131 mmol; 63%) as an ivory solid. LCMS (ESI) m/z
458.
Synthesis of Triazole 1019
[0212] Azide 85 (0.135 g, 0.337 mmol) was dissolved in 1.5 mL THF
and dimethyl-prop-2-ynyl-amine (72 .mu.L, 0.674 mmol) was added,
followed by i-Pr.sub.2NEt (117 .mu.L, 0.674 mmol) and
copper(I)iodide (0.064 g, 0.337 mmol). The mixture was allowed to
stir overnight at room temperature (the solvents evaporated
overnight with positive pressure from argon gas). The residue was
suspended in ethyl acetate and methylene chloride and filtered
through celite. The pad of celite was washed with ethyl acetate and
methylene chloride, and the combined organic washes were
evaporated. The residue was chromatographed on silica using a
gradient mixture of methanol/methylene chloride (0% to 14%) and the
product obtained was triturated with methylene chloride and
pentane. The tan solid was collected to afford triazole 1019 (0.072
g, 0.149 mmol; 44%). LCMS (ESI) m/z 485.
Example 8
Synthesis of Compounds 1020-1021
[0213] Scheme 8 illustrates the synthesis of compounds 1020-1021.
Bromoketone 86 was subjected to alkylation with thioureas 87a and
87b to afford thiazoles 88a and 88b respectively. Coupling of 88a
and 88b with boronate 81 yielded thiazoles 1020 and 1021.
##STR00614##
Synthesis of Thiazole 88a
[0214] Bromoketone 86 (0.29 g, 1.0 mmol) was dissolved in dioxane
(10 mL). Thiourea 87a (0.19 g, 1.2 mmol) and potassium carbonate
(0.28 g, 2 mmol) were added sequentially and the resulting slurry
stirred at 50.degree. C. for 4 h. The mixture was cooled to room
temperature, diluted with 100 mL CH.sub.2Cl.sub.2, and washed with
sat. aq. NaHCO.sub.3, and brine. The aqueous washes were
back-extracted with CH.sub.2Cl.sub.2 (2.times.50 mL). The combined
organic extracts were dried over K.sub.2CO.sub.3, filtered and
concentrated in vacuo to afford 88a as a yellow solid (0.32 g)
which was used without further purification. LCMS (ESI) m/z 353
(M+H).sup.+.
Synthesis of Thiazole 1020
[0215] The crude aryl bromide 88a obtained above (0.20 g, 0.56
mmol), boronate ester 81 (0.25 g, 0.66 mmol), and K.sub.2CO.sub.3
(0.14 g, 1.0 mmol) were combined with a 1:1:1 mixture of toluene,
ethanol and water (2 mL each). The slurry was degassed by
alternately applying high vacuum to the reaction mixture and
flushing with dry argon. The reaction vessel was then sealed and
heated in an 80.degree. C. oil bath for 14 h. The reaction mixture
was cooled to room temperature, diluted with 100 mL 9:1
CH.sub.2Cl.sub.2/MeOH, and washed with water and brine (50 mL
each). The aqueous washes were back-extracted once with 50 mL 9:1
CH.sub.2Cl.sub.2/MeOH. The combined organic extracts were dried on
K.sub.2CO.sub.3, filtered, and concentrated in vacuo to afford 0.48
g of a brown solid which was purified by silica gel chromatography
(25 mm.times.6'' column eluted with 7:3 acetone/hexane) to yield
1020 as an off-white solid (0.17 g, 0.32 mmol). LCMS (ESI) m/z 525
(M+H).sup.+.
Synthesis of Thiazole 1021
[0216] Compound 21 was synthesized according to the procedure
described above for 1020, using thiourea 88b in place of 88a. The
reaction yielded 1021 as a white solid (0.12 g, 0.21 mmol). LCMS
(ESI) m/z 561 (M+H).sup.+.
Example 9
Synthesis of Compounds 1022-1025
[0217] Scheme 9 illustrates the synthesis of compounds 1022-1025.
Azetidine 89 was deprotected and alkylated with chloride 90 to
afford amide 91. The amide of 91 was dehydrated with
trifluoroacetic anhydride to produce nitrile 1022. The alkylation
of 1,2,3-triazole with benzyl chloride 90 gave triazole 1023.
Similarly, the alkylation of 5-aminotetrazole with benzyl chloride
90 yielded a mixture of tetrazole 1024 and tetrazole 1025.
##STR00615##
Synthesis of Chloride 90
[0218]
N-[3-(2-fluoro-4'-hydroxymethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-y-
lmethyl]-acetamide 51 (3.0 g, 8.4 mmol) 51 was dissolved in
CH.sub.2Cl.sub.2 (20 mL) and Hunig's base (2 mL). Methanesulfonyl
chloride (1.4 mL, 12.6 mmol) was added dropwise and the resulting
solution stirred at room temperature for 4 h. The mixture was
poured into 100 mL sat. aqueous NaHCO.sub.3 and extracted with
CH.sub.2Cl.sub.2 (3.times.50 mL). The combined organic extracts
were washed with brine, dried over MgSO.sub.4, filtered, and
concentrated to give 3.9 g of an oily yellow solid. The crude
material was purified by silica gel chromatography to give chloride
90 as an off-white solid (2.7 g, 7.2 mmol). LCMS (ESI) m/z 377
(M+H).sup.+, 418 (M+CH.sub.3CN+H).sup.+, 440
(M+CH.sub.3CN+Na).sup.+.
Synthesis of Amide 91
[0219] A solution of 89 (J. Med. Chem. 1993, 36, 801) (33 mg, 0.17
mmol) in CH.sub.2Cl.sub.2 (1.0 mL) was treated with 4.0 M
HCl-dioxane (0.2 mL) and stirred at 23.degree. C. for 2 h. The
reaction mixture was evaporated and the residue dissolved in DMF
(1.0 mL) and treated with benzyl chloride 90 (63 mg, 0.17 mmol) and
Hunig's base (0.17 mL, 1.0 mmol) and stirred at 60.degree. C. for 2
h. The reaction mixture was cooled to 23.degree. C., diluted with
H.sub.2O (10 mL) and extracted with CH.sub.2Cl.sub.2 (4.times.25
mL), dried (Na.sub.2SO.sub.4) and evaporated. The crude residue was
purified by preparative TLC (1% NH.sub.4OH-10% MeOH-89%
CH.sub.2Cl.sub.2) to afford 91 (36 mg; 50%) as a tan powder. LCMS
(ESI) m/z 441.1 (M+H).sup.+.
Synthesis of Nitrile 1022
[0220] A solution of 91 (26 mg, 0.06 mmol) in CH.sub.2Cl.sub.2 (1.0
mL) was treated with pyridine (0.02 mL, 0.2 mmol) and
trifluoroacetic anhydride (0.035 mL, 0.21 mmol) and stirred at
0.degree. C. for 1 h. The reaction mixture was directly purified by
preparative TLC (1% NH.sub.4OH-10% MeOH-89% CH.sub.2Cl.sub.2) to
afford 1022 (6.0 mg; 24%) as a tan powder. LCMS (ESI) m/z 423.1
(M+H).sup.+.
Synthesis of Triazole 1023
[0221] A solution of 90 (0.19 g, 0.50 mmol) in DMF (2.0 mL) was
treated with 1,2,3-triazole (0.058 mL, 1.0 mmol) and cesium
carbonate (Cs.sub.2CO.sub.3, 0.33 g, 1.0 mmol) and stirred at
23.degree. C. for 16 h. The reaction mixture was diluted with
H.sub.2O (100 mL) and the resulting precipitate was isolated by
filtration and purified by preparative TLC (10% MeOH-45%
CH.sub.2Cl.sub.2-45% EtOAc) to afford 1023 (39 mg; 19%) as a white
powder. LCMS (ESI) m/z 473.2 (M+CH.sub.3CN+Na).sup.+.
Synthesis of Tetrazoles 1024 and 1025
[0222] A solution of 90 (0.19 g, 0.50 mmol) in DMF (2.0 mL) was
treated with 5-aminotetrazole (87 mg, 1.0 mmol) and
Cs.sub.2CO.sub.3 (0.33 g, 1.0 mmol) and stirred at 23.degree. C.
for 12 h. The reaction mixture was diluted with H.sub.2O (100 mL)
and the resulting precipitate was isolated by filtration and
suspended in 50 mL of a 1:1 mixture of CH.sub.2Cl.sub.2 and MeOH.
The insoluble material (55 mg; 26%) was isolated by filtration and
assigned the structure of 1024. LCMS (ESI) m/z 426.1 (M+H).sup.+.
The soluble material was isolated by evaporation and purified by
preparative TLC (1% NH.sub.4OH-10% MeOH-89% CH.sub.2Cl.sub.2) to
afford a white powder assigned the structure of 1025 (39 mg; 19%).
LCMS (ESI) m/z 489.2 (M+CH.sub.3CN+Na).sup.+.
Example 10
Synthesis of Compounds 1026 and 1027
[0223] Scheme 10 illustrates the synthesis of compounds 1026 and
1027. Azide 53 was converted to triazole 1026, which was then
subsequently cyclized to compound 1027.
##STR00616##
Synthesis of Triazole 1026
[0224] A solution of azide 53 (383 mg, 1.0 mmol) in ethanol (4.0
mL) was treated with cyanoacetamide (101 mg, 1.2 mmol) and a
solution of sodium ethoxide (21% wt solution in ethanol, 648 mg,
0.75 mL) at room temperature under N.sub.2. The resulting reaction
mixture was stirred for 10 min at room temperature before being
warmed up to reflux for 2 h. When TLC showed that the reaction was
complete, the reaction mixture was cooled down to room temperature
before being treated with H.sub.2O (10 mL). The white precipitate
was then collected by filtration, washed with H.sub.2O (2.times.10
mL), and dried in vacuo to afford the desired triazole 1026 (312
mg; 67%) as an off-white powder, which was of sufficient purity to
be used directly in subsequent reactions. LCMS (ESI) m/z 468
(M+H).
Synthesis of Compound 1027
[0225] A suspension of 1026 (165 mg, 0.353 mmol) in anhydrous THF
(5 mL) was treated with p-toluenesulfonic acid monohydrate (34.2
mg, 0.18 mmol) and trimethyl orthoformate (374 mg, 0.386 mL, 3.53
mmol) at 25.degree. C. under N.sub.2, and the resulting mixture was
warmed up to reflux for 2 h. The solvents were removed in vacuo,
and the residue was directly purified by column chromatography
(5-10% MeOH/CH.sub.2Cl.sub.2 gradient elution) to afford the
desired compound 1027 (42 mg; 25%) as a white powder. LCMS (ESI)
m/z 478 (M+H).sup.+.
Example 11
Synthesis of Triazole 1028
[0226] A suspension of azide 53 (124 mg, 0.324 mmol) in anhydrous
1,4-dioxane (5.0 mL) was treated with propargyl alcohol (182 mg,
0.19 mL, 3.24 mmol) at 25.degree. C., and the resulting reaction
mixture was warmed up to reflux for 12 h. When TLC and LCMS showed
the reaction was complete, the reaction mixture was concentrated in
vacuo, and the residue was directly purified by column
chromatography (0-5% MeOH/CH.sub.2Cl.sub.2 gradient elution) to
afford triazole 1028 (93.9 mg; 66%) as a pale-yellow solid. LCMS
(ESI) m/z 440 (M+H).sup.+.
Example 12
Synthesis of Piperazine 1029 and Piperidine 1030
[0227] Scheme 11 illustrates the reductive amination chemistry used
to synthesize 1029 and 1030.
##STR00617##
Synthesis of Piperazine 1029
[0228] A solution of aldehyde 92 (made from iodide 50 and
4-formylboronic acid in the same fashion as
N-[3-(2-fluoro-4'-hydroxymethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethy-
l]-acetamide in Example 1) (180 mg, 0.5 mmol) and
2-piperidin-4-yl-ethanol (65 mg, 0.065 mL, 0.5 mmol) in anhydrous
THF (4.0 mL) and anhydrous DMF (1.0 mL) was treated with sodium
triacetoxyborohydride (160 mg, 0.75 mmol) at 25.degree. C., and the
resulting mixture was stirred at 25.degree. C. for 12 h. When TLC
and LCMS showed the reductive amination reaction was complete, the
reaction mixture was concentrated in vacuo. The residue was
directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford piperazine 1029
(306 mg; 65%) as a colorless oil, which solidified upon standing at
room temperature in vacuo. LCMS (ESI) m/z 471 (M+H).sup.+.
Synthesis of Piperidine 1030
[0229] A solution of aldehyde 92 (356 mg, 1.0 mmol) and
2-piperazin-1-yl-ethanol (130 mg, 0.123 mL, 1.0 mmol) in anhydrous
THF (8.0 mL) and anhydrous DMF (1.6 mL) was treated with sodium
triacetoxyborohydride (NaB(OAc).sub.3H, 318 mg, 1.5 mmol) at
25.degree. C., and the resulting mixture was stirred at 25.degree.
C. for 12 h. When TLC and LCMS showed the reductive amination
reaction was complete, the reaction mixture was concentrated in
vacuo. The residue was directly purified by flash column
chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient elution) to
afford piperidine 1030 (169 mg; 72%) as a colorless oil, which
solidified upon standing at room temperature in vacuo. LCMS (ESI)
m/z 470 (M+H).sup.+.
Example 13
Synthesis of Imidazole 1031
[0230] Scheme 12 depicts the synthesis of tetrazole derivative
1031. D-p-Hydroxyphenyl-glycine was converted to triflate 95, which
was subsequently coupled to boronate 81 to afford alcohol 96.
Mesylation of 96, followed by displacement with the anion of
imidazole and deprotection of the BOC group yielded imidazole
derivative 1031.
##STR00618## ##STR00619##
Synthesis of Triflate 95
[0231] A solution of D-p-hydroxyphenylglycine (23.8 g, 142.3 mmol)
and potassium carbonate (39.3 g, 284.6 mmol) in THF (200 mL) and
H.sub.2O (200 mL) was treated with di-tert-butyl dicarbonate
(BOC.sub.2O, 34.14 g, 156.6 mmol) at 25.degree. C., and the
resulting reaction mixture was stirred at 25.degree. C. for 2 h.
When TLC and LCMS showed that the reaction was complete, the
reaction mixture was treated with ethyl acetate (200 mL) and
H.sub.2O (200 mL). The two layers were separated, and the aqueous
solution was extracted with ethyl acetate (200 mL), and the
combined organic extracts were discarded. The aqueous layer was
then acidified with a 2 N HCl aqueous solution to pH 4 before being
extracted with ethyl acetate (2.times.200 mL). The combined organic
extracts were then washed with water (2.times.100 mL) and saturated
aqueous NaCl solution (100 mL), dried over MgSO.sub.4, and
concentrated in vacuo. The residual white solids were further dried
in vacuo to afford the crude desired acid 93 (36.5 g; 96%), which
was of suitable purity for use in subsequent reactions.
[0232] A solution of acid 93 (4.005 g, 15 mmol) in anhydrous THF
(20 mL) was treated dropwise with a 1 M solution of BH.sub.3-THF in
THF (30 mL, 30 mmol) at 0-5.degree. C., and the resulting reaction
mixture was stirred at 0-5.degree. C. for an additional 2 h. When
TLC and LCMS showed that the reduction reaction was complete, the
reaction mixture was treated with water (50 mL) and ethyl acetate
(50 mL). The mixture was then stirred at 25.degree. C. for 30 min
before being separated, and the aqueous layer was extracted with
ethyl acetate (2.times.50 mL). The combined organic extracts were
then washed with water (2.times.20 mL) and saturated aqueous NaCl
solution (20 mL), dried over MgSO.sub.4, and concentrated in vacuo.
The residue was then directly purified by flash column
chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient elution) to
afford desired alcohol 94 (2.50 g; 66%) as a white powder which was
of suitable purity for use in subsequent reactions.
[0233] A suspension alcohol 94 (670 mg, 2.65 mmol) in
CH.sub.2Cl.sub.2 (10 mL) was treated with N-phenyltrifluoromethane
sulfonamide (947 mg, 2.65 mmol) and triethylamine (535.3 mg, 0.74
mL, 5.3 mmol) at 25.degree. C., and the resulting reaction mixture
was stirred at 25.degree. C. for an additional 2 h. When TLC and
LCMS showed that the reaction was complete, the reaction mixture
was quenched with water (10 mL) and CH.sub.2Cl.sub.2 (20 mL). The
two layers were then separated, and the aqueous layer was extracted
with CH.sub.2Cl.sub.2 (2.times.20 mL). The combined organic
extracts were then washed with water (2.times.10 mL) and saturated
aqueous NaCl solution (10 mL), dried over MgSO.sub.4, and
concentrated in vacuo. The residue was then directly purified by
flash column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford triflate 95 (945 mg; 93%) as a white powder
which was of suitable purity for use in subsequent reactions.
Synthesis of Alcohol 96
[0234] A solution of boronate 81 (2.162 g, 5.72 mmol) and triflate
95 (1.70 g, 4.4 mmol) in toluene (24 mL) was treated with solid
potassium carbonate (1.82 g, 13.2 mmol), ethanol (8.0 mL) and
H.sub.2O (8.0 mL) at room temperature, and the resulting reaction
mixture was degassed three times under a steady stream of argon
before being treated with Pd(dppf).sub.2Cl.sub.2 (184 mg, 0.22
mmol) at room temperature. The reaction mixture was then degassed
three times again under a steady stream of argon before being
warmed up to reflux for 2 h. When TLC and LCMS showed that the
reaction was complete, the reaction mixture was cooled down to room
temperature before being treated with water (20 mL) and ethyl
acetate (20 mL). The two layers were separated, and the aqueous
layer was extracted with ethyl acetate (2.times.20 mL). The
combined organic extracts were washed with water (2.times.20 mL)
and saturated aqueous NaCl solution (20 mL), dried over MgSO.sub.4,
and concentrated in vacuo. The residue was then purified by flash
column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford
(1-{4'-[5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl--
4-yl}-2-hydroxyethyl)carbamic acid tert-butyl ester 96 (1.543 g;
72%) as yellow oil, which solidified upon standing at room
temperature in vacuo.
Synthesis of Mesylate 97
[0235] A suspension of alcohol 96 (694 mg, 1.43 mmol) in anhydrous
CH.sub.2Cl.sub.2 (10 mL) was treated with diisopropylethylamine
(388 mg, 0.522 mL, 2.85 mmol) and methanesulfonyl chloride (196 mg,
0.132 mL, 1.71 mmol) at 0-5.degree. C., and the resulting reaction
mixture was stirred at 0-5.degree. C. for an additional 2 h. When
TLC and LCMS showed that the reaction was complete, the reaction
mixture was quenched with water (10 mL). The two layers were
separated, and the aqueous layer was extracted with
CH.sub.2Cl.sub.2 (2.times.10 mL). The combined organic extracts
were washed with water (2.times.10 mL) and saturated aqueous NaCl
solution (10 mL), dried over MgSO.sub.4, and concentrated in vacuo.
The residue was then purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford mesylate 97 (647
mg; 80%) as a pale-yellow solid, which was of suitable purity for
use in subsequent reactions.
Synthesis of Imidazole 98
[0236] A solution of imidazole (41 mg, 0.6 mmol) in anhydrous THF
(3 mL) was treated with NaH (60% oil dispersion, 29 mg, 0.72 mmol)
at 0.degree. C., and the resulting mixture was stirred at
0-5.degree. C. for 30 min before a solution of mesylate 97 (170 mg,
0.3 mmol) in anhydrous DMF (3.0 mL) was added. The resulting
reaction mixture was then stirred at 0-5.degree. C. for 30 min
before being gradually warmed up to room temperature for 12 h. When
TLC and LCMS showed that the reaction was complete, the solvents
were removed in vacuo, and the residue was directly purified by
flash column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford imidazole 98 (46 mg; 29%) as a yellow solid.
Synthesis of Imidazole 1031
[0237] A solution of imidazole 98 (23 mg, 0.043 mmol) in MeOH (1.0
mL) was treated with a solution of 4 N HCl in 1,4-dioxane (3.0 mL),
and the resulting reaction mixture was stirred at room temperature
for 30 min. When TLC and LCMS showed that the reaction was
complete, the solvents were removed in vacuo, and the desired
N-{3-[4'-(1-amino-2-imidazol-1-yl-ethyl)-2-fluoro-biphenyl-4-yl]-2-oxo-ox-
azolidin-5-ylmethyl}acetamide hydrochloride 1031 (18.8 mg; 100%)
was obtained as a yellow solid. LCMS (ESI) m/z 438 (M+H).sup.+.
Example 14
Synthesis of tetrazoles 1032-1034
[0238] Scheme 13 depicts the synthesis of tetrazole derivatives
1032-1034. Iodide 99 was converted to boronate 100 which served as
the coupling partner for bromide 101 to afford tetrazole 102.
Deprotection of 102 afforded tetrazole amine 1032, which was
subsequently acylated to afford tetrazole 1033 and 1034.
##STR00620##
Synthesis of Iodide 99
[0239] A solution of known
5-aminomethyl-3-(3-fluoro-4-iodo-phenyl)-oxazolidin-2-one (2.02 g,
6.0 mmol; see U.S. Pat. Nos. 5,523,403 and 5,565,571) and potassium
carbonate (1.66 g, 12.0 mmol) in THF (20 mL) and H.sub.2O (20 mL)
was treated with BOC.sub.2O (1.334 g, 6.12 mmol) at 25.degree. C.,
and the resulting reaction mixture was stirred at 25.degree. C. for
2 h. When TLC and LCMS showed the reaction was complete, the
reaction mixture was treated with ethyl acetate (20 mL) and
H.sub.2O (20 mL). The two layers were separated, and the aqueous
solution was extracted with ethyl acetate (20 mL), and the combined
organic extracts were then washed with water (2.times.10 mL) and
saturated aqueous NaCl solution (10 mL), dried over MgSO.sub.4, and
concentrated in vacuo. The residual white solids were further dried
in vacuo to afford the crude, desired iodide 99 (2.40 g; 92%),
which was of suitable purity for use in subsequent reactions.
Synthesis of Boronate 100
[0240] A solution of iodide 99 (1.11 g, 2.55 mmol) in 1,4-dioxane
(25 mL) was treated with 4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
(489 mg, 0.56 mL, 3.82 mmol) and triethylamine (772 mg, 1.07 mL,
7.65 mmol) at room temperature, and the resulting reaction mixture
was degassed three times under a steady stream of argon before
being treated with Pd(dppf).sub.2Cl.sub.2 (107 mg, 0.13 mmol) at
room temperature. The reaction mixture was then degassed three
times again under a steady stream of argon before being warmed up
to reflux for 6 h. When TLC and LCMS showed that the reaction was
complete, the reaction mixture was cooled down to room temperature
before being treated with water (20 mL) and ethyl acetate (20 mL).
The two layers were separated, and the aqueous layer was extracted
with ethyl acetate (2.times.20 mL). The combined organic extracts
were washed with water (2.times.20 mL) and saturated aqueous NaCl
solution (20 mL), dried over MgSO.sub.4, and concentrated in vacuo.
The residual brown oil was then purified by flash column
chromatography (10-30% EtOAc-hexanes gradient elution) to afford
boronate 100 (646 mg; 58%) as a brown oil, which solidified upon
standing at room temperature in vacuo and was of suitable purity
for use in subsequent reactions.
Synthesis of Bromide 101
[0241] A solution of 4-bromobenzylamine hydrochloride (2.22 g, 10.0
mmol) in acetic acid (30 mL) was treated with triethyl orthoformate
(2.964 g, 3.29 mL, 20.0 mmol) and sodium azide (2.30 g, 20.0 mmol)
at room temperature, and the resulting reaction mixture was
subsequently stirred at reflux for 12 h. When TLC and LCMS showed
that the reaction was complete, the reaction mixture was cooled
down to room temperature, and the cooled reaction mixture was
poured into ice-water (100 mL). The precipitate was then collected
by filtration, washed with water (2.times.20 mL), and dried in
vacuo to afford crude bromide 101 (460 mg; 19%) as a white solid,
which was of suitable purity for use in subsequent reactions.
Synthesis of Tetrazole 102
[0242] A solution of boronate 100 (658 mg, 1.5 mmol) and bromide
101 (300 mg, 1.25 mmol) in toluene (9.0 mL) was treated with solid
potassium carbonate (621 mg, 4.5 mmol), ethanol (3.0 mL) and
H.sub.2O (3.0 mL) at room temperature, and the resulting reaction
mixture was degassed three times under a steady stream of argon
before being treated with Pd(dppf).sub.2Cl.sub.2 (52.3 mg, 0.063
mmol) at room temperature. The reaction mixture was then degassed
three times again under a steady stream of argon before being
warmed up to reflux for 3 h. When TLC and LCMS showed that the
reaction was complete, the reaction mixture was cooled down to room
temperature before being treated with water (10 mL) and ethyl
acetate (20 mL). The two layers were separated, and the aqueous
layer was extracted with ethyl acetate (2.times.10 mL). The
combined organic extracts were washed with water (2.times.5 mL) and
saturated aqueous NaCl solution (5 mL), dried over MgSO.sub.4, and
concentrated in vacuo. The residue was then purified by flash
column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford tetrazole 102 (357 mg; 61%) as a yellow oil,
which solidified upon standing at room temperature in vacuo.
Synthesis of Tetrazole 1032
[0243] A solution of tetrazole 102 (350 mg, 0.748 mmol) in EtOAc
(5.0 mL) was treated with a solution of 4 N HCl in 1,4-dioxane (5.0
mL), and the resulting reaction mixture was stirred at room
temperature for 30 min. When TLC and LCMS showed that the reaction
was complete, the solvents were removed in vacuo, and the residue
was treated with an aqueous sodium bicarbonate solution (10 mL) and
EtOAc (15 mL). The mixture was stirred at room temperature for 30
min before the two layers were separated. The aqueous layer was
extracted with EtOAc (10 mL), and the combined organic extracts
were washed with H.sub.2O (10 mL) and saturated aqueous NaCl
solution (10 mL), dried over MgSO.sub.4, and concentrated in vacuo
to afford tetrazole amine 1032 (266 mg; 97%) as a pale-yellow
solid. LCMS (ESI) m/z 369 (M+H).sup.+.
Synthesis of Tetrazole 1033
[0244] A suspension of tetrazole amine 1032 (74 mg, 0.2 mmol) in
anhydrous CH.sub.2Cl.sub.2 (5.0 mL) was treated with
diisopropylethylamine (52 mg, 0.07 mL, 0.4 mmol) and chloroacetyl
chloride (34 mg, 0.024 mL, 0.3 mmol) at 0-5.degree. C., and the
resulting reaction mixture was stirred at 0-5.degree. C. for 2 h.
When TLC and LCMS showed the reaction was complete, the reaction
mixture was concentrated in vacuo. The residue was directly
purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford tetrazole 1033
(43 mg; 48% yield) as a white solid. LCMS (ESI) m/z 445
(M+H).sup.+.
Synthesis of Tetrazole 1034
[0245] A suspension of tetrazole amine 1032 (74 mg, 0.2 mmol) in
anhydrous CH.sub.2Cl.sub.2 (5.0 mL) was treated with
diisopropylethylamine (52 mg, 0.07 mL, 0.4 mmol) and dichloroacetyl
chloride (44 mg, 0.029 mL, 0.3 mmol) at 0-5.degree. C., and the
resulting reaction mixture was stirred at 0-5.degree. C. for 2 h.
When TLC and LCMS showed the reaction was complete, the reaction
mixture was concentrated in vacuo. The residue was directly
purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford tetrazole 1034
(41 mg; 43% yield) as a white solid. LCMS (ESI) m/z 479
(M+H).sup.+.
Example 15
Synthesis of Compounds 1035 and 1036
[0246] Scheme 14 depicts the synthesis of tetrazole derivatives
1035 and 1036. Aldehyde 103 was reduced to 104 which was coupled to
boronate 81 to yield alcohol 105. Mesylation of 105, followed by
displacement with sodium azide, yielded azide 107. Reduction of 107
to amine 108 was followed by conversion to tetrazole 1035.
Cycloaddition of azide 107 with trimethylsilylacetylene, followed
by desilylation, afforded triazole 1036.
##STR00621##
Synthesis of Aldehyde 103
[0247] A solution of 2,5-dibromopyridine (25 g, 105.5 mmol) in
toluene (1.24 L) was cooled down to -78.degree. C. before being
treated dropwise with a 2.5 M solution of n-BuLi in hexane (50.6
mL, 126.6 mmol) at -78.degree. C. under N.sub.2. The resulting
reaction mixture was stirred at -78.degree. C. for 1 h before being
treated with anhydrous DMF (11.6 g, 12.2 mL, 158.0 mmol) at
-78.degree. C. The reaction mixture was stirred at -78.degree. C.
for an additional 1 h before being gradually warmed up to room
temperature for 6 h. When TLC and LCMS showed that the reaction was
complete, the reaction mixture was quenched with water (200 mL).
The two layers were separated, and the aqueous layer was extracted
with ethyl acetate (2.times.50 mL). The combined organic extracts
were then washed with H.sub.2O (2.times.200 mL), and saturated
aqueous NaCl solution (100 mL), and dried over MgSO.sub.4. The
solvents were then removed in vacuo, and the residual pale-yellow
oil was purified by flash column chromatography (0-15% EtOAc-hexane
gradient elution) to afford aldehyde 103 (10.2 g; 52%) as a
pale-yellow solid.
Synthesis of Bromide 104
[0248] A solution aldehyde 103 (4.91 g, 26.4 mmol) in methanol (120
mL) was treated with sodium borohydride (1.18 g, 31.7 mmol) at
0-5.degree. C., and the resulting reaction mixture was stirred at
0-5.degree. C. for an additional 1 h. When TLC and LCMS showed that
the reaction was complete, the reaction mixture was quenched with
water (20 mL). The solvents were then removed in vacuo, and the
residue was directly purified by flash column chromatography (5-25%
EtOAc-hexane gradient elution) to afford bromide 104 (4.23 g; 85%)
as a white solid.
Synthesis of Alcohol 105
[0249] A solution of boronate 81 (11.05 g, 29.2 mmol) and bromide
104 (4.227 g, 22.5 mmol) in toluene (150 mL) was treated with solid
potassium carbonate (9.315 g, 67.5 mmol), ethanol (50 mL) and
H.sub.2O (50 mL) at room temperature, and the resulting reaction
mixture was degassed three times under a steady stream of argon
before being treated with Pd(dppf).sub.2Cl.sub.2 (564 mg, 0.675) at
room temperature. The reaction mixture was then degassed three
times again under a steady stream of argon before being warmed up
to reflux for 1 h. When LCMS showed that the reaction was complete,
the reaction mixture was cooled down to room temperature before
being treated with water (200 mL) and ethyl acetate (100 mL). The
two layers were separated, and the aqueous layer was extracted with
ethyl acetate (2.times.50 mL). The combined organic extracts were
washed with water (2.times.50 mL) and saturated aqueous NaCl
solution (50 mL), dried over MgSO.sub.4, and concentrated in vacuo.
The residue was then purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford alcohol 105
(6.16 g; 76%) as a grey solid.
Synthesis of Azide 107
[0250] A suspension of alcohol 105 (2.15 g, 6.0 mmol) in
CH.sub.2Cl.sub.2 (25 mL) was treated with diisopropylethylamine
(1.551 g, 2.10 mL, 12.0 mmol) and methanesulfonyl chloride (756 mg,
0.511 mL, 6.6 mmol) at 0-5.degree. C., and the resulting reaction
mixture was stirred at 0-5.degree. C. for an additional 2 h. When
TLC and LCMS showed that the reaction was complete, the reaction
mixture was treated with water (20 mL) and CH.sub.2Cl.sub.2 (40
mL). The two layers were separated, and the aqueous layer was
extracted with CH.sub.2Cl.sub.2 (20 mL). The combined organic
extracts were washed with water (20 mL) and saturated aqueous NaCl
solution (20 mL), dried over MgSO.sub.4, and concentrated in vacuo.
The residue was then purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford mesylate 106
(2.47 g; 94%) as a yellow solid.
[0251] A solution of mesylate 106 (874 mg, 2.0 mmol) in DMF (8.0
mL) was treated with sodium azide (260 mg, 4.0 mmol) at room
temperature, and the resulting reaction mixture was warmed up to
40-45.degree. C. for 3 h. When TLC and LCMS showed that the
reaction was complete, the reaction mixture was treated with water
(20 mL), and the precipitate was collected by filtration, washed
with water (2.times.10 mL), and dried in vacuo to afford crude
azide 107 (699 mg; 91%) as a grey solid, which was of suitable
purity for use in subsequent reactions.
Synthesis of Amine 108
[0252] A suspension of azide 107 (2.611 g, 6.8 mmol) in THF (25 mL)
was treated with water (0.13 mL, 68 mmol) and triphenylphosphine
(PPh.sub.3, 2.14 g, 8.2 mmol) at room temperature, and the
resulting reaction mixture was subsequently stirred at room
temperature for 12 h. When TLC and LCMS showed that the reaction
was complete, the solvents were removed in vacuo, and the residue
was directly purified by flash column chromatography (0-15%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford amine 108 (2.233
g; 92%) as a yellow solid.
Synthesis of Tetrazole 1035
[0253] A solution of amine 108 (90 mg, 0.25 mmol) in acetic acid
(3.0 mL) was treated with triethyl orthoformate (0.1 mL) and sodium
azide (40 mg) at room temperature, and the resulting reaction was
subsequently stirred at reflux for 4 h. When TLC and LCMS showed
that the reaction was complete, the reaction mixture was cooled
down to room temperature and concentrated in vacuo. The residue was
then directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford tetrazole 1035
(43 mg; 36%) as a white solid. LCMS (ESI) m/z 412 (M+H).sup.+.
Synthesis of Triazole 1036
[0254] A solution of azide 107 (142 mg, 0.37 mmol) in DMF (5 mL)
was treated with thimethylsilyl acetylene (0.5 mL) at room
temperature, and the resulting reaction mixture was subsequently
stirred at 70-80.degree. C. for 12 h. When TLC and LCMS showed that
the reaction was complete, the reaction mixture was cooled down to
room temperature before being concentrated in vacuo. The residue
was then directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford triazole 109
(152 mg; 85%) as a pale-yellow oil, which was directly used in the
subsequent reaction.
[0255] A solution of triazole 109 (152 mg, 0.315 mmol) in THF (10
mL) was treated with a 1N solution of tetrabutylammonium fluoride
in THF (2.0 mL) at 0-5.degree. C., and the resulting reaction
mixture was stirred at 0-5.degree. C. for 1 h before being
gradually warmed up to room temperature for 10 h. When TLC and LCMS
showed that the reaction was complete, the reaction mixture was
cooled down to room temperature before being concentrated in vacuo.
The residue was then directly purified by flash column
chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient elution) to
afford triazole 1036 (67 mg; 52%) as a pale-yellow oil, which
solidified upon standing at room temperature in vacuo. LCMS (ESI)
m/z 411 (M+H).sup.+.
Example 16
Synthesis of Triazole 1037
[0256] A solution of mesylate 52 (436 mg, 1.0 mmol) in anhydrous
DMF (5 mL) was treated with 1,2,4-triazole sodium salt (182 mg, 2.0
mmol) at 0-5.degree. C., and the resulting reaction mixture was
stirred at 0-5.degree. C. for 1 h before being gradually warmed up
to room temperature for 10 h. When TLC and LCMS showed that the
reaction was complete, the reaction mixture was concentrated in
vacuo. The residue was then directly purified by flash column
chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient elution) to
afford triazole 1037 (388 mg; 95%) as a white solid. LCMS (ESI) m/z
410 (M+H).sup.+.
Example 17
Synthesis of Piperazine 1038
[0257] A suspension of the aldehyde 92 (142 mg, 0.4 mmol) in MeOH
(4.0 mL) and THF (1.0 mL) was treated with
1-(3-chloro-5-trifluoromethyl-pyridin-2-yl)piperazine (106 mg, 0.4
mmol) and sodium triacetoxyborohydride (160 mg, 0.8 mmol) at
25.degree. C., and the resulting reaction mixture was stirred at
25.degree. C. for 6 h. When TLC and LCMS showed the reductive
amination reaction was complete, the reaction mixture was
concentrated in vacuo. The residue was directly purified by flash
column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford piperazine 1038 (38 mg; 16% yield) as a
colorless oil, which solidified upon standing at room temperature
in vacuo. LCMS (ESI) m/z 607 (M+H).sup.+.
Example 18
Synthesis of Tetrazoles 1039-1042
[0258] Scheme 15 shows the synthesis of compounds 1039-1042.
Nitrile 110 is converted to tetrazole 1039, which was deprotected
to afford tetrazole 1040. Tetrazole 1039 is methylated to afford
1041, which was subsequently deprotected to yield 1042.
##STR00622##
Synthesis of Nitrile 110
[0259] A suspension of aldehyde 92 (1.884 g, 5.3 mmol) in MeOH (25
mL) was treated with a solution of NaCN (312 mg, 6.4 mmol) in
H.sub.2O (10 mL) and a solution of ammonium chloride (340 mg, 6.4
mmol) in H.sub.2O (15 mL) at 25.degree. C., and the resulting
mixture was stirred at 25.degree. C. for 30 min before being warmed
up to 50.degree. C. for 1 h. When TLC and LCMS showed that the
reaction was complete, the reaction mixture was cooled down to room
temperature before being treated with H.sub.2O (25 mL) at
25.degree. C., and the resulting mixture was cooled down to
0-5.degree. C. for 1 h. The solid precipitates were collected by
filtration, washed with H.sub.2O (2.times.20 mL) and 20%
EtOAc/hexane (2.times.20 mL), and dried in vacuo. The crude desired
N-{3-[4'-(amino-cyano-methyl)-2-fluoro-biphenyl-4-yl]-2-oxo-oxazolidin-5--
ylmethyl}-acetamide (1.801 g; 89% yield) was obtained as off-white
solids, which by HPLC and .sup.1H NMR was of sufficient purity to
be used in subsequent reactions. LCMS (ESI) m/z 383
(M+H).sup.+.
[0260] A solution of
N-{3-[4'-(amino-cyano-methyl)-2-fluoro-biphenyl-4-yl]-2-oxo-oxazolidin-5--
ylmethyl}-acetamide obtained above (1.70 g, 4.45 mmol) in THF (40
mL) and H.sub.2O (40 mL) was treated with benzyl chloroformate (940
mg, 5.34 mmol) and potassium carbonate (1.23 g, 8.9 mmol) at
25.degree. C., and the resulting reaction mixture was stirred at
25.degree. C. for 2 h. When TLC and LCMS showed the reaction was
complete, the reaction mixture was quenched with H.sub.2O (20 mL)
and EtOAc (50 mL). The two layers were separated, and the aqueous
layer was extracted with EtOAc (50 mL). The combined organic
extracts were washed with water (2.times.20 mL), and saturated
aqueous NaCl solution (20 mL), dried over MgSO.sub.4, and
concentrated in vacuo. The residue was then purified by column
chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient elution) to
afford the desired nitrile 110 (2.20 g; 96%) as a colorless oil,
which solidified upon standing at room temperature in vacuo. This
material by .sup.1H NMR was found to be a mixture of two
diastereomers. LCMS (ESI) m/z 517 (M+H).sup.+.
Synthesis of Tetrazole 1039
[0261] A solution of 0.130 g (2.52 mmol) of nitrile 110, 0.033 g
(5.04 mmol) of NaN.sub.3, and 0.028 g (1.26 mmol) of zinc bromide
(ZnBr.sub.2) in 9 ml of isopropanol/H.sub.2O (1:2) was allowed to
stir at reflux for 24 h. Once the reaction mixture cooled down, it
was diluted with 1 N HCl, extracted with MeOH/CH.sub.2Cl.sub.2
(1:3) (40 ml.times.3), and the combined organic layers were washed
with brine, dried over MgSO.sub.4, and evaporated to give 0.050 g
of tetrazole 1039 as a mixture of tautomers. LCMS (ESI) m/z 560
(M+H).sup.+.
Synthesis of Tetrazole 1040
[0262] A solution of 0.030 g of 1039 and 0.020 g of palladium on
carbon (Pd/C) (10%) in 6 ml of (1:1 H.sub.2O/THF) was allowed to
stir at 25.degree. C. under H.sub.2 atmosphere (balloon) for 16 h.
The reaction mixture was filtered through celite, and washed with
MeOH/CH.sub.2Cl.sub.2. The filtrate was concentrated, washed with
small amount of EtOAc, then dried via vacuum to give 0.010 g of
tetrazole 1040. LCMS (ESI) m/z 426 (M+H).sup.+.
Synthesis of Methyl Tetrazole 1041
[0263] A solution of 0.218 g (0.39 mmol) of 1039, 0.080 g (0.58
mmol) of K.sub.2CO.sub.3, and 0.061 g (0.43 mmol) of methyl iodide
(MeI) in 5 ml of DMF was allowed to stir at 25.degree. C. for 16 h.
The reaction solvent was removed by vacuum. The residue was
dissolved in a mixture of MeOH/CH.sub.2Cl.sub.2 (1:1), filtered
through a pipette column, and the filtrate was concentrated to give
the crude product 1041 in the amount of about 0.220 g. A small
amount was purified through preparative HPLC. LCMS (ESI) m/z 574
(M+H).sup.+.
Synthesis of Methyl Tetrazole 1042
[0264] A solution of 0.220 g of 1041 and 0.020 g of Pd (10% on
carbon) in 3 ml of DMF was allowed to stir at 25.degree. C. under
H.sub.2 atmosphere (balloon) for 24 h. The solvents were removed by
rotary evaporation, the residue was then dissolved in a mixture of
MeOH/CH.sub.2Cl.sub.2, and filtered through celite. The filtrate
was concentrated and further purified by preparative HPLC to give
0.052 g of methyl tetrazole 1042. LCMS (ESI) m/z 440
(M+H).sup.+.
Example 19
Synthesis of Pyrazole 1043
[0265] To a suspension of 0.048 g (2.0 mmol) of NaH and 0.125 g
(1.83 mmol) of pyrazole in 8 ml of DMF at 0.degree. C. was added
0.400 g (0.92 mmol) of mesylate 52. Then, the reaction mixture was
warmed up to 25.degree. C., and was allowed to stir for 3 h. The
DMF was removed and the residue was purified by preparative TLC to
give 0.360 g of pyrazole 1043 (96% yield). LCMS (ESI) m/z 409
(M+H).sup.+.
Example 20
Synthesis of Compounds 1044-1046
[0266] Scheme 16 depicts the synthesis of aryl bromides 112-114
required for the synthesis of compounds 1044-1046. Epoxide 111 was
treated with 1-formyl piperazine to afford a mixture of 112 and
113. Epoxide ring-opening of 111 with imidazole afforded 114. These
bromides were coupled with boronate 81 to deliver the target
compounds 1044-1046.
##STR00623##
Synthesis of epoxide 111
[0267] To a solution of 4-bromostyrene (5.00 g, 26.8 mmol) in
CH.sub.2Cl.sub.2 (130 mL) was added 4-methylmorpholine N-oxide
(NMO, 12.90 g, 107.1 mmol, anhydrous) and Jacobsen catalyst
((1S,2S)-(+)-[1,2-(cyclohexanodiamino-N,N'-bis(3,5-di-t-butyl-salicyliden-
e)]manganese(III) chloride, 850 mg, 1.34 mmol). The solution was
cooled to -78.degree. C., then m-chloroperbenzoic acid (r-CPBA,
7.40 g, 42.8 mmol) was added in four portions every 10 min. The
mixture was stirred at -78.degree. C. for 2 h. The reaction was
quenched by addition of sodium thiosulfate (Na.sub.2S.sub.2O.sub.3)
solution (10.0 g in 30 mL water), then the cooling bath was
removed, and water (70 mL), 1N sodium hydroxide (NaOH, 60 mL) was
added. The aqueous phase was extracted with CH.sub.2Cl.sub.2 (30
mL.times.3), dried with Na.sub.2SO.sub.4, and evaporated. The
residue was purified by flash chromatography (4:100
Et.sub.2O/Hexane) to yield 5.20 g epoxide 111 (98% yield).
General Procedure for the Synthesis of Bromides 112-114 from
Epoxide 111
[0268] To a suspension of epoxide 111 (1 mmol, 1 eq) in
acetonitrile (3.0 mL) at room temperature was added lithium
perchlorate (LiClO.sub.4, 1.05 mmol, 1.05 eq). After the formation
of a clear solution, the amine (1.5 mmol, 1.5 eq) was added. The
mixture was stirred at room temperature or at 60.degree. C. The
solvent was removed under vacuum and the residue was purified by
flash chromatography.
Conditions for 112 and 113: room temperature, 16 h, flash
chromatography (3:100 MeOH/CH.sub.2Cl.sub.2). Yield of 112: 132 mg;
Yield of 113: 42 mg. Conditions for 114: 60.degree. C., 4 h, flash
chromatography (3:100 MeOH/CH.sub.2Cl.sub.2). Yield of 114: 103 mg.
General Procedure for the Synthesis of Compounds 1044-1046 from
Bromides 112-114
[0269] A suspension of bromide intermediate (1 eq), boronate 81 (1
eq), PdCl.sub.2(dppf).sub.2 (0.05 eq), and K.sub.2CO.sub.3 (4 eq)
in a mixture of dioxane/EtOH/H.sub.2O (ratio of 3:1:1) was degassed
by a stream of argon. The mixture was stirred at 75.degree. C. to
85.degree. C. for 3 to 15 h. The solvent was removed by vacuum and
the residue was purified by flash chromatography to afford the
product.
Conditions for 1044: 80.degree. C., 3.5 h, flash chromatography
(4:100 MeOH/CH.sub.2Cl.sub.2); Yield 150 mg. LCMS (ESI) m/z 485
(M+H).sup.+. Conditions for 1045: 80.degree. C., 3.5 h, flash
chromatography (5:100 MeOH/CH.sub.2Cl.sub.2); Yield 52 mg. LCMS
(ESI) m/z 485 (M+H).sup.+. Conditions for 1046: 80.degree. C., 2.5
h, flash chromatography (10:100 MeOH/CH.sub.2Cl.sub.2); Yield 155
mg. LCMS (ESI) m/z 439 (M+H).sup.+.
Example 21
Synthesis of Compounds 1047 and 1048
[0270] Scheme 17 depicts the synthesis of tetrazoles 1047 and 1048.
Azides 53 and 85 were reduced to amines 115 and 116 respectively.
These amines were then converted to triazoles 1047 and 1048 by
treatment with sodium azide and trimethylorthoformate in hot acetic
acid.
##STR00624##
Synthesis of Amine 54
[0271] Amine 54 was prepared from azide 53 according to the method
described in Example 1.
Synthesis of Amine 116
[0272] Azide 85 (1.10 g, 2.74 mmol) was dissolved in 17 mL THF and
0.6 mL water. Triphenylphosphine (1.30 g, 4.96 mmol) was added, and
the mixture was heated to reflux for 4 h. The mixture was allowed
to stir overnight at room temperature, and was partitioned between
ethyl acetate and 20 mL 2N aqueous HCl. The organic layer was
extracted with 20 mL 2N aqueous HCl, and then the aqueous layer was
basified with 85 mL 1N aqueous NaOH. The cloudy aqueous phase was
extracted with ethyl acetate (2.times.), and 5% methanol/methylene
chloride (2.times.). The combined organic extracts were dried over
Na.sub.2SO.sub.4, and evaporated. The residue was chromatographed
on silica gel using a gradient elution of methylene chloride then
methanol/methylene chloride (up to 10% methanol) to afford amine
116 (0.587 g, 1.57 mmol; 57%) as a tan solid. LCMS (ESI) m/z 376
(M+H).sup.+.
Synthesis of Tetrazole 1047
[0273] A solution of amine 54 (0.20 g, 0.56 mmol) in acetic acid (5
mL) was treated with sodium azide (0.05 g, 0.84 mmol) followed by
triethylorthoformate (0.15 mL, 0.90 mmol).
[0274] The reaction mixture was heated to reflux for 4 h. The
mixture was cooled and added to ice water (10 mL). After standing
at room temperature for 48 h, the precipitated product was
collected by filtration and washed with cold CH.sub.3OH to yield
tetrazole 1047 (101 mg; 50%) as a white solid. LCMS (ESI) m/z 474
(M+H).sup.+.
Synthesis of Tetrazole 1048
[0275] Tetrazole 1048 was made from amine 116 using the same
procedure for the synthesis of 1047. LCMS (ESI) m/z 429.
Example 22
Synthesis of Compounds 1049-1054
Synthesis of 1049
[0276] A solution of mesylate 52 (0.10 g, 0.24 mmol) in dimethyl
sulfoxide (DMSO, 2.0 mL) was treated with ethyl 4-pyrazole
carboxylate (0.03 g, 0.24 mmol), K.sub.2CO.sub.3 (0.06 g, 0.46
mmol) and the mixture was heated to 90.degree. C. for 16 h. The
reaction mixture was cooled to room temperature, diluted with ethyl
acetate (100 mL), and washed with brine (2.times.50 mL). The
organic phase was dried and evaporated. The residue was purified by
preparative thin layer chromatography (using 95% CH.sub.2Cl.sub.2,
5% MeOH as eluant) to provide 1049. LCMS (ESI) m/z 481
(M+H).sup.+.
Synthesis of 1050
[0277] This compound was made from mesylate 52 and
4-(hydroxymethyl)imidazole using the same procedure described for
the synthesis of 1049. LCMS (ESI) m/z 439 (M+H).sup.+.
Synthesis of 1051
[0278] This compound was made from mesylate 52 and
4-pyrazolecarboxylic acid using the same procedure described for
the synthesis of 1049. LCMS (ESI) m/z 453 (M+H).sup.+.
Synthesis of 1052
[0279] This compound was made from mesylate 52 and 4-methylpyrazole
using the same procedure described for the synthesis of 1049. LCMS
(ESI) m/z 423 (M+H).sup.+.
Synthesis of 1053
[0280] This compound was made from mesylate 52 and 3-aminopyrazole
using the same procedure for the synthesis of 1049. LCMS (ESI) m/z
424 (M+H).sup.+.
Synthesis of 1054
[0281] This compound was made from mesylate 52 and pyrrole using
the same procedure for the synthesis of 1049. LCMS (ESI) m/z 408
(M+H).sup.+.
Example 23
Synthesis of Aldehyde 1055
[0282] A solution of amine 54 (0.20 g, 0.56 mmol) in acetic acid (5
mL) was treated with 2,5-dimethoxy-3-tetrahydrofurancarboxaldehyde
(0.12 g, 0.78 mmol). The reaction mixture was heated to reflux for
2 h. The mixture was cooled and the solvent removed under high
vacuum. The residue was purified by preparative thin layer
chromatography (using 95% CH.sub.2Cl.sub.2, 5% MeOH as eluant) to
provide 1055. LCMS (ESI) m/z 436 (M+H).sup.+.
Example 24
Synthesis of Tetrazole 1056
[0283] A solution of mesylate 52 (0.50 g, 1.14 mmol) in
acetonitrile (CH.sub.3CN, 5 mL) was treated with tetrazole (12 mL,
5.73 mmol), and triethylamine (0.8 mL, 5.73 mmol), and the mixture
was heated to reflux for 18 h. The reaction mixture was cooled to
room temperature and diluted with ethyl acetate (100 mL), and
washed with brine (2.times.50 mL). The organic phase was dried and
evaporated. The residue was purified by preparative thin layer
chromatography (using 95% CH.sub.2Cl.sub.2, 5% MeOH as eluant) to
provide 1056. LCMS (ESI) m/z 411.
Example 25
Synthesis of Imidazole 1084
[0284] Scheme 18 depicts the synthesis of imidazole 1084.
##STR00625##
Synthesis of iodide 120
[0285] To a suspension of alcohol 117 (5 g, 14.84 mmol) in
CH.sub.2Cl.sub.2 (80 mL) was added triethyl amine (2.5 mL, 17.8
mmol) and methanesulphonyl acid chloride (1.4 mL, 17.8 mmol) at
0.degree. C. and stirred the clear solution for 1 h at the same
temperature. The reaction mixture was poured into brine solution
(100 mL) and extracted with CH.sub.2Cl.sub.2 (2.times.50 mL). The
combined organic layer was washed with brine solution (3.times.100
mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated to
yield mesylate 118. To this was added NaN.sub.3 (2 g, 29.7 mmol)
and DMF (50 mL) and the mixture was heated to 80.degree. C.
overnight. The solution was poured into a mixture of ethyl acetate
(150 mL) and water (100 mL). The organic layer was separated and
the aqueous portion was extracted with ethyl acetate (3.times.50
mL). The combined organic layer was washed with brine (1.times.150
mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated to
yield 5.4 g of azide 119.
[0286] A solution of aizde 119 (5.4 g, 14.84 mmol) and
trimethylsilyl acetylene (10.48 mL, 74.2 mmol) in DMF (20 mL) was
heated to 90.degree. C. for 12 h. The reaction mixture was
concentrated and treated with TBAF (60 mL, 1M in THF) and acetic
acid (2 mL, 29.7 mmol) and stirred at ambient temperature for 12 h.
The solution was concentrated and poured into a mixture of
saturated NH.sub.4Cl (50 mL), ethyl acetate (150 mL) and brine
solution (50 mL). The organic layer was separated and the aqueous
portion was extracted with ethyl acetate (3.times.50 mL). The
combined organic layer was dried over anhydrous Na.sub.2SO.sub.4,
concentrated and the solid thus obtained was washed with water
(5.times.200 mL) to yield 5.7 g of tetrazole derivative 120. LCMS
(ESI) m/e 389 (M+H.sup.+).
Synthesis of Alcohol 122
[0287] To a mixture of tetrazole 120 (5.7 g, 14.84 mmol), boronic
acid 121 (2.9 g, 19.29 mmol), K.sub.2CO.sub.3 (6.0 g, 44.52 mmol)
and Pd(PPh.sub.3).sub.4 (857 mg, 5 mol %) was added toluene (120
mL), ethyl alcohol (40 mL) and water (40 mL). The reaction mixture
was degassed, flushed with argon, and refluxed for 4 h. The solvent
was concentrated under reduced pressure and the residue thus
obtained was poured into water (2000 mL). The pale yellow solid was
filtered, and dried at 40.degree. C. under vacuum to yield 4.76 g
of alcohol 122. LCMS (ESI) m/e 369 (M+H.sup.+).
Synthesis of Chloride 123
[0288] To a solution of alcohol 122 (4.6 g, 12.5 mmol) and Hunig's
base (6.4 mL, 38.75 mmol) in DMF (40 mL) and CH.sub.2Cl.sub.2 (30
mL) was added methanesulphonyl chloride (2.9 mL, 37.5 mmol) at
0.degree. C., and the resulting solution was stirred at ambient
temperature for 3 h. The solution was concentrated to remove the
CH.sub.2Cl.sub.2 and poured into water (1000 mL). The pale yellow
solid was filtered and successively washed with water (5.times.200
mL), 10% ethyl acetate in hexanes (5.times.100 mL) and 50% ether in
hexanes (5.times.100 mL). The resulting solid was dried at
40.degree. C. under vacuum to yield 4.5 g of chloride 123. LCMS
(ESI) m/e 387 (M+H.sup.+).
Synthesis of 1084
[0289] To a solution of imidazole (31 mg, 0.224 mmol) in DMF (3 mL)
was added NaH (17 mg, 0.448 mmol) at 0.degree. C., and the solution
was stirred for 20 min at 0.degree. C. Chloride 123 was added and
the reaction was stirred at ambient temperature for 90 min. The
reaction mixture was concentrated and purified by flash
chromatography over silica gel (96:4 CH.sub.2Cl.sub.2/MeOH) to
yield 65 mg of 1084. LCMS (ESI) m/e 419 (M+H.sup.+).
Example 26
Synthesis of Imidazole 1086
[0290] Scheme 19 depicts the synthesis of imidazole 1086.
##STR00626##
[0291] To a solution of imidazole 124 (0.25 g, 0.56 mmol) in dry
CH.sub.2Cl.sub.2 (3 mL) was added 1-Methyl magnesium bromide
(EtMgBr) in THF (0.62 mL, 0.62 mmol) at room temperature. After
stirring for 45 min, oxazolidinone 90 (0.233 g, 0.62 mmol) was
added to the mixture and stirring continued overnight. The reaction
was quenched with aqueous NH.sub.4Cl (20 mL), extracted with
CH.sub.2Cl.sub.2 (25 mL) and dried over Na.sub.2SO.sub.4. The
solvent was evaporated to yield 125 as a solid residue. The crude
was dissolved in 10% MeOH in CH.sub.2Cl.sub.2 (10 mL), and 1N HCl
in diethyl ether (2 mL, 2 mmol) was added, followed by stirring for
3 h. The solvent was evaporated and the residue was partitioned
between dilute NH.sub.4OH (30 mL) and CH.sub.2Cl.sub.2 (30 mL). The
layers were separated, the aqueous layer was back extracted with
CH.sub.2Cl.sub.2 (2.times.30 mL), and the combined organic layer
was dried over Na.sub.2SO.sub.4. The solvent was evaporated and the
crude product was purified on silica gel column, eluting with 1-8%
MeOH in CH.sub.2Cl.sub.2 to yield imidazole 1086 as a thick oil
which precipitated to white solid in diethyl ether (0.051 g, 22%).
LCMS (ESI) m/e 409.0 (M+H).sup.+.
Example 27
Synthesis of Compound 1101
[0292] Scheme 20 depicts the synthesis of compound 1101.
##STR00627##
Synthesis of Alcohol 126
[0293] To a stirred solution of 0.050 g (0.14 mmol) of aldehyde 92
and 0.010 g (0.17 mmol) of aminoethanol in 5 ml of DMF was added
0.059 g (0.28 mmol) of NaB(OAc).sub.3H. The reaction mixture was
stirred for 2 h. DMF was removed in vacuo, and the residue was
purified by preparative TLC to give 0.055 g of alcohol 126. MS
(M+1): 438.
Synthesis of Alcohol 127
[0294] A solution of 0.050 g (0.11 mmol) of 126, 0.030 g (0.14
mmol) of (BOC).sub.2O, 0.038 g (0.46 mmol) of NaHCO.sub.3 in 10 ml
of THF:H.sub.2O (4:1) was stirred at 25.degree. C. for 6 h. The
reaction mixture was diluted with water (30 ml) and extracted with
CH.sub.2Cl.sub.2 (50 ml.times.3). The combined organic layers were
washed with brine (40 ml), dried over MgSO.sub.4, and concentrated
to give 0.040 g of alcohol 127. MS (M+1): 501.
Synthesis of Compound 1101
[0295] A solution of 0.126 g (0.25 mmol) of alcohol 127 and 0.11 ml
(0.75 mmol) of Et.sub.3N in 5 ml of DMF was heated to 60.degree. C.
for 24 h. The reaction mixture was cooled and the solvent was
removed in vacuo. The residue was purified via preparative TLC to
yield 0.033 g of compound 1101. MS (M+1): 428.
Example 28
Synthesis of Imidazole 1113
[0296] Scheme 21 depicts the synthesis of imidazole 1113.
##STR00628##
[0297] A mixture of chloride 90 (113 mg, 0.3 mmol),
2-aminoimidazole sulfate 127 (119 mg, 0.9 mmol),
N,N-diisopropylethylamine (0.26 mL, 1.5 mmol) and KI (17 mg, 0.1
mmol) in DMF (5 mL) was stirred at room temperature for 12 h. The
reaction was concentrated in vacuo, and the crude product was
purified by preparative thin layer chromatography (10:1:0.1
CH.sub.2Cl.sub.2: MeOH:NH.sub.3.H.sub.2O) to afford 90 mg of 1113
in a yield of 71%. MS (ESI): 424.0 (100%, (M+H).sup.+).
Example 29
Synthesis of Isoxazole 2001
[0298] Scheme 22 depicts the reaction leading to isoxazole 2001.
Hydroxyisoxazole 201 was coupled to alcohol 51 using the Mitsunobu
reaction to yield isoxazole 2001.
##STR00629##
Synthesis of isoxazole 2001
[0299] The known isoxazole 201 was synthesized from methyl
tetrolate as reported in literature (Iwai, I. et al. Chem. Pharm.
Bull. 1966, 14, 1277-1286). To a suspension of isoxazole 201 (33
mg, 0.279 mmol), alcohol 51 (100 mg, 0.335 mmol) and triphenyl
phosphine (95 mg, 0.363 mmol) was added diisopropyl
azodicarboxylate (DIAD, 0.072 mL, 0.363 mmol) at -20.degree. C. The
reaction mixture was warmed to ambient temperature and stirred for
3 h. The solution was concentrated and purified by flash
chromatography (4% MeOH in 1:1 CH.sub.2Cl.sub.2/EtOAc) to yield 64
mg of 2001. LCMS (ESI) m/z 440 (M+H).sup.+.
Example 30
Synthesis of Compounds 2002-2006
[0300] Scheme 23 illustrates the reductive amination chemistry
leading to compounds 2002-2006. Aldehyde 92 is treated with various
amines in the presence of a reducing agent to yield the desired
targets.
##STR00630##
Synthesis of Triazole 2002
[0301] A suspension of the aldehyde 92 (178 mg, 0.5 mmol) in THF
(4.0 mL) was treated with [1,2,4]triazol-4-ylamine (84 mg, 1.0
mmol) and acetic acid (0.02 mL) at room temperature, and the
resulting reaction mixture was stirred at room temperature for 1 h
before lithium aluminumhydride (38 mg, 1.0 mmol) was added at room
temperature. The resulting reaction mixture was stirred at room
temperature for an additional 1 h. When TLC and LCMS showed the
reaction was complete, the reaction mixture was concentrated in
vacuo, and the residue was directly purified by column
chromatography (0-5% MeOH/CH.sub.2Cl.sub.2 gradient elution) to
afford the desired triazole 2002 (40 mg; 19%) as a yellow solid.
LCMS (ESI) m/z 425 (M+H).sup.+.
Synthesis of Isoxazole 2003
[0302] A suspension of aldehyde 92 (107 mg, 0.3 mmol) in MeOH (4.0
mL) and THF (1.0 mL) was treated with 3-methyl-isoxazol-5-ylamine
(59 mg, 0.6 mmol) and sodium triacetoxyborohydride (127 mg, 0.6
mmol) at 25.degree. C., and the resulting reaction mixture was
stirred at 25.degree. C. for 6 h. When TLC and LCMS showed the
reductive amination reaction was complete, the reaction mixture was
concentrated in vacuo. The residue was directly purified by flash
column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford the desired isoxazole 2003 (12 mg; 9% yield) as
a colorless oil, which solidified upon standing at room temperature
in vacuo. LCMS (ESI) m/z 439 (M+H).sup.+.
Synthesis of Isoxazole 2004
[0303] A solution of aldehyde 92 (107 mg, 0.3 mmol) in MeOH (3.0
mL) and THF (3.0 mL) was treated with 5-methyl-isoxazol-3-ylamine
(59 mg, 0.6 mmol) and sodium triacetoxyborohydride (127 mg, 0.6
mmol) at 25.degree. C., and the resulting reaction mixture was
stirred at 25.degree. C. for 6 h. When TLC and LCMS showed the
reductive amination reaction was complete, the reaction mixture was
concentrated in vacuo. The residue was directly purified by flash
column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford isoxazole 2004 (41 mg; 31%) as a colorless oil,
which solidified upon standing at room temperature in vacuo. LCMS
(ESI) m/z 439 (M+H).sup.+.
Synthesis of Carbamate 2005
[0304] A suspension of aldehyde 92 (142 mg, 0.4 mmol) in MeOH (4.0
mL) and THF (1.0 mL) was treated with
4-amino-piperidine-1-carboxylic acid ethyl ester (69 mg, 0.4 mmol)
and sodium triacetoxyborohydride (160 mg, 0.8 mmol) at 25.degree.
C., and the resulting reaction mixture was stirred at 25.degree. C.
for 6 h. When TLC and LCMS showed the reductive amination reaction
was complete, the reaction mixture was concentrated in vacuo. The
residue was directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford carbamate 2005
(98 mg; 48% yield) as a colorless oil, which solidified upon
standing at room temperature in vacuo. LCMS (ESI) m/z 513
(M+H).sup.+.
Synthesis of Bicyclic Diamine 2006
[0305] A suspension of aldehyde 92 (142 mg, 0.4 mmol) in MeOH (4.0
mL) and THF (1.0 mL) was treated with
1-aza-bicyclo[2.2.2]oct-3-ylamine (80 mg, 0.4 mmol) and sodium
triacetoxyborohydride (160 mg, 0.8 mmol) at 25.degree. C., and the
resulting reaction mixture was stirred at 25.degree. C. for 6 h.
When TLC and LCMS showed the reductive amination reaction was
complete, the reaction mixture was concentrated in vacuo. The
residue was directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford diamine 2006 (71
mg; 38% yield) as a colorless oil, which solidified upon standing
at room temperature in vacuo. LCMS (ESI) m/z 467 (M+H).sup.+.
Example 31
Synthesis of Compounds 2007 and 2008
Synthesis of Amide 2007
[0306] To a solution of anthranilamide (74 mg, 0.532 mmol) and
mesylate 52 (100 mg, 0.229 mmol) in DMF (2.0 mL) was added Hunig's
base (185 .mu.L, 1.06 mmol). The mixture was stirred at 80.degree.
C. for 16 h, then the mixture was concentrated by vacuum. The
residue was directly isolated by reverse-phase preparative HPLC, to
give 112 mg of 2007 as a white powder in 88% yield. LCMS (ESI) m/z
477 (M+H).sup.+.
Synthesis of Amide 2008
[0307] To a solution of 3-aminothiophene-2-carboxamide (67 mg,
0.459 mmol) and mesylate 52 (100 mg, 0.229 mmol) in DMF (2.0 mL)
was added Hunig's base (160 .mu.L, 0.916 mmol). The mixture was
stirred at 80.degree. C. for 16 h, then the mixture was
concentrated under vacuum. The residue was directly isolated by
flash chromatography on silica gel (5:100 MeOH/CH.sub.2Cl.sub.2 as
eluant), to afford 51 mg of 2008 as a white powder in 46% yield.
LCMS (ESI) m/z 482 (M+Na).sup.+.
Example 32
Synthesis of Compounds 2009 and 2010
[0308] Scheme 24 depicts the synthesis of 2009 and 2010 from D- and
L-cycloserine respectively via alkylation with mesylate 52.
##STR00631##
Synthesis of Cycloserine Derivative 2009
[0309] A mixture of D-cycloserine 202 (0.22 g, 2.04 mmol) and
mesylate 52 (0.30 g, 0.68 mmol) in anhydrous CH.sub.2Cl.sub.2 (5
mL), MeOH (5 mL) and Hunig's base (2 mL) was heated to reflux for 3
h. The solvent was evaporated and the crude was purified on silica
gel column, eluting with CH.sub.2Cl.sub.2/MeOH 20:1 then with
CH.sub.2Cl.sub.2/MeOH/NH.sub.4OH 20:1:0.04 to 16:1:0.04 to give a
white solid. The isolated solid was titurated with
Et.sub.2O/CH.sub.3CN 1:1 (15 mL) and the suspension filtered to
give analytically pure 2009 as a white solid (0.072 g, 24%). LCMS
(ESI) m/z 443 (M+H).sup.+.
Synthesis of Cycloserine Derivative 2010
[0310] Compound 2010 was synthesized from L-cycloserine 203 and
mesylate 52 as described above for the synthesis of 2009. LCMS
(ESI) m/z 443 (M+H).sup.+.
Example 33
Synthesis of Azetidine 2011
[0311] A mixture of aldehyde 92 (100 mg, 0.28 mmol) and tert-butyl
3-amino-azetidine-1-carboxylate (58 mg, 0.34 mmol) in THF (2 mL)
and DMF (0.5 mL) was stirred at room temperature for 1 h. Sodium
triacetoxyborohydride (120 mg, 0.56 mmol) was added. After stirring
at room temperature for 2 h, the reaction was concentrated, and the
residue was dissolved in CH.sub.2Cl.sub.2, washed with water, and
dried over MgSO.sub.4. The CH.sub.2Cl.sub.2 solution was treated
with trifluoroacetic acid (0.5 mL) at room temperature. After
stirring for 1 h, the mixture was concentrated and purified by
preparative thin layer chromatography (10:1:0.05
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 45 mg of 2011 in
a yield of 39%. LCMS (ESI) m/z 413.1 (M+H).sup.+.
Example 34
Synthesis of Thiadiazoles 2012-2013
[0312] As Scheme 25 illustrates, thiadiazole 2012 was synthesized
from chlorothiadiazole 205 by substitution with amine 54 followed
by BOC deprotection. Acylation of 2012 with aminoacid fragments
afforded thiadiazoles 2013 and 2014.
##STR00632##
Synthesis of chlorothiadiazole 205
[0313] To a solution of BOC-aminoacetoamidine 204 (3.11 g, 18 mmol)
in CH.sub.2Cl.sub.2 (60 mL) was added 3M NaOH (12.6 mL, 37.7 mmol)
at -10.degree. C. Under strong stirring, half of a solution of
trichloromethanesulfenyl chloride (Cl.sub.3CSCl, 1.96 mL, 18 mmol)
in CH.sub.2Cl.sub.2 (30 mL) was slowly added. Then an additional 3M
NaOH (12.6 mL, 37.7 mmol) was added, followed by the remaining
Cl.sub.3CSCl solution. The mixture was stirred at -10.degree. C.
for 30 min and then at 0.degree. C. for 15 min before being diluted
with ice-water (50 mL) and extracted with in CH.sub.2Cl.sub.2
(2.times.80 mL). The combined organic layer was washed with brine
(1.times.20 mL), dried over Na.sub.2SO.sub.4 and the solvent was
evaporated. The crude residue was purified on silica gel eluting
with hexanes/ethyl acetate 6:1, yielding 205 as a yellow oil (2.9
g; 65%). .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 5.12 (s 1H),
4.42-4.40 (m, 2H), 1.29 (s, 9H).
Synthesis of Thiadiazole 2012
[0314] To a solution of the amine 54 (1.0 g, 2.8 mmol) in MeOH (15
mL) and DMF (3 mL) was added chlorothiadiazole 205 (800 mg, 3.1
mmol) and Hunig's base (1 mL, 5.6 mmol). The mixture was stirred at
50.degree. C. overnight and then poured into 5%
Na.sub.2CO.sub.3/ice (20 mL) and extracted with 9:1
CH.sub.2Cl.sub.2-isopropanol (2.times.100 mL). The combined organic
layer was dried over Na.sub.2SO.sub.4 and the solvent evaporated.
The crude residue was purified on silica gel eluting with 10:1
ethyl acetate/CH.sub.2Cl followed by 95:5 ethyl acetate/MeOH,
yielding white crystals, which were dissolved in 4M HCl in dioxane
(20 mL). The mixture was stirred at room temperature for 2 h. The
suspension was filtered and washed with ether (2.times.10 mL), and
dried at high vacuum, yielding 2012 (830 mg; 93%). LCMS (ESI) m/z
471 (M+H).sup.+.
Synthesis of Thiadiazole 2013
[0315] To a solution of thiadiazole 2012 (150 mg, 0.30 mmol) in
CH.sub.2Cl.sub.2 (4 mL) and DMF (3 mL) was added Hunig's base (0.16
mL, 0.90 mmol), (L)-BOC-Ala-OH (67 mg, 0.36 mmol) and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI,
79 mg, 0.42 mmol). The mixture was stirred overnight at room
temperature, then additional amounts of (L)-BOC-Ala-OH (34 mg, 0.18
mmol), EDCI (40 mg, 0.21 mmol) and Hunig's base (0.08 mL, 0.44
mmol) were added. The mixture was stirred at room temperature
overnight, poured into 1N HCl-ice (20 mL), and extracted with
CH.sub.2Cl.sub.2-isopropanol 95:5 (2.times.50 mL). The combined
organic layer was washed with water (15 mL), 5% sodium carbonate
(Na.sub.2CO.sub.3, 15 mL), water (15 mL), brine (15 mL), and then
dried over Na.sub.2SO.sub.4 and the solvent evaporated. The crude
residue was purified on silica gel eluting with ethyl acetate/MeOH
95:5. The residue was dissolved in 4M HCl in dioxane (7 mL). The
mixture was stirred at room temperature for 2 h and then
evaporated. The residue was diluted with ether (3 mL), filtered,
and the solid washed with ether (2.times.5 mL), then dried at high
vacuum, yielding 2013 (122 mg; 91%). LCMS (ESI) m/z 542
(M+H).sup.+.
Synthesis of Thiadiazole 2014
[0316] To a solution of thiadiazole 2012 (150 mg, 0.30 mmol) in
CH.sub.2Cl.sub.2 (3 mL) and DMF (3 mL) was added Hunig's base (0.08
mL, 0.45 mmol) and (L)-BOC-Lys (BOC)--OSu (157 mg, 0.36 mmol). The
mixture was stirred overnight at room temperature, poured into 5%
Na.sub.2CO.sub.3-ice (20 mL), extracted with
CH.sub.2Cl.sub.2-isopropanol 95:5 (3.times.50 mL), dried over
Na.sub.2SO.sub.4 and the solvent evaporated. The crude residue was
purified on silica gel eluting with ethyl acetate followed by 5:1
ethyl acetate/MeOH. The BOC-protected material obtained was
dissolved in 4M HCl in dioxane (6 mL) and MeOH (2 mL), stirred at
room temperature for 3 h and then evaporated. The residue was
diluted with ether (6 mL), filtered, washed with ether (2.times.5
mL) and dried at high vacuum, yielding 2014 (100 mg; 50%). LCMS
(ESI) m/z 599 (M+H).sup.+.
Example 35
Synthesis of Compounds 2015-2019
[0317] As Scheme 26 illustrates, benzyl chloride 90 served as
alkylating agent for thiolates or thiols to afford compounds
2015-2019.
##STR00633##
Synthesis of Tetrazole 2015
[0318] A solution of chloride 90 (0.15 g, 0.40 mmol) in DMF (2 mL)
was treated with 5-mercapto-4-methyltetrazole, sodium salt,
dihydrate (0.14 g, 0.80 mmol) and stirred at 23.degree. C. for 0.5
h. The reaction mixture was diluted with water and the precipitate
was recovered by vacuum filtration to afford tetrazole 2015 as a
white powder (63%). LCMS (ESI) m/z 456 (M+H).sup.+.
Synthesis of Triazole 2016
[0319] Tetrazole 2016 was prepared with chloride 90 (0.30 g, 0.80
mmol) and 4-mercapto-1,2,3-triazole, sodium salt, (0.20 g, 1.6
mmol) according to the procedure above used to synthesize tetrazole
2015 to afford 2016 as a yellow powder (0.29 g, 0.66 mmol, 82%).
LCMS (ESI) m/z 442 (M+Na).sup.+.
Synthesis of Compound 2017
[0320] Compound 2017 was prepared with chloride 90 (0.20 g, 0.53
mmol) and 2-thiobarbituric acid, sodium salt, (0.18 g, 1.1 mmol)
according to the procedure above used to synthesize tetrazole 2015
to afford 2017 as a white powder (0.078 g, 0.16 mmol; 30%). LCMS
(ESI) m/z 507 (M+Na).sup.+.
Synthesis of Mercaptopyridine 2018
[0321] A solution of chloride 90 (0.20 g, 0.53 mmol) in DMF (2.7
mL) was treated with cesium carbonate (0.21 g, 0.64 mmol) and
2-mercaptopyridine (0.071 g, 0.64 mmol) and was stirred at
23.degree. C. for 0.5 h. The reaction mixture was diluted with
water and the precipitate was recovered by vacuum filtration to
afford 2018 as a yellow powder (91%). LCMS (ESI) m/z 452
(M+H).sup.+.
Synthesis of Mercaptopyridine 2019
[0322] Mercaptopyridine 2019 was prepared with chloride 90 (0.20 g,
0.53 mmol), cesium carbonate (0.21 g, 0.64 mmol), and
4-mercaptopyridine (0.071 g, 0.64 mmol) according to the procedure
above used to synthesize 2018 to afford a yellow powder (0.078 g,
0.16 mmol; 30%). LCMS (ESI) m/z 452 (M+H).sup.+.
Example 36
Synthesis of Sulfoxides 2020-2023
[0323] As Scheme 27 illustrates, sulfides 2015, 2016, 2019, and
2018 were oxidized under controlled conditions to afford sulfoxides
2020-2023 respectively.
##STR00634##
Synthesis of Sulfoxide 2020
[0324] A solution of 2015 (0.020 g, 0.044 mmol) in chloroform (0.44
mL) and methanol (0.050 mL) was treated with 3-chloroperoxybenzoic
acid (77%, 0.010 g, 0.044 mmol) and stirred at 23.degree. C. for 12
h. The reaction mixture was diluted with methylene chloride, washed
with saturated aqueous sodium bicarbonate, dried over
Na.sub.2SO.sub.4, and the solvent removed in vacuo. The crude
product was purified with preparative TLC (1:4.5:4.5 MeOH/ethyl
acetate/CH.sub.2Cl.sub.2) to afford 2020 as a white powder (3.6 mg,
0.008 mmol; 19%). LCMS (ESI) m/z 495 (M+Na).sup.+.
Synthesis of Sulfoxide 2021
[0325] Sulfoxide 2021 was prepared from sulfide 2016 (0.030 g,
0.068 mmol) and 3-chloroperoxybenzoic acid (77%, 0.015 g, 0.068
mmol) according to the procedure described above for the synthesis
of sulfoxide 2020 to afford a white powder (0.021 g, 0.046 mmol;
68%). LCMS (ESI) m/z 480 (M+Na).sup.+.
Synthesis of sulfoxide 2022
[0326] Sulfoxide 2022 was prepared from sulfide 2019 (0.080 g, 0.18
mmol) and 3-chloroperoxybenzoic acid (77%, 0.040 g, 0.18 mmol)
according to the procedure described above for the synthesis of
sulfoxide 2020 to afford a white powder (0.021 g, 0.094 mmol; 52%).
LCMS (ESI) m/z 468 (M+H).sup.+.
Synthesis of Sulfoxide 2023
[0327] Sulfoxide 2023 was prepared from sulfide 2018 (0.10 g, 0.22
mmol) and 3-chloroperoxybenzoic acid (77%, 0.050 g, 0.22 mmol)
according to the procedure described above for the synthesis of
sulfoxide 2020 to afford a white powder (0.068 g, 0.15 mmol; 66%).
LCMS (ESI) m/z 466.
Example 37
Synthesis of Sulfones 2024 and 2025
[0328] As Scheme 28 illustrates, sulfides 2015 and 2016 were
oxidized with excess 3-chloroperoxybenzoic acid to afford sulfones
2024 and 2025.
##STR00635##
Synthesis of Sulfone 2024
[0329] A solution of sulfide 2015 (0.020 g, 0.044 mmol) in
chloroform (0.44 mL) and methanol (0.050 mL) was treated with
3-chloroperoxybenzoic acid (77%, 0.030 g, 0.13 mmol) and stirred at
23.degree. C. for 1 h and then heated to 50.degree. C. for 12 h.
The reaction mixture was cooled to 23.degree. C., diluted with
methylene chloride, washed with saturated aqueous sodium
bicarbonate, dried (Na.sub.2SO.sub.4), and the solvent removed in
vacuo. The crude product was purified by preparative TLC (5% MeOH
in CH.sub.2Cl.sub.2) to afford sulfone 2024 as a white powder (3.6
mg; 17%). LCMS (ESI) m/z 489 (M+H).sup.+.
Synthesis of Sulfone 2025
[0330] A solution of sulfide 2016 (0.050 g, 0.11 mmol) in
chloroform (1.1 mL) and methanol (0.1 mL) was treated with
3-chloroperoxybenzoic acid (77%, 0.076 g, 0.34 mmol) and stirred at
23.degree. C. for 2 h. The precipitate was recovered through vacuum
filtration to yield sulfone 2025 as a white solid (0.020 g; 37%).
LCMS (ESI) m/z 474 (M+H).sup.+.
Example 38
Synthesis of Mercaptotriazole 2026
[0331] A solution of mesylate 64 (0.012 g, 0.027 mmol) in DMF (0.14
mL) was treated with 4-mercapto-1,2,3-triazole, sodium salt (7 mg,
0.054 mmol) and was stirred at 45.degree. C. for 2 h. The solvent
was removed in vacuo and the crude product was purified by
preparative TLC (5% MeOH in CH.sub.2Cl.sub.2) to afford
mercaptotriazole 2026 as a white solid (3.1 mg; 24%). LCMS (ESI)
m/z 456 (M+H).sup.+.
Example 39
Synthesis of Compounds 2027-2033
[0332] As Scheme 29 illustrates, benzyl chloride 90 was used to
alkylate thiols 207a-g to provide compounds 2027-2033
respectively.
##STR00636##
Synthesis of Tetrazole 2027
[0333] Benzyl chloride 90 (0.20 g, 0.53 mmol) was dissolved in DMF
(5 mL). Thiol 207a (62 mg, 0.53 mmol) and cesium carbonate (0.20 g,
0.64 mmol) were added sequentially and the resulting slurry stirred
at room temperature for 4 h. The mixture was poured into 70 mL
H.sub.2O and stirred for 1 h. The solids were filtered, rinsed with
ether and dried under vacuum to afford tetrazole 2027 as a brown
solid (187 mg, 0.36 mmol). LCMS (ESI) m/z 514 (M+H).sup.+.
Synthesis of Triazole 2028
[0334] Triazole 2028 was synthesized by the process described for
2027 above using thiol 207b in place of 207a to yield 138 mg of
triazole 2028 as a yellow solid (0.30 mmol). LCMS (ESI) m/z 457
(M+H).sup.+.
Synthesis of Thiadiazole 2029
[0335] Thiadiazole 2029 was synthesized by the process described
for 2027 above using thiol 207c in place of 207a to yield 147 mg of
thiadiazole 2029 as a white solid (0.32 mmol). LCMS (ESI) m/z 481
(M+Na).sup.+, 522 (M+Na+CH.sub.3CN).sup.+.
Synthesis of Thiazole 2030
[0336] Thiazole 2030 was synthesized by the process described for
2027 above using thiol 207d in place of 207a to yield 129 mg of
thiazole 2030 as a white solid (0.28 mmol). LCMS (ESI) m/z 458
(M+H).sup.+, 521 (M+Na+CH.sub.3CN).
Synthesis of Thiazole 2031
[0337] Thiazole 2031 was synthesized by the process described for
2027 above using thiol 207e in place of 207a to yield 155 mg of
thiazole 2031 as an off-white solid (0.33 mmol). LCMS (ESI) m/z 472
(M+H).sup.+.
Synthesis of Imidazole 2032
[0338] Imidazole 2032 was synthesized by the process described for
2027 above using thiol 207f in place of 207a to yield 91 mg of
imidazole 2032 as a white solid (0.21 mmol). LCMS (ESI) m/z 441
(M+H).sup.+.
Synthesis of Triazole 2033
[0339] Triazole 2033 was synthesized by the process described for
2027 above using thiol 207 g in place of 207a to yield 91 mg of
triazole 2033 as a white solid (0.21 mmol). LCMS (ESI) m/z 456
(M+H).sup.+, 478 (M+Na).sup.+, 519 (M+Na+CH.sub.3CN).sup.+.
Example 40
Synthesis of Compounds 2034-2039
[0340] As Scheme 30 illustrates, compounds 2027 and 2029-2033 were
oxidized to afford sulfoxides 2034-2039 respectively.
##STR00637##
Synthesis of Sulfoxide 2034
[0341] Tetrazole 2027 (80 mg, 0.16 mmol) was dissolved in 3:1
CH.sub.1Cl.sub.2/MeOH (3 mL). m-CPBA was added (75% pure; 39 mg,
0.17 mmol) and the mixture was stirred at room temperature for 6 h.
The reaction mixture was poured into 50 mL ether and stirred for 1
h. The solids were filtered and dried in vacuo to give sulfoxide
2034 as an off-white solid (55 mg, 0.10 mmol). LCMS (ESI) m/z 530
(M+H).sup.+.
Synthesis of Sulfoxide 2035
[0342] Sulfoxide 2035 was synthesized by the process described
above for 2034 starting with thiadiazole 2029 in place of tetrazole
2027 to yield 39 mg of 2035 as a white solid (0.08 mmol). LCMS
(ESI) m/z 497 (M+Na).sup., 538 (M+Na+CH.sub.3CN).sup.+.
Synthesis of Sulfoxide 2036
[0343] Sulfoxide 2036 was synthesized by the process described
above for 2034 starting with thiazole 2030 in place of tetrazole
2027 to yield 48 mg of 2036 as an off-white solid (0.10 mmol). LCMS
(ESI) m/z 496 (M+Na).sup.+, 537 (M+Na+CH.sub.3CN).sup.+.
Synthesis of Sulfoxide 2037
[0344] Sulfoxide 2037 was synthesized by the process described
above for 2034 starting with thiazole 2031 in place of tetrazole
2027 to yield 44 mg of 2037 as an off-white solid (0.09 mmol). LCMS
(ESI) m/z 488 (M+H).sup.+, 510 (M+Na).sup.+, 551
(M+Na+CH.sub.3CN).sup.+.
Synthesis of Sulfoxide 2038
[0345] Sulfoxide 2038 was synthesized by the process described
above for 2034 starting with imidazole 2032 in place of tetrazole
2027 to yield 51 mg of 2038 as a white solid (0.11 mmol). LCMS
(ESI) m/z 457 (M+H).sup.+.
Synthesis of Sulfoxide 2039
[0346] Sulfoxide 2039 was synthesized by the process described
above for 2034 starting with triazole 2033 in place of tetrazole
2027 to yield 48 mg of 2039 as a white solid (0.10 mmol). LCMS
(ESI) m/z 472 (M+H).sup.+494 (M+Na).sup.+, 535
(M+Na+CH.sub.3CN).sup.+.
Example 41
Synthesis of Compound 2040
[0347] A solution of mesylate 106 (43.7 mg, 1.0 mmol) in anhydrous
DMF (4.0 mL) was treated with 1H-5-mercapto-1,2,3-triazole sodium
salt (24.6 mg, 2.0 mmol) at room temperature, and the resulting
reaction mixture was stirred at room temperature overnight. When
TLC and LCMS showed that the reaction was complete, the reaction
mixture was concentrated in vacuo, and the residue was directly
purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford mercaptotriazole
2040 (29.0 mg; 66%) as a pale-yellow solid. LCMS (ESI) m/z 443
(M+H).sup.+.
Example 42
Synthesis of Compounds 2043 and 2044
Synthesis of Compound 2043
[0348] A solution of amine 54 (0.070 g, 0.20 mmol) in DMF (1.0 mL)
was treated with triethylamine (0.055 mL, 0.40 mmol) and
1-methyl-1H-imidazole-4-sulfonyl chloride (0.039 mg, 0.22 mmol) and
stirred at 23.degree. C. for 30 minutes. The solvent was removed in
vacuo, and the crude product was purified by flash chromatography
(4.5:4.5:1 methylene chloride/ethyl acetate/methanol) to afford
compound 2043 (0.054 g, 0.11 mmol, 55%). MS (ESI): 502
(M+H).sup.+.
Synthesis of Compound 2044
[0349] A solution of amine 54 (0.070 g, 0.20 mmol) in DMF (1.0 mL)
was treated with triethylamine (0.055 mL, 0.40 mmol) and
6-morpholin-4-yl-pyridine-3-sulfonyl chloride (0.057 g, 0.22 mmol)
and stirred at 23.degree. C. for 30 minutes. The solvent was
removed in vacuo, and the crude product was purified by flash
chromatography (0-10% methanol in 1:1 ethyl acetate/methylene
chloride) to afford compound 2044 (0.052 g, 0.09 mmol, 45%). MS
(ESI): 584 (M+H).sup.+.
Example 43
Synthesis of Compound 2047
[0350] A solution of chloride 90 (0.19 g, 0.50 mmol) in DMF (5 mL)
was treated with 3-mercapto-1,2,4-triazole (0.20 g, 1.0 mmol) and
Cs.sub.2CO.sub.3 (0.33 g, 1.0 mmol), and stirred at 23.degree. C.
for 1 h. The reaction mixture was diluted with H.sub.2O (45 mL),
and the resulting precipitate filtered, washed with H.sub.2O and
dried under vacuum to afford compound 2047 (0.139 g, 0.315 mmol,
63%) as a white powder. MS (ESI): 442 (M+H).sup.+.
Example 44
Synthesis of Compound 2050
[0351] Scheme 31 depicts the synthesis of compound 2050.
##STR00638##
[0352] To a solution of 0.050 g (0.15 mmol) of aldehyde 92 and
0.026 g (0.30 mmol) of aminoisoxazole in 2 ml of TFA at 25.degree.
C. was added 0.018 g (0.30 mmol) of sodium cyanoborohydride
(NaBH.sub.3CN). The reaction mixture was stirred at 25.degree. C.
for 4 h. The TFA was removed, and the residue was purified by
preparative TLC to give 0.040 g of compound 2050. MS (M+1):
425.
Example 45
Synthesis of Compounds 3001-3004
[0353] As Scheme 32 illustrates, bromide 301 was coupled to
boronate 81 to yield pyridyl derivative 3001. Successive oxidations
provided sulfoxide 3002, sulfone 3003, and the pyridyl N-oxide
3004.
##STR00639## ##STR00640##
Synthesis of Bromide 301
[0354] A suspension of 4-bromomethylpyridine hydrochloride (1.59 g,
6.3 mmol) in THF (10 mL) was treated dropwise with a solution of
potassium carbonate (3.33 g, 24.0 mmol) in H.sub.2O (6 mL) at
0-5.degree. C., and the resulting mixture was stirred at
0-5.degree. C. for 10 min before being treated dropwise with a
solution of 4-bromo-benzenethiol (1.14 g, 6.0 mmol) in THF (5.0 mL)
at 0-5.degree. C. under N.sub.2. The resulting reaction mixture was
subsequently stirred at 0-5.degree. C. for an additional 20 min.
When TLC and LCMS showed that the reaction was complete, the
reaction mixture was treated with water (15 mL) and ethyl acetate
(25 mL). The two layers were separated, and the aqueous layer was
extracted with ethyl acetate (2.times.20 mL). The combined organic
extracts were washed with water (2.times.15 mL) and saturated
aqueous NaCl solution (10 mL), dried over MgSO.sub.4, and
concentrated in vacuo. The residue was purified by flash column
chromatography (5-25% EtOAc-hexane gradient elution) to afford the
desired 4-(4-bromo-phenylsulfanylmethyl)pyridine 301 (1.374 g; 82%)
as a pale-yellow solid, which was directly used in subsequent
reactions.
Synthesis of Compound 3001
[0355] A solution of boronate 81 (200 mg, 0.53 mmol) and bromide
301 (150 mg, 0.53 mmol) in toluene (9 mL) was treated with solid
potassium carbonate (220 mg, 1.6 mmol), ethanol (3.0 mL) and
H.sub.2O (3.0 mL) at room temperature, and the resulting reaction
mixture was degassed three times under a steady stream of argon
before being treated with Pd(dppf).sub.2Cl.sub.2 (16 mg, 0.013
mmol) at room temperature. The reaction mixture was then degassed
three times again under a steady stream of argon before being
warmed up to reflux for 2 h. When LCMS showed that the reaction was
complete, the reaction mixture was cooled down to room temperature
before being treated with water (10 mL) and ethyl acetate (20 mL).
The two layers were separated, and the aqueous layer was extracted
with ethyl acetate (2.times.10 mL). The combined organic extracts
were washed with water (2.times.10 mL) and saturated aqueous NaCl
solution (10 mL), dried over MgSO.sub.4, and concentrated in vacuo.
The residue was then purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford compound 3001
(177 mg; 74%) as a yellow oil, which solidified upon standing at
room temperature in vacuo. LCMS (ESI) m/z 452 (M+H).sup.+.
Synthesis of Sulfoxide 3002
[0356] A solution of compound 3001 (58 mg, 0.13 mmol) in
CH.sub.2Cl.sub.2 (2.0 mL) and MeOH (0.5 mL) was treated with m-CPBA
(22 mg, 0.13 mmol) at room temperature, and the resulting reaction
mixture was stirred at room temperature for 2 h. The solvents were
removed, and the residue was directly purified by flash column
chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient elution) to
afford sulfoxide 3002 (43 mg; 71%) as a colorless oil, which
solidified upon standing at room temperature in vacuo. LCMS (ESI)
m/z 468 (M+H).sup.+.
Synthesis of Sulfone 3003
[0357] A solution of sulfoxide 2002 (22 mg, 0.047 mmol) in
CH.sub.2Cl.sub.2 (2.0 mL) and MeOH (0.5 mL) was treated with
nm-CPBA (9.0 mg, 0.047 mmol) at room temperature, and the resulting
reaction mixture was stirred at room temperature for 2 h. The
solvents were removed, and the residue was directly purified by
flash column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford sulfone 3003 (16 mg; 71%) as a colorless oil,
which solidified upon standing at room temperature in vacuo. LCMS
(ESI) m/z 484 (M+H).sup.+.
Synthesis Of Pyridyl N-Oxide 3004
[0358] A solution of sulfone 3003 (16 mg, 0.033 mmol) in
CH.sub.2Cl.sub.2 (1.0 mL) and MeOH (0.5 mL) was treated with m-CPBA
(6.0 mg, 0.033 mmol) at room temperature, and the resulting
reaction mixture was stirred at room temperature for 2 h. The
solvents were removed, and the residue was directly purified by
flash column chromatography (0-5% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford the pyridyl N-oxide 3004 (11 mg; 67% yield) as
colorless oil, which solidified upon standing at room temperature
in vacuo. LCMS (ESI) m/z 500 (M+H).sup.+.
Example 46
Synthesis of Compound 3005
[0359] Scheme 33 illustrates the synthesis of compound 3005.
##STR00641##
Synthesis of Bromide 303
[0360] 4-bromobenzenesulfonyl chloride 302 (2.56 g, 10 mmol) was
added to a solution of 4-aminomethylpyridine (1.08 g, 10 mmol) and
triethylamine (2 mL, 14.3 mmol) in THF (20 mL) at 0.degree. C.
After stirring at same temperature for 1 h, 50 mL of cool water was
added. A white solid was collected by filtration, washing with
EtOAc and dried in vacuum to give 3.10 g of bromide 303 in a yield
of 95%.
Synthesis of Compound 3005
[0361] Bromide 303 (327 mg, 1 mmol), boronate 81 (378 mg, 1 mmol),
Pd(dppf).sub.2Cl.sub.2 (40 mg, 0.05 mmol) and K.sub.2CO.sub.3 (414
mg, 3 mmol) were dissolved 8 mL of a mixture of dioxane:EtOH:
H.sub.2O (3:1:1) under argon atmosphere. After heating at
100.degree. C. for 12 hours, the reaction was added to 20 mL of
cool water. The organic solvent was removed in vacuo and the crude
product was collected by filtration. The crude product was treated
with active charcoal and recrystallized in a mixed solvent system
(1:2:2 MeOH:CH.sub.2Cl.sub.2:acetone) to give 155 mg of 3005 in a
yield of 31%. MS (ESI): 499.1 (100%, (M+H).sup.+).
Example 47
Synthesis of Amide 4008
[0362] A solution of amine 54 (36 mg, 0.1 mmol) in DMF was treated
with quinoline-4-carboxylic acid (26 mg, 0.15 mmol, 1.5 equiv) at
25.degree. C. under N.sub.2, and the resulting mixture was treated
with EDCI (28.5 mg, 0.15 mmol, 1.5 equiv) at 25.degree. C. under
N.sub.2. The reaction mixture was subsequently stirred at
25.degree. C. for 12 h. When TLC and HPLC showed the coupling
reaction was complete, the reaction mixture was concentrated in
vacuo. The residue was then directly purified by flash column
chromatography (0-7% MeOH--CH.sub.2Cl.sub.2 gradient elution) to
afford the desired amide 4008 (36.4 mg, 71% yield) as an off-white
powder. LCMS (ESI) m/e 513 (M.sup.++H).
Example 48
General Synthesis of Carboxylic Acid-Loaded Tfp Resins and
Synthesis of Amide 4011
[0363] A suspension of polymeric
4-hydroxy-2,3,5,6-tetrafluorophenol (TFP, J. Comb. Chem. 2000, 2,
691) amide resin (1.00 g, 1.27 mmol) in DMF (10 mL) was shaken for
10 minutes in a 70 mL polypropylene cartridge and then treated with
indole-6-carboxylic acid (1.02 g, 6.35 mmol),
3-hydroxybenzotriazole (18 mg, 0.13 mmol), and
diisopropylcarbodiimide (1.2 mL, 7.6 mmol). The reaction mixture
was shaken for 18 h at 23.degree. C., and then the resin was washed
with DMF (10.times.50 mL), THF (10.times.50 mL), and methylene
chloride (10.times.50 mL) and dried in vacuo.
[0364] A suspension of the above TFP ester (35 mg) in 1 mL of DMF
was treated with amine 54 (10 mg, 0.027 mmol) and shaken for 18 h
in a 10 mL polypropylene cartridge. The filtrate was collected and
dried to give amide 4011 (11 mg, 0.022 mmol, 81%) as a yellow
solid. .sup.1HNMR (300 MHz, 10:1 CDCl.sub.3: CD.sub.3OD): .delta.
7.89 (s, 1H), 7.75-7.71 (m, 1H), 7.55-7.52 (m, 1H), 7.46-7.30 (m,
6H), 7.16 (dd, J=8, 2 Hz, 1H), 6.45-6.44 (m, 1H), 4.70-4.68 (m,
1H), 4.60-4.59 (m, 2H), 4.03-3.97 (m, 1H), 3.73-3.71 (m, 4H),
3.58-3.42 (m, 2H), 3.27-3.25 (m, 1H), 1.90 (s, 3H). LCMS (ESI) m/e
501.0 (M+H).sup.+.
Example 49
Synthesis of Amides 4010 and 4012-4105
Synthesis of Amide 4010
[0365] Amide 4010 was prepared from the TFP ester of
N-methylpyrrole-2-carboxylic acid (477 mg, 3.81 mmol), which was
prepared according to the general method of Example 48. The TFP
ester was reacted with amine 54 using the acylation procedure of
Example 48 to synthesize amide 4011. The desired amide 4010 was
obtained as a solid (10 mg, 0.022 mmol, 81%). .sup.1HNMR (300 MHz,
10:1 CDCl.sub.3: CD.sub.3OD): .delta. 7.71-7.56 (m, 6H), 7.33 (dd,
J=9, 2 Hz, 1H), 6.93-6.92 (m, 1H), 6.77 (dd, J=4, 2 Hz, 1H), 6.55
(dd, J=12, 6 Hz, 2H), 6.27 (dd, J=4, 3 Hz, 1H), 4.77-4.69 (m, 1H),
4.54-4.52 (m, 2H), 4.02-3.96 (m, 1H), 3.90 (s, 3H), 3.73 (dd, J=9,
7 Hz, 1H), 3.62-3.58 (m, 2H), 1.96 (s, 3H). LCMS (ESI) m/e 465.0
(M+H).sup.+.
Synthesis of Amide 4012
[0366] Amide 4012 was prepared from the TFP ester of
3-methylsulfonylbenzoic acid (1.27 g, 6.35 mmol), which was
prepared according to the general method of Example 48. The TFP
ester was reacted with amine 54 using the acylation procedure of
Example 48 to synthesize amide 4011. The desired amide 4012 was
obtained as a solid (13 mg, 0.024 mmol, 89%). .sup.1HNMR (300 MHz,
10:1 CDCl.sub.3: CD.sub.3OD): .delta. 8.31-8.30 (m, 1H), 8.14-8.11
(m, 1H), 8.00-7.97 (m, 1H), 7.64-7.58 (m, 2H), 7.45-7.29 (m, 6H),
7.12 (dd, J=9, 2 Hz, 1H), 4.73-4.71 (m, 1H), 4.59-4.58 (m, 2H),
4.05-3.99 (m, 1H), 3.73 (dd, J=9, 7 Hz, 1H), 3.61-3.44 (m, 6H),
3.30-3.27 (m, 1H), 3.03 (s, 3H). LCMS (ESI) m/e 540.1
(M+H).sup.+.
Synthesis of Amide 4013
[0367] Amide 4013 was prepared from the TFP ester of
4-fluorobenzoic acid (890 mg, 6.35 mmol), which was prepared
according to the general method of Example 48. The TFP ester was
reacted with amine 54 using the acylation procedure of Example 48
to synthesize amide 4011. The desired amide 4013 was obtained as a
solid (12 mg, 0.025 mmol, 93%). LCMS (ESI) m/e 480.0
(M+H).sup.+.
Synthesis of Amide 4014
[0368] Amide 4014 was prepared from the TFP ester of piperonylic
acid (1.05 g, 6.35 mmol), which was prepared according to the
general method of Example 48. The TFP ester was reacted with amine
54 using the acylation procedure of Example 48 to synthesize amide
4011. The desired amide 4014 was obtained as a solid (13 mg, 0.026
mmol, 96%). .sup.1HNMR (300 MHz, CDCl.sub.3): .delta. 7.72-7.70 (m,
1H), 7.54-7.28 (m, 8H), 7.24-7.23 (m, 1H), 7.17 (dd, J=9, 2 Hz,
1H), 5.93 (s, 2H), 4.65-4.79 (m, 1H), 4.54-4.52 (m, 2H), 4.05-3.99
(m, 1H), 3.72 (dd, J=9, 7 Hz, 1H), 3.55-3.48 (m, 2H), 3.28-3.26 (m,
2H), 1.92 (s, 3H). LCMS (ESI) nm/e 506.0 (M+H).sup.+.
Synthesis of Amide 4015
[0369] Amide 4015 was prepared from the TFP ester of
5-methoxyindole-2-carboxylic acid (486 mg, 2.54 mmol), which was
prepared according to the general method of Example 48. The TFP
ester was reacted with amine 54 using the acylation procedure of
Example 48 to synthesize amide 4011. The desired amide 4015 was
obtained as a solid (10 mg, 0.019 mmol, 70%). .sup.1HNMR (300 MHz,
10:1 CDCl.sub.3: CD.sub.3OD): .delta. 7.87-7.79 (m, 1H), 7.48-7.14
(m, 7H), 6.94 (s, 1H), 6.89-6.81 (m, 2H), 4.67-4.61 (m, 1H),
4.54-4.52 (m, 2H), 4.02-3.93 (m, 2H), 3.71-3.61 (s, 3H), 1.89 (s,
3H). LCMS (ESI) m/e 531.1 (M+H).sup.+.
Example 50
Synthesis of Amine 4016
[0370] A solution of amine 54 (36 mg, 0.1 mmol) in a mixture of THF
and DMF (3:1, v/v) was treated with quinoline-4-carboxaldehyde (16
mg, 0.1 mmol, 1.0 equiv) at 25.degree. C. under argon, and the
resulting reaction mixture was stirred at 25.degree. C. for 30 min
before being treated with sodium triacetoxyborohydride
(NaB(OAc).sub.3H, 33 mg, 0.15 mmol, 1.5 equiv) at 25.degree. C. The
reaction mixture was subsequently stirred at 25.degree. C. for 6 h.
When TLC and HPLC showed the reductive amination reaction was
complete, the reaction mixture was concentrated in vacuo. The
residue was then directly purified by flash column chromatography
(0-7% MeOH--CH.sub.2Cl.sub.2 gradient elution) to produce the
desired
N-[3-(2-fluoro-4'-{[(quinolin-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-
-oxo-oxazolidin-5-ylmethyl]-acetamide 4016 (32.9 mg, 66% yield) as
pale-yellow oil, which solidified upon standing at room temperature
in vacuo. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.85 (s, 3H,
COCH.sub.3), 3.44 (t, 2H, J=5.4 Hz), 3.79 (dd, 1H, J=6.4, 9.2 Hz),
3.88 (s, 2H), 4.17 (t, 1H, J=9.1 Hz), 4.30 (s, 2H), 4.77 (m, 1H),
7.41 (dd, 1H, J=2.0, 8.0 Hz), 7.51-7.63 (m, 8H, aromatic-H), 7.74
(t, 1H, J=8.0 Hz), 8.04 (d, 1H, J=8.0 Hz), 8.18 (d, 1H, J=8.0 Hz),
8.27 (t, 1H, J=5.8 Hz, NHCOCH.sub.3), 8.87 (d, 1H, J=8.0 Hz). LCMS
(ESI) nm/e 499 (M+H).sup.+.
Example 51
Synthesis of Amines 4018-4026
Synthesis of Amine 4018
[0371] To a solution of 0.032 g (0.089 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) were added 0.009 g (0.080 mmol)
of 4-pyridylcarboxaldehyde and 0.027 g (0.12 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction were removed
via rotary evaporation and the residue was then purified on a
preparative TLC plate to give 7.0 mg of 4018. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.57 (s, 1H), 8.48 (d, J=4.2 Hz, 1H),
7.91-7.33 (a series of multiplet peaks, 9H), 2.05 (s, 3H). LCMS
(ESI) nm/e 449 (M+H).sup.+.
Synthesis of Amine 4019
[0372] To a solution of 0.080 g (0.22 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) were added 0.032 g (0.20 mmol)
of 2-quinolinecarboxaldehyde and 0.094 g (0.44 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction were removed
via rotary evaporation, and the residue was then purified on a
preparative TLC plate to give 44 mg of 4019. .sup.1H NMR (300 MHz,
CD.sub.3OD+CDCl.sub.3): .delta. 8.32 (d, J=5.4 Hz, 1H), 8.06 (d,
J=5.4 Hz, 1H), 7.94 (d, J=6 Hz, 1H), 7.79-7.36 (a series of
multiplet peaks, 10H), 4.83 (m, 1H), 3.97 (s, 1H), 2.05 (s, 3H).
LCMS (ESI) m/e 499 (M+H).sup.+.
Synthesis of 4020
[0373] To a solution of 0.080 g (0.22 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) was added 0.030 g (0.20 mmol)
of 2-benzofurancarboxaldehyde and 0.094 g (0.44 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction were removed
via rotary evaporation, and the residue was then purified on a
preparative TLC plate to give 49 mg of 4020. .sup.1H NMR (300 MHz,
CD.sub.3OD+CDCl.sub.3): .delta. 7.44-7.01 (a series of multiplet
peaks, 11H), 6.62 (s, 1H), 3.92 (s, 2H), 3.82 (s, 2H), 3.75-3.60
(m, 1H). LCMS (ESI) nm/e 488 (M+H).sup.+.
Synthesis of Amine 4021
[0374] To a solution of 0.080 g (0.22 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) were added 0.032 g (0.20 mmol)
of 3-quinolinecarboxaldehyde and 0.094 g (0.44 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction was removed via
rotary evaporation, and the residue was then purified on a
preparative TLC plate to give 49 mg of 4021. .sup.1H NMR (300 MHz,
CD.sub.3OD+CDCl.sub.3): .delta. 8.89 (s, 1H), 8.33 (s, 1H), 8.03
(d, J=5.4 Hz, 1H), 7.95 (d, J=5.4 Hz, 1H), 7.80.about.7.34 (a
series of multiple peaks, 9H), 1.98 (s, 3H). LCMS (ESI) m/e 499
(M+H).sup.+.
Synthesis of Amine 4022
[0375] To a solution of 0.100 g (0.28 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) were added 0.042 g (0.27 mmol)
of 1-naphthaldehyde and 0.119 g (0.56 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction were removed
via rotary evaporation, and the residue was then purified on a
preparative TLC plate to give 49 mg of 4022. .sup.1H NMR (300 MHz,
CD.sub.3OD+CDCl.sub.3): .delta. 7.98.about.7.24 (a series of
multiple peaks, 14H), 2.00 (s, 3H). LCMS (ESI) nm/e 498
(M+H).sup.+.
Synthesis of Amine 4023
[0376] To a solution of 0.100 g (0.28 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) were added 0.024 g (0.25 mmol)
of 3-furaldehyde and 0.119 g (0.56 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction were removed
via rotary evaporation, and the residue was then purified on a
preparative TLC plate to give 32 mg of 4023. .sup.1H NMR (300 MHz,
CD.sub.3OD+CDCl.sub.3): .delta. 7.50-7.22 (a series of multiple
peaks, 9H), 6.39 (s, 1H), 1.90 (s, 3H). LCMS (ESI) nm/e 438
(M+H).sup.+.
Synthesis of Amine 4024
[0377] To a solution of 0.100 g (0.28 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) were added 0.027 g (0.25 mmol)
of 2-pyridylcarboxaldehyde and 0.089 g (0.42 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction was removed via
rotary evaporation, and the residue was then purified on a
preparative TLC plate to give 30.0 mg of 4024. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 8.39 (s, 1H), 8.30 (d, J=2.1 Hz, 1H),
7.70.about.7.21 (a series of multiplet peaks, 9H), 1.86 (s, 3H).
LCMS (ESI) m/e 449 (M+H).sup.+.
Synthesis of Amine 4025
[0378] To a solution of 0.100 g (0.28 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) were added 0.027 g (0.25 mmol)
of 3-pyridylcarboxaldehyde and 0.089 g (0.42 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction were removed
via rotary evaporation, and the residue was then purified on a
preparative TLC plate to give 30.0 mg of 4025. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 8.57 (s, 1H), 8.48 (d, J=4.2 Hz, 1H),
7.91-7.33 (a series of multiplet peaks, 9H), 2.05 (s, 3H). LCMS
(ESI) m/e 449 (M+H).sup.+.
Synthesis of Amine 4026
[0379] To a solution of 0.100 g (0.28 mmol) of amine 54 in 3 mL of
MeOH/THF (2:1, with 1% acetic acid) were added 0.024 g (0.25 mmol)
of 2-furaldehyde and 0.089 g (0.42 mmol) of sodium
triacetoxyborohydride at room temperature. The reaction mixture was
allowed to stir at 25.degree. C. until the aldehyde was consumed
based on TLC analysis. The solvents of the reaction were removed
via rotary evaporation, and the residue was then purified on a
preparative TLC plate to give 26.6 mg of 4026. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 7.52.about.7.26 (a series of multiplet
peaks, 10H), 1.87 (s, 3H). LCMS (ESI) m/e 438 (M+H).sup.+.
Example 52
Synthesis of Amine 4038
Method A
[0380] A solution of 8.00 g (115.9 mmol) of isoxazole and 31.30 g
(139.1 mmol) of N-iodosuccinimide in 60 ml of trifluoroacetic acid
was heated to 50.degree. C. for 6 h. The reaction mixture was
cooled and evaporated at 0.degree. C. to remove the majority of
trifluoroacetic acid. The residue was then dissolved in 200 ml of
diethyl ether, washed sequentially with saturated NaHCO.sub.3 (40
ml.times.4), 10% sodium thiosulfate (40 ml.times.2), and brine (40
ml), dried over MgSO.sub.4, filtered and concentrated to give 16.50
g of the desired 4-iodoisoxazole product. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 8.44 (s, 1H), 8.29 (s, 1H).
[0381] To a solution of 6.80 g (34.8 mmol) of 4-iodoisoxazole in
200 ml of THF at -100.degree. C. was added dropwise 22.9 ml (36.6
mmol) of n-BuLi (1.6 M in hexanes). The reaction mixture was
allowed to stir for 30 min. Ethyl formate (3.08 ml, 38.4 mmol) was
added to the mixture, and the mixture was stirred further for 30
min at -100.degree. C. Hydrochloric acid (36.60 ml of 1 N HCl in
ether) was added at -100.degree. C., and the reaction mixture was
allowed to warm gradually to 25.degree. C. The mixture was diluted
with ether (200 ml), washed sequentially with saturated NaHCO.sub.3
(100 ml) and brine (100 ml), dried over MgSO.sub.4, filtered and
concentrated (at 0.degree. C.) to give .about.2.00 g of the desired
isoxazole-4-carbaldehyde (based on estimation from .sup.1H NMR;
contaminated with residual EtOH) of suitable purity for use in
subsequent reactions. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.
10.01 (s, 1H), 9.05 (s, 1H), 8.68 (s, 1H).
[0382] A solution of 4.00 g (11.2 mmol) of amine 54, 1.03 g (10.6
mmol) of isoxazole-4-carbaldehyde, and 4.750 g (22.4 mmol) of
NaB(OAc).sub.3H in 30 ml of DMF with 1.0 ml of acetic acid was
stirred at 25.degree. C. for 4 h. The reaction solvents were
removed by rotary evaporation. The residue was purified by silica
gel column chromatography using 5% MeOH in CH.sub.2Cl.sub.2 as
eluent to give 1.57 g of amine 4038 plus 1.58 g of the imine
intermediate. LCMS (ESI) m/e 439 (M+H).sup.+.
Method B
[0383] A solution of 1.00 g (5.05 mmol) of
isoxazol-4-ylmethyl-carbamic acid tert-butyl ester in 10 ml of 4.0
N HCl in dioxane was stirred at 25.degree. C. for 6 h. The reaction
mixture was then diluted with 30 ml of diethyl ether and filtered.
The solid was washed with diethyl ether and dried to give 0.65 g of
C-isoxazol-4-yl-methylamine hydrochloride salt of suitable purity
for use in subsequent reactions. .sup.1H NMR (300 MHz, DMSO):
.delta. 9.02 (s, 1H), 8.68 (s, 1H), 3.94 (q, J=6, 1H).
[0384] A solution of aldehyde 92 (0.150 g, 0.42 mmol),
C-isoxazol-4-yl-methylamine hydrochloride salt (0.068 g, 0.51 mmol)
obtained above, and NaB(OAc).sub.3H (0.268 g, 1.26 mmol) in 5 ml of
DMF was stirred at 25.degree. C. for 2 h. The reaction solvent was
removed by rotary evaporation, and the residue was purified by
preparative thin-layer chromatography to give 0.160 g of amine
4038. LCMS (ESI) m/e 439 (M+H).sup.+.
Example 53
Synthesis of Amine 4215
[0385] Scheme 34 depicts the synthesis of amine 401 used in the
synthesis of compound 4215.
##STR00642##
Synthesis of Amine 401
[0386] A solution of aldehyde 92 (3.56 g, 10.0 mmol) in anhydrous
DMF (20 mL) was treated with a 2 N solution of methylamine in THF
(25 mL, 50.0 mmol) and sodium triacetoxyborohydride (3.20 g, 15.0
mmol) at room temperature, and the resulting reaction mixture was
stirred at room temperature for 6 h. When TLC and LCMS showed that
the reaction was complete, the reaction mixture was quenched with
H.sub.2O (40 mL), and the resulting mixture was stirred at room
temperature for 30 min. The solid precipitate was then collected by
filtration, washed with H.sub.2O (2.times.50 mL), and dried in
vacuo. This crude material was subsequently purified by flash
column chromatography (5-15% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford amine 401 (2.26 g; 61%) as an off-white solid.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.03 (s, 3H,
COCH.sub.3), 2.46 (s, 3H, NMe), 3.62 (t, 2H, J=5.4 Hz), 3.86 (s,
2H, Ar--CH.sub.2)), 3.96 (dd, 1H, J=6.4, 9.2 Hz), 4.35 (t, 1H,
J=9.2 Hz), 4.90-4.99 (m, 1H), 7.58-7.80 (m, 7H, aromatic-H), 8.45
(t, 1H, J=5.8 Hz, NHCOCH.sub.3); LCMS (ESI) m/z 372
(M+H).sup.+.
Synthesis of Amine 4215
[0387] A solution of amine 401 (0.070 g, 0.19 mmol) in methanol (2
mL) and acetic acid (0.020 mL) was treated with
quinoline-3-carboxaldehyde (0.033 g, 0.21 mmol) and sodium
triacetoxyborohydride (0.080 g, 0.38 mmol) and stirred at
23.degree. C. for 2 h. Additional sodium triacetoxyborohydride
(0.080 g, 0.38 mmol) and acetic acid (0.020 mL) were added, and the
reaction mixture was stirred for 16 h. The solvent was removed in
vacuo, and the residue was dissolved in THF (3 mL) and acetic acid
(0.020 mL) and treated with quinoline-3-carboxaldehyde (0.015 g,
0.095 mmol) and sodium triacetoxyborohydride (0.080 g, 0.38 mmol)
and stirred for 9 h. Additional sodium triacetoxyborohydride (0.080
g, 0.38 mmol) was added, and the reaction mixture was stirred for
60 h. The reaction mixture was diluted with methylene chloride (30
mL) and washed with saturated aqueous sodium bicarbonate (25 mL).
Drying over Na.sub.2SO.sub.4 and evaporation of solvent yielded
crude product, which was purified by flash chromatography (18:1:0.1
methylene chloride:methanol:ammonium hydroxide, 5-10% methanol in
1:1 methylene chloride:ethyl acetate) to afford amine 4215 as a
solid (0.030 g, 0.059 mmol; 31%). LCMS (ESI) m/z 513
(M+H).sup.+.
Example 54
Synthesis of Sulfide 4216 and Sulfoxide 4217
[0388] Scheme 35 depicts the synthesis of compounds 4216 and 4217.
Benzyl chloride 90 is displaced with thiolacetic acid to afford
thioacetate 402. Hydrolysis of 402 afforded thiol 403 which was
alkylated with 2-bromomethylpyridine to yield sulfide 4216.
Oxidation of 4216 then provided sulfoxide 4217.
##STR00643##
Synthesis of Chloride 90
[0389] Alcohol 51 (3.0 g, 8.4 mmol) was dissolved in
CH.sub.2Cl.sub.2 (20 mL) and Hunig's base (2 mL). Methanesulfonyl
chloride (1.4 mL, 12.6 mmol) was added dropwise and the resulting
solution stirred at rt for 4 h. The mixture was poured into 100 mL
sat. aqueous NaHCO.sub.3 and extracted with CH.sub.2Cl.sub.2
(3.times.50 mL). The combined organic extracts were washed with
brine, dried over MgSO.sub.4, filtered, and concentrated to give
3.9 g of an oily yellow solid. The crude material was purified by
silica gel chromatography to give chloride 90 as an off-white solid
(2.7 g, 7.2 mmol). LCMS (ESI) m/z 377 (M+H).sup.+, 418
(M+CH.sub.3CN+H).sup.+, 440 (M+CH.sub.3CN+Na).sup.+.
Synthesis of Thioester 402
[0390] Under an argon atmosphere, thiolacetic acid (1.55 mL, 21.7
mmol) was added to a mixture of chloride 90 (4.08 g, 10.8 mmol) and
Cs.sub.2CO.sub.3 (3.52 g, 10.8 mmol) in DMF (25 mL). The reaction
was stirred at room temperature for 2 hours. Then 50 mL of water
was added. The off-white product 402 (4.3 g) was collected by
filtration in a yield of 96%. LCMS (ESI) m/z 417 (M+H).sup.+.
Synthesis of Thiol 403
[0391] LiOH (360 mg, 15 mmol) was added to a solution of 402 (4.3
g, 10.3 mmol) in a mixture of THF (50 mL), MeOH (50 mL) and water
(20 mL). After stirring for 30 minutes at room temperature under
argon atmosphere, the insoluble solid was removed by filtration.
The filtrate was diluted with water (50 mL), concentrated to remove
organic solvents, then neutralized with 10% HCl. The off-white
product 403 (3.5 g) was collected by filtration in a yield of 91%.
LCMS (ESI) m/z 375 (M+H).sup.+.
Synthesis of Sulfide 4216
[0392] A solution of sulfide 403 (0.20 g, 0.54 mmol) in
tetrahydrofuran (1.3 mL), methanol (1.3 mL), and dimethylformamide
(1.3 mL) was treated with sodium methoxide
[0393] (25% in methanol, 0.24 mL, 1.1 mmol) and
2-(bromomethyl)pyridine and stirred at 23.degree. C. for 0.5 h. The
reaction mixture was diluted with methylene chloride (25 mL),
washed with water (25 mL), and the water layer was extracted with
methylene chloride (25 mL). The combined organic fractions were
dried over Na.sub.2SO.sub.4, and evaporated in vacuo to yield crude
product, which was purified by preparative thin-layer
chromatography (5% methanol/methylene chloride) to afford 4216 as a
white powder (0.12 g, 0.26 mmol; 48%). LCMS (ESI) m/z 466
(M+H).sup.+.
Synthesis of Sulfoxide 4217
[0394] A solution of 4216 (0.11 g, 0.23 mmol) in methylene chloride
(2.3 mL) was treated with 3-chloroperoxybenzoic acid (0.051 g, 0.23
mmol) and stirred at 23.degree. C. for 15 minutes.
[0395] The solvent was evaporated in vacuo and the crude product
was purified by flash chromatography (5% methanol/methylene
chloride) to afford 4217 as a white powder (0.093 g, 0.19 mmol;
83%). LCMS (ESI) m/z 482 (M+H).sup.+.
Example 55
Synthesis of Compounds 4218-4220
Synthesis of Amine 4218
[0396] A solution of amine 54 (0.600 g, 1.68 mmol),
1-methyl-indole-3-carboxaldehyde (0.254 g, 1.60 mmol), and
NaB(OAc).sub.3H (0.712 g, 3.36 mmol) in 30 ml of MeOH with a few
drops of acetic acid was stirred at 25.degree. C. for 24 h. The
reaction solvents were removed by rotary evaporation. The residue
was purified by preparative TLC plate to give 0.070 g of amine
4218. LCMS (ESI) m/z 501 (M+H).sup.+.
Synthesis of Amine 4219
[0397] A solution of amine 54 (0.060 g (0.17 mmol),
tetrahydrofuran-3-carboxaldehyde (0.016 g, 0.16 mmol), and
NaB(OAc).sub.3H (0.071 g, 0.34 mmol) in 5 ml of MeOH with a few
drops of acetic acid was stirred at 25.degree. C. for 6 h. The
reaction solvents were removed by rotary evaporation. The residue
was purified by preparative TLC plate to give 0.057 g of amine
4219. LCMS (ESI) m/z 442 (M+H).sup.+.
Synthesis of Amine 4220
[0398] A solution of amine 54 (0.500 g, 1.40 mmol),
1,2,3-thiadiazole-4-carboxaldehyde (0.152 g, 1.33 mmol), and
NaB(OAc).sub.3H (0.594 g, 2.80 mmol) in 8 ml of DMF with a few
drops of acetic acid was stirred at 25.degree. C. for 2 h. The
reaction solvents were removed by rotary evaporation. The residue
was purified by preparative TLC to give 0.484 g of amine 4220. LCMS
(ESI) m/z 492 (M+H).sup.+.
Example 56
Synthesis of Compound 4221
[0399] A solution of amine 54 (79.0 mg, 0.22 mmol) in anhydrous DMF
(3 mL) was treated with 3-(2-oxo-1,2-dihydro-pyridin-3-yl)-acrylic
acid (36.3 mg, 0.22 mmol) and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (62.7
mg, 0.33 mmol) at room temperature, and the resulting reaction
mixture was stirred at 25.degree. C. for 12 h. When TLC and LCMS
showed that the reaction was complete, the reaction mixture was
concentrated in vacuo. The residue was directly purified by flash
column chromatography (0-7% MeOH--CH.sub.2Cl.sub.2 gradient
elution) to afford amide 4221 (45.5 mg; 41%) as a white solid. LCMS
(ESI) m/z 505 (M+H).sup.+.
Example 57
Synthesis of Amidine 4222
[0400] Scheme 36 illustrates the synthesis of amidine 4222. Nitrile
404 and furfurylamine were heated together in the presence of
copper chloride to yield amidine 4222.
##STR00644##
Synthesis of Nitrile 404
[0401] This compound was made from 4-cyanophenylboronic acid and
iodide 50 as described above for the synthesis of alcohol 51.
Synthesis of Amidine 4222
[0402] Under an argon atmosphere, a mixture of nitrile 404 (98 mg,
0.28 mmol), furfurylamine (27 mg, 0.28 mmol) and copper (I)
chloride (CuCl, 28 mg, 0.28 mmol) in DMSO (2 mL) was heated at
80.degree. C. for 48 h. The reaction was diluted with
CH.sub.2Cl.sub.2, washed with saturated Na.sub.2CO.sub.3 and dried
under vacuum. The crude product was purified by chromatography
(5:1:0.05 CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 4222
(14 mg; 11%). LCMS (ESI) m/z 451 (M+H).sup.+.
Example 58
Synthesis of Amide 4223
[0403] Scheme 37 illustrates the synthesis of amide 4223.
2,5-Dibromopyridine is converted to activated pyridyl ester 405
which is then treated with histamine to provide amide 406. The
Suzuki coupling of 406 and boronate 81 gave the final target amide
4223.
##STR00645##
Synthesis of Ester 405
[0404] Under an argon atmosphere, triethylamine (0.31 mL, 2.25
mmol) was added to a mixture of 2,5-dibromopyridine (355 mg, 1.5
mmol), palladium acetate (16.8 mg. 0.075 mmol), Xantphos
(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 43.4 mg, 0.075
mmol) and N-hydroxysuccinimide (241.5 mg, 2.1 mmol) in DMSO (2 mL).
The solution was purged with carbon monoxide for 15 min and stirred
under a carbon monoxide balloon at 80.degree. C. for 16 h. The
reaction mixture was then cooled to room temperature, diluted with
20 mL of ethyl acetate and washed with saturated sodium bicarbonate
solution and water. The organic phase was dried over sodium sulfate
and evaporated to give crude product. Chromatography on silica gel
using hexane:acetone (3:1) provided ester 405 (75 mg; 17%).
.sup.1HNMR (300 MHz, CDCl.sub.3) .delta. 8.85 (m, 1H), 8.06 (m,
2H), 2.90 (s, 4H).
Synthesis of Amide 406
[0405] A mixture of active ester 405 (350 mg, 1.17 mmol), histamine
dihydrochloride (216 mg, 1.17 mmol) and Et.sub.3N (0.33 mL, 2.34
mmol) in CH.sub.2Cl.sub.2 (5 mL) was stirred at room temperature
for 1 h. The reaction was washed with brine and dried under vacuum.
The crude product was purified by chromatography (15:1:0.05
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 406 (280 mg;
81%). LCMS (ESI) m/z 295 (M+H).sup.+.
Synthesis of Amide 4223
[0406] Under an argon atmosphere, a mixture of 406 (230 mg, 0.78
mmol), boronate 81 (295 mg, 0.78 mmol), Pd(dppf).sub.2Cl.sub.2 (19
mg, 0.023 mmol) and K.sub.2CO.sub.3 (323 mg, 2.34 mmol) in 5 mL of
a mixture of dioxane/EtOH/H.sub.2O (3:1:1) was heated at 10.degree.
C. for 12 h. The reaction was concentrated and the residue was
dissolved in MeOH (2 mL) and CH.sub.2Cl.sub.2 (10 mL). Inorganic
salts were removed by filtration. The filtrate was concentrated and
purified by chromatography (15:1:0.05
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford amide 4223 (106
mg; 29%). LCMS (ESI) m/z 467 (M+H).sup.+.
Example 59
Synthesis of Amides 4224 and 4225
[0407] Scheme 38 illustrates the synthesis of amides 4224 and 4225.
Aryl bromides 407 and 408 were coupled to boronate 81 to afford
4224 and 4225 respectively.
##STR00646##
Synthesis of Amide 4224
[0408] A mixture of 4-bromobenzoyl chloride (110 mg, 0.5 mmol),
1,2,4-oxadiazol-3-yl-methylamine hydrochloride (68 mg, 0.5 mmol),
DMF (1 drop) and Et.sub.3N (0.33 mL, 2.34 mmol) in CH.sub.2Cl.sub.2
(5 mL) was stirred at room temperature for 4 h. The reaction was
washed with brine and dried under vacuum to afford crude amide 407.
The amide 407 obtained was added to a mixture of boronate 81 (189
mg, 0.5 mmol), Pd(dppf).sub.2Cl.sub.2 (20 mg, 0.025 mmol) and
K.sub.2CO.sub.3 (207 mg, 1.5 mmol) in 5 mL of dioxane/EtOH/H.sub.2O
(3:1:1) under an argon atmosphere. After being heated at
100.degree. C. for 12 h, the reaction was diluted with water and
MeOH, and then filtered through celite. The filtrate was
concentrated to remove organic solvent. The crude product was
collected by filtration and further purified by chromatography
(25:1:0.05 CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 4224
(45 mg; 32%). LCMS (ESI) m/z 452 (M-H).sup.+.
Synthesis of Amide 4225
[0409] A mixture of 4-bromobenzoyl chloride (29 mg, 0.132 mmol),
1,2,4-thiadiazol-3-yl-methylamine hydrochloride (20 mg, 0.132
mmol), DMF (1 drop) and Et.sub.3N (27 mg, 0.264 mmol) in THF (4 mL)
was stirred at room temperature for 2 h. The reaction was
concentrated, dissolved in CH.sub.2Cl.sub.2, washed with brine and
dried under vacuum to afford crude amide 408. The resultant amide
408 obtained above was added to a mixture of boronate 81 (50 mg,
0.132 mmol), Pd(dppf).sub.2Cl.sub.2 (6 mg, 0.0066 mmol) and
K.sub.2CO.sub.3 (55 mg, 0.396 mmol) in 2 mL of
dioxane/EtOH/H.sub.2O (3:1:1) under an argon atmosphere. After
being heated at 100.degree. C. for 12 h, the reaction was
concentrated, dissolved in EtOAc, washed with brine and dried under
vacuum. The crude product was purified by chromatography on silica
gel (25:1:0.05 CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford
amide 4225 (30 mg; 48%). LCMS (ESI) m/z 470 (M+H).sup.+.
Example 60
Synthesis of Sulfide 4226
[0410] Under an argon atmosphere, sodium methoxide (NaOMe, 25% by
wt. in MeOH, 95 mg, 0.44 mmol) was added to a solution of thiol 403
(75 mg, 0.2 mmol) and epibromohydrin (30 mg, 0.22 mmol) in MeOH (3
mL) and THF (3 mL). After stirring at room temperature for 2 h, the
reaction was concentrated. The residue was dissolved
CH.sub.2Cl.sub.2, washed with brine, dried over MgSO.sub.4 and
concentrated under vacuum. The crude product was purified by
chromatography on silica gel (25:1:0.05
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford sulfide 4226 (55
mg; 61% as a mix of diastereomers). LCMS (ESI) m/z 453
(M+Na).sup.+.
Example 61
Synthesis of Amines 4227-4229
Synthesis of Amine 4227
[0411] A suspension of aldehyde 92 (107 mg, 0.3 mmol) in anhydrous
THF (2 mL) and anhydrous methanol (MeOH, 2 mL) was treated with
2-(1H-imidazol-4-yl)-ethylamine (110.0 mg, 0.6) and sodium
triacetoxyborohydride (127 mg, 0.6 mmol) at room temperature, and
the resulting reaction mixture was stirred at room temperature for
6 h. When TLC and LCMS showed that the reaction was complete, the
reaction mixture was concentrated in vacuo. This residue was
directly purified by flash column chromatography (0-10%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford amine 4227 (24
mg, 135.3 mg; 18%) as an off-white solid. LCMS (ESI) m/z 452
(M+H).sup.+.
Synthesis of Amine 4228
[0412] A suspension of aldehyde 92 (107 mg, 0.3 mmol) in anhydrous
THF (2 mL) and anhydrous methanol (MeOH, 2 mL) was treated with
2-(5-methyl-1H-indol-3-yl)-ethylamine hydrochloride (126.0 mg, 0.6
mmol) and sodium triacetoxyborohydride (127 mg, 0.6 mmol) at room
temperature, and the resulting reaction mixture was stirred at room
temperature for 12 h. When TLC and LCMS showed that the reaction
was complete, the reaction mixture was concentrated in vacuo. This
residue was directly purified by flash column chromatography (0-10%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford amine 4228 (32
mg; 21%) as off-white solids. LCMS (ESI) m/z 515 (M+H).sup.+.
Synthesis of Amine 4229
[0413] A suspension of aldehyde 92 (107 mg, 0.3 mmol) in anhydrous
THF (2 mL) and anhydrous methanol (2 mL) was treated with
(5-methyl-isoxazol-3-yl)-methylamine (67.0 mg, 0.6 mmol) and sodium
triacetoxyborohydride (127 mg, 0.6 mmol) at room temperature, and
the resulting reaction mixture was stirred at room temperature for
12 h. When TLC and LCMS showed that the reaction was complete, the
reaction mixture was concentrated in vacuo. This residue was
directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford amine 4229 (34
mg; 25%) as an off-white solid. LCMS (ESI) m/z 453 (M+H).sup.+.
Example 62
Synthesis of Amines 4230 and 4231
[0414] Scheme 39 shows the synthesis of amines 4230 and 4231. Known
alcohol 409 (see U.S. Pat. Nos. 5,523,403 and 5,565,571) is coupled
to 4-formylphenylboronic acid to afford alcohol 410 which is then
converted to mesylate 411. Alkylation of mesylate 411 with the
appropriate nucleophiles affords biaryl aldehydes 412 and 413 which
are transformed to amines 4230 and 4231 respectively by reductive
amination chemistry.
##STR00647## ##STR00648##
Synthesis of Alcohol 410
[0415] A suspension of alcohol 409 (5.07 g, 15.0 mmol) in toluene
(30 mL) was treated with 4-formylphenylboronic acid (3.15 g, 21.0
mmol), K.sub.2CO.sub.3 (6.22 g, 45.0 mmol), EtOH (10 mL), and
H.sub.2O (10 mL) at 25.degree. C., and the resulting mixture was
degassed three times under a steady stream of argon at 25.degree.
C. Pd(dppf).sub.2Cl.sub.2 (370 mg, 0.45 mmol) was subsequently
added to the reaction mixture, and the resulting reaction mixture
was degassed three times again before being warmed to gentle reflux
for 2 h. When TLC and LCMS showed the coupling reaction was
complete, the reaction mixture was cooled to room temperature
before being treated with H.sub.2O (100 mL). The resulting mixture
was then stirred at room temperature for 10 min before being cooled
to 0-5.degree. C. for 1 h. The solid precipitate was collected by
filtration, washed with H.sub.2O (2.times.40 mL) and 20%
EtOAc/hexane (2.times.40 mL), and dried in vacuo. The crude alcohol
410 (4.62 g; 98%) was obtained as a brown solid, which by HPLC and
.sup.1H NMR was found to be of suitable purity to be used in
subsequent reactions. LCMS (ESI) m/z 316 (M+H).sup.+.
Synthesis of Mesylate 411
[0416] A solution of the crude alcohol 410 (4.2 g, 13.3 mmol) in
CH.sub.2Cl.sub.2 (50 mL) was treated with diisopropylethylamine
(2.6 g, 3.5 mL, 20.0 mmol) at 25.degree. C., and the resulting
mixture was cooled to 0-5.degree. C. before being treated dropwise
with methanesulfonyl chloride (1.83 g, 1.25 mL, 16.0 mmol) at
0-5.degree. C. The resulting reaction mixture was subsequently
stirred at 0-5.degree. C. for 2 h. When TLC and LCMS showed the
reaction was complete, the reaction mixture was treated with
H.sub.2O (50 mL) at 0-5.degree. C. The mixture was then
concentrated in vacuo to remove most of the CH.sub.2Cl.sub.2, and
the resulting slurry was treated with H.sub.2O (50 mL). The mixture
was stirred at room temperature for 10 min before being cooled to
0-5.degree. C. for 30 min. The solid precipitate was collected by
filtration, washed with H.sub.2O (2.times.40 mL) and 20%
EtOAc/hexane (2.times.20 mL), and dried in vacuo. The crude
mesylate 411 (4.60 g; 88%) was obtained as a brown solid, which by
.sup.1H NMR and HPLC was found to be of suitable purity to be used
in subsequent reactions. LCMS (ESI) m/z 394 (M+H).sup.+.
Synthesis of Aldehyde 412
[0417] A solution of mesylate 411 (393 mg, 0.1 mmol) in anhydrous
DMF (4 mL) was treated with 1H-1,2,4-triazole sodium salt (100 mg,
1.1 mmol) at room temperature, and the resulting reaction mixture
was warmed to 40.degree. C. and stirred at 40.degree. C. for 4 h.
When TLC and LCMS showed that the reaction was complete, the
reaction mixture was concentrated in vacuo. This residue was
directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford aldehyde 412
(318.4 mg; 87%) as an off-white solid. LCMS (ESI) m/z 367
(M+H).sup.+.
Synthesis of Amine 4230
[0418] A suspension of aldehyde 412 (90.0 mg, 0.25 mmol) in
anhydrous THF (2 mL) and anhydrous DMF (2 mL) was treated with
C-pyridin-4-yl-methylamine (29.0 mg, 0.27 mmol) and sodium
triacetoxyborohydride (106.0 mg, 0.5 mmol) at room temperature, and
the resulting reaction mixture was stirred at room temperature for
6 h. When TLC and LCMS showed that the reaction was complete, the
reaction mixture was concentrated in vacuo. This residue was
directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford amine 4230 (47.0
mg; 41%) as an off-white solid. LCMS (ESI) m/z 459 (M+H).sup.+.
Synthesis of Aldehyde 413
[0419] A solution of 1-methyl-1H-tetrazole-5-thiol sodium salt
(174.0 mg, 1.5 mmol) in anhydrous THF (5 mL) was treated with NaH
(60% oil dispersion in mineral oil, 60.0 mg, 1.5 mmol) at
0-5.degree. C., and the resulting reaction mixture was stirred at
0-5.degree. C. for 1 h. The mixture was then treated with mesylate
411 (393.0 mg, 1.0 mmol) and anhydrous DMF (5 mL) at 0-5.degree.
C., and the resulting reaction mixture was gradually warmed to room
temperature before being warmed to 40.degree. C. for 4 h. When TLC
and LCMS showed that the reaction was complete, the reaction
mixture was concentrated in vacuo. This residue was directly
purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford aldehyde 413
(272.6 mg; 66%) as an off-white solid. LCMS (ESI) m/z 414
(M+H).sup.+.
Synthesis of Amine 4231
[0420] A suspension of aldehyde 413 (100.0 mg, 0.24 mmol) in
anhydrous THF (2 mL) and anhydrous DMF (2 mL) was treated with
C-pyridin-4-yl-methylamine (29.0 mg, 0.27 mmol) and
sodiumborohydride (15.0 mg, 0.24 mmol) at room temperature, and the
resulting reaction mixture was stirred at room temperature for 12
h. When TLC and LCMS showed that the reaction was complete, the
reaction mixture was concentrated in vacuo. This residue was
directly purified by flash column chromatography (0-5%
MeOH--CH.sub.2Cl.sub.2 gradient elution) to afford amine 4231 (44.0
mg; 36%) as an off-white solid. LCMS (ESI) m/z 506 (M+H).sup.+.
Example 63
Synthesis of Amine 4233
[0421] Scheme 40 shows the synthesis of isoxadiazole 4233.
BOC-Aminoacetonitrile was converted to hydroxyamidine 414 which was
then cyclyzed to isoxadiazole 415. Reductive amination of 415 with
aldehyde 92 afforded amine 4233.
##STR00649##
Synthesis of Hydroxyamidine 414
[0422] To a solution of BOC-aminoacetonitrile (6.0 g, 38 mmol) in
EtOH (60 mL) was added 50% aq. hydroxylamine (4.5 mL, 77 mmol) and
the mixture was refluxed for 5 h. The solvents were evaporated and
the residue redissolved in CH.sub.2Cl.sub.2 (100 mL), dried over
Na.sub.2SO.sub.4 and again evaporated, yielding hydroxyamidine 414
(7 g; 96%). .sup.1H-NMR, (300 MHz, CDCl.sub.3) .delta. 5.43-5.39 (m
1H), 5.12-5.03 (m, 3H), 3.75 (d, J=5 Hz, 2H), 1.46 (s, 9H).
Synthesis of Isoxadiazole 415
[0423] To a solution of 414 (2.8 g, 14.7 mmol) in CH.sub.2Cl.sub.2
(45 mL) was added Et.sub.3N (4.1 mL, 29.5 mmol), formic acid (0.72
mL, 19.2 mmol), EDCI (4.24 g, 22 mmol), and DMAP (89 mg, 0.7 mmol).
The mixture was stirred at room temperature for 3 h, evaporated to
ca. 15 mL, diluted with ethyl acetate (50 mL), washed with 1M
citric acid (20 mL), water (2.times.20 mL), brine (1.times.20 mL),
dried over Na.sub.2SO.sub.4 and the solvent evaporated. The crude
residue was dissolved in pyridine (11 mL) and stirred at
105.degree. C. for 4.5 h, poured into 1M citric acid-ice (100 mL)
and extracted with ethyl acetate (2.times.50 mL). The combined
organic layer was washed with water (2.times.15 mL), brine
(1.times.15 mL), dried over Na.sub.2SO.sub.4 and the solvent
evaporated. The residue was dissolved in 4M HCl in dioxane (7 mL).
The mixture was stirred at room temperature for 2 h and then
evaporated and diluted with ether (3 mL). The solution was filtered
and the solid was washed with ether (2.times.5 mL) and dried under
high vacuum to yield 415 (855 mg; 83%). .sup.1H-NMR, (300 MHz,
d.sub.6-DMSO) .delta. 9.6 (s, 1H), 8.77 (br s, 3H), 4.09 (m,
2H).
Synthesis of Amine 4233
[0424] Amine 4233 was synthesized from 415 and aldehyde 92 using
the same conditions described in Example 53 for the synthesis of
amine 401 from aldehyde 92. LCMS (ESI) m/z 441 (M+H).sup.+.
Example 64
Synthesis of Amine 4234
[0425] Scheme 41 depicts the synthesis of amine 4234. Known ester
416 (Liebigs Annalen der Chemie 1979, 1370) was reduced to alcohol
417 which was manipulated to amine salt 418 via standard chemistry.
Reductive amination of 418 with aldehyde 19 yielded amine 4234.
##STR00650##
Synthesis of Alcohol 417
[0426] To a solution of the oxazole 416 (500 mg, 4.4 mmol) in MeOH
(20 mL) was added sodium borohydride (NaBH.sub.4, 540 mg, 17.5
mmol). The mixture was stirred at room temperature for 2 h, then
NaBH.sub.4 (540 mg, 17.5 mmol) was added. After 1 h an additional
amount of NaBH.sub.4 (270 mg, 9.0 mmol) was added. After stirring
for 2 h, the mixture was quenched with 5% Na.sub.2CO.sub.3 (2 mL)
and evaporated. The crude residue was purified on silica gel
eluting with ether, yielding 417 as a clear oil (300 mg; 86%).
.sup.1H-NMR, (300 MHz, CDCl.sub.3) .delta. 7.82 (s, 1H), 7.57 (s,
1H), 4.57 (s, 2H).
Synthesis of Amine Hydrochloride 418 Alcohol 417 was converted to
amine salt 418 following the procedure described above to make
amine 54 from alcohol 51. The crude material was taken up HCl in
dioxane and then triturated with ether to isolate the salt as was
described above for amine salt 415.
Synthesis of Amine 4234
[0427] This amine was synthesized from 418 and aldehyde 92 using
the same conditions described above for the synthesis of amine 401
from aldehyde 92. LCMS (ESI) m/z 439 (M+H).sup.+.
Example 65
Synthesis of Amine 4235
[0428] Scheme 42 depicts the synthesis of amine 4235 from aldehyde
419 and amine salt 418.
##STR00651##
Synthesis of Aldehyde 419
[0429] Aldehyde 419 was synthesized from
5-bromo-pyridine-2-carboxaldehyde and boronate ester 81 as
described above for the synthesis of amide 4223.
Synthesis of Amine 4235
[0430] Amine 4235 was synthesized from aldehyde 419 and amine salt
418 using the same conditions described in Example 53 for the
synthesis of amine 401 from aldehyde 92. LCMS (ESI) m/z 440
(M+H).sup.+.
Example 66
Synthesis of Compound 4208
[0431] Scheme 43 depicts the synthesis of compound 4208.
##STR00652##
[0432] To a solution of tert-Butyl N-(2-oxoethyl)carbamate (4.0 g,
25.1 mmol) in MeOH (80 mL) was added K.sub.2CO.sub.3 (10.4 g, 75.4
mmol) followed by tosylmethylisocyanide (TOSMIC, 4.91 g, 25.1
mmol). The suspension was refluxed for 1 h and then evaporated. The
residue was poured into ice-water (100 mL) and extracted with ethyl
acetate (2.times.50 mL). The combined organic extracts were washed
with water (2.times.20 mL), brine (lx 20 mL), dried over
Na.sub.2SO.sub.4 and evaporated. The residue was purified on silica
gel eluting with hexanes/ethyl acetate 1:1, yielding a faint yellow
oil which was directly dissolved in 4 M HCl in dioxane (15 mL),
stirred for 45 min., and evaporated. The residue was crystallized
with ether (10 mL) and filtered, yielding amine 420 (1.50 g, 42%).
.sup.1H-NMR, (300 MHz, d-DMSO .delta. 8.73 (br.s 3H), 8.48 (s, 1H),
7.28 (s, 1H), 4.20-4.12 (m, 2H).
[0433] Compound 4208 was synthezised from amine 420 and aldehyde 92
using the same conditions described in Example 53 for the synthesis
of amine 401 from aldehyde 92. LCMS (ESI): 439.1 (M+H).sup.+.
Example 67
Synthesis of Compound 4136
[0434] A solution of amine 54 (0.070 g, 0.20 mmol) in DMF (1.0 ml)
was treated with triethylamine (0.055 ml, 0.40 mmol) and
2-phthalimidoethanesulfonyl chloride (0.059 mg, 0.22 mmol) and
stirred at 23.degree. C. for 3.5 h. Additional
2-phthalimidoethanesulfonyl chloride (0.081 mg, 0.30 mmol) and
triethylamine (0.087 ml, 0.63 mmol) were added, and the reaction
mixture was stirred for 16 h. The reaction mixture was diluted with
methylene chloride (20 ml), washed with 1 M hydrochloric acid (20
ml), and washed with saturated aqueous sodium bicarbonate (20 ml).
Drying over Na.sub.2SO.sub.4 and evaporation of solvent yielded
crude product, which was purified by flash chromatography (2.5-5%
methanol in 1:1 methylene chloride/ethyl acetate) to afford
compound 4136 (0.082 g, 0.14 mmol, 70%). MS (ESI): 617
(M+Na).sup.+.
Example 68
Synthesis of Compound 4239
[0435] Scheme 44 depicts the synthesis of compound 4208.
##STR00653##
Synthesis of Azide 422
[0436] To a solution of bromoacetic acid (1.0 g, 2.8 mmol) and
1-hydroxybenzotriazole hydrate (HOBT, 0.44 g, 3.4 mmol) in DMF (15
mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDC.HCl, 0.66 g, 3.4 mmol) and amine 54 (0.45 g, 3.2
mmol) in a rapid succession. The resulting mixture was stirred at
room temperature overnight. The solvent was evaporated and the
crude product was suspended in water (about 40 mL). The suspension
was filtered and the residue was washed with water, diethyl ether
(about 50 mL) and dried in vacuo to give analytically pure compound
421 as white solid in quantitative yield.
[0437] Compound 421 was dissolved in DMF (10 mL) and NaN.sub.3
(0.55 g, 8.0 mmol) was added. The mixture was heated at 60.degree.
C. overnight and solvent evaporated off. The crude was suspended in
water (about 40 mL), filtered, and the residue was washed with
water, diethyl ether (about 50 mL) and dried in vacuo to give
analytically pure azide 422 as white solid (0.97 g, 69.3%). LCMS
(ESI): 441 (M+H).sup.+.
Synthesis of Triazole 4239
[0438] Azide 422 (0.25 g, 0.57 mmol) and TMS-acetylene (0.28 g,
2.84 mmol) were dissolved in DMF (5 mL) and the mixture was heated
at 90.degree. C. for 24 h under an argon atmosphere. The solvent
was evaporated off, leaving a solid residue. The residue was
suspended in water, filtered and dried in vacuo. To the solution of
this residue in THF (5 mL) was added IM TBAF in THF (1.14 mL) and
acetic acid (0.04 mL, 0.57 mmol), and the mixture was stirred at
room temperature overnight, after which time TLC showed a complete
consumption of the starting material. The solvent was evaporated
off and the crude was suspended in diethyl ether (about 40 mL). The
suspension was filtered, and the residue was washed in succession
with CH.sub.2Cl.sub.2 (about 50 mL), 10% CH.sub.3CN in diethyl
ether (about 50 mL), diethyl ether (about 20 mL). The residue was
air dried to give analytically pure triazole 4239 as white solid
(0.238 g, 89.6%). LCMS (ESI): 467.1 (M+H).sup.+.
Example 69
Synthesis of Compound 4252
[0439] A solution of the methanesulfonic acid
5-{4-[5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-pyri-
din-2-ylmethyl ester 106 (220 mg, 0.5 mmol) in DMF (4.0 mL) was
treated with C-isoxazol-4-yl-methylamine (68 mg, 0.5 mmol, 1.0
equiv) at room temperature, and the resulting reaction mixture was
warmed to 60.degree. C. and stirred for 6 hours. When TLC and MS
showed the reaction to be complete, the reaction mixture was
concentrated in vacuo, and the residue was directly purified by
column chromatography (0-5% MeOH/CH.sub.2Cl.sub.2 gradient elution)
to afford the desired
N-{3-[3-Fluoro-4-(6-{[(isoxazol-4-ylmethyl)-amino]-methyl}-pyridin-3-yl)--
phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 4252 (22 mg, 10%) as
off-white solids. LCMS (EI): 440 (M.sup.++H).
Example 70
Synthesis of Compound 4262
[0440] Scheme 45 depicts the synthesis of compound 4262.
##STR00654##
[0441] To a solution of 0.060 g (0.17 mmol) of aldehyde 92 and
0.056 g (0.25 mmol) of the HCl salt of amine 423 in 3 ml of DMF was
added 0.071 g (0.34 mmol) of NaB(OAc).sub.3H. The reaction mixture
was stirred at 25.degree. C. for 2 h. The DMF was removed, and the
residue was purified by preparative TLC to give 0.041 g of compound
424. MS (M+1): 525.
[0442] To a solution of 0.012 g (0.023 mmol) of 424 and 0.03 ml
(0.027 mmol) of TBAF (1 M in THF) in 4 ml of CH.sub.2Cl.sub.2 was
added a few drops of acetic acid, and the mixture was stirred at
0.degree. C. for 4 h. The reaction solvents were removed by rotary
evaporation, and the residue was purified by preparative TLC to
give 0.008 g of compound 4262. MS (M+1): 489.
Example 71
Synthesis of Triazole 4276
[0443] Scheme 46 depicts the synthesis of triazole 4276.
##STR00655##
Synthesis of Alkyne 425
[0444] To a solution of chloride 90 (2 g, 5.3 mmol) and Hunig's
base (diisopropylethylamine, 1.7 mL, 10 mmol) in DMF (15 mL) was
added a solution of N-methyl propargylamine (0.55 g mg, 8.0 mmol)
in DMF (1 mL). After stirring at room temperature for 16 h, the DMF
was removed in vacuo. The crude product was purified by preparative
thin layer chromatography (10:1:0.05
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 2.05 g of alkyne
425 in a yield of 95%. MS (ESI): 410.1 (100%) (M+Na).sup.+.
Synthesis of Compound 4276
[0445] A mixture of alkyne 425 (1.8 g, 4.4 mmol), sodium azide
(0.43 g, 6.6 mmol), ammonium chloride (0.35 g, 6.6 mmol), copper(I)
iodide (84 mg, 0.44 mmol) and Hunig's base (3.5 mL, 20 mmol) in DMF
(10 mL) was heated under argon atmosphere at 80.degree. C. for 48
h. The DMF was removed in vacuo, and the residue was dissolved in
MeOH (5 mL), CH.sub.2Cl.sub.2 (50 mL), conc. ammonium hydroxide (20
mL) and saturated ammonium chloride solution (20 mL). After
stirring at room temperature for 2 h, the organic phase was
separated, washed with saturated NH.sub.4Cl solution and water,
dried over MgSO.sub.4, and concentrated. The crude product was
purified by preparative thin layer chromatography (10:1:0.05
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 1.75 mg of
triazole 4276 in a yield of 88%. MS (ESI): 453.1 (100%)
(M+H).sup.+, 475.2 (M+Na).sup.+.
Example 72
Synthesis of Triazole 4278
[0446] Scheme 47 depicts the synthesis of triazole 4278.
##STR00656##
Synthesis of Alkyne 426
[0447] A mixture of amine 54 (422 mg, 1.18 mmol), butyn-3-yl
tosylate (265 mg, 1.18 mmol), Hunig's base (diisopropylethylamine,
0.2 mL, 1.15 mmol) and potassium iodide (17 mg, 0.1 mmol) in DMF (5
mL) was heated at 70.degree. C. 15 h. The DMF was removed in vacuo.
The residue was dissolved in a mixed solvent of THF (10 mL) and
water (2 mL), K.sub.2CO.sub.3 (276 mg, 2 mmol), and then
di-tert-butyl dicarbonate (218 mg, 1 mmol) was added. The reaction
was stirred at room temperature for 12 h, and the THF was removed
in vacuo. 40 mL of EtOAc was added and the solution was washed with
water, dried over MgSO.sub.4 and concentrated. The crude product
was purified by preparative thin layer chromatography (15:1:0.05
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 210 mg of alkyne
426 in a yield of 22%. MS (ESI): 410.1, 532.1 (M+Na).sup.+, 573.1
(100%).
Synthesis of Triazole 427
[0448] A mixture of alkyne 426 (150 mg, 0.29 mmol), sodium azide
(29 mg, 0.44 mmol), ammonium chloride (24 mg, 0.44 mmol), copper(I)
iodide (56 mg, 0.29 mmol) and Hunig's base (0.26 mL, 1.5 mmol) in
DMF (3 mL) was heated under argon atmosphere at 80.degree. C. for
24 h. The DMF was removed in vacuo, and the residue was dissolved
in CH.sub.2Cl.sub.2 and conc. ammonium hydroxide solution. The
organic phase was separated, washed with saturated NH.sub.4Cl
solution and water, dried over MgSO.sub.4, and concentrated. The
crude product was purified by preparative thin layer chromatography
(15:1:0.05 CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 155
mg of triazole 427 in a yield of 95%. MS (ESI): 453.1 (100%), 575.1
(M+Na).sup.+.
Synthesis of Compound 4278
[0449] To a solution of triazole 427 (155 mg, 0.28 mmol) in
CH.sub.2Cl.sub.2 (5 mL) and MeOH (1 mL) was added 2 mL of HCl
solution (4.0 M in dioxane). After stirring at room temperature for
15 h, the reaction was concentrated and washed with EtOAc/MeOH to
give 130 mg of compound 4278 in a yield of 95%. MS (ESI): 453.1.1
(100%) (M+H).sup.+.
Example 73
Synthesis of Compounds 4316 and 4314
Synthesis of Morpholine 4316
[0450] Scheme 48 depicts the synthesis of morpholine 4316.
##STR00657##
[0451] Known bromide 428 was synthesized from morpholine and
bromoacetyl bromide as reported in the literature (Thompson, W. J.
et al. J. Med. Chem. 1992, 35, 1685). To a solution of amine 54 (86
mg, 0.23 mmol) in a mixture of methyl alcohol (2 mL), methylene
chloride (2 mL) and Hunig's base (2 mL) was added bromide 428 (32
mg, 0.23 mmol) at 0.degree. C. The reaction mixture was warmed to
room temperature and heated over an oil bath at 80.degree. C. for
18 h. The solution was concentrated and purified by flash
chromatography over silica gel (14:1:0.05 CH.sub.2Cl.sub.2/MeOH:
NH.sub.4OH) to yield 66 mg of compound 4316. .sup.1HNMR (300 MHz,
CD.sub.3OD): .delta. 7.50-7.22 (m, 7H), 4.77-4.69 (m, 1H), 4.06 (t,
J=9 Hz, 1H), 3.77 (dd, J=6, 3 Hz, 1H), 3.70 (s, 1H), 3.55-3.46 (m,
8H), 3.39-3.36 (m, 3H), 3.34-3.30 (m, 2H), 1.86 (s, 3H). LCMS (ESI)
m/e 485 (M+H).sup.+.
Synthesis of Piperazine 4314
[0452] Scheme 49 depicts the synthesis of piperazine 4314.
##STR00658##
[0453] Bromide 429 was synthesized from tert-Butyl 1-piperazine
carboxylate and bromoacetyl bromide following literature procedures
(Thompson, W. J. et al. J. Med. Chem. 1992, 35, 1685). .sup.1HNMR
(300 MHz, CDCl.sub.3): .delta. 3.86 (s, 2H), 3.61-3.41 (m, 8H),
1.46 (s, 9H). Compound 430 was synthesized from amine 54 and
bromide 429 using the same procedure as described for compound
4316. LCMS (ESI) m/e 584 (M+H).sup.+. A solution of 430 (50 mg,
0.085 mmol) in CH.sub.2Cl.sub.2-CF.sub.3COOH (1:1, 4 mL) was
stirred at 0.degree. C. for 1 h. The reaction mixture was
concentrated and the crude product after purification (7:1:0.05
CH.sub.2Cl.sub.2/MeOH/NH.sub.4OH) afforded 35 mg of compound 4314.
.sup.1HNMR (300 MHz, CD.sub.3OD): .delta. 7.51-7.23 (m, 7H),
4.73-4.67 (m, 1H), 4.07 (t, J=9 Hz, 1H), 3.75 (dd, J=8, 3 Hz, 1H),
3.73 (s. 2H), 3.48-3.41 (m, 6H), 3.24 (s, 2H), 3.21-3.19 (m, 2H),
2.75-2.65 (m, 4H), 1.87 (s, 3H). LCMS (ESI) m/e 484
(M+H).sup.+.
Example 74
Synthesis of Triazole 5001
[0454] Scheme 50 depicts the synthesis of triazole 5001.
##STR00659##
Synthesis of Triazole 501
[0455] A mixture of 1H-1,2,3-triazole-5-thiol sodium salt 502 (246
mg, 2 mmol) and 2-(Boc-amino)ethyl bromide 503 (448 mg, 2 mmol) in
DMF (2 mL) was stirred at room temperature for 2 h. 50 mL of EtOAc
was added and the solution was washed with water, dried over
MgSO.sub.4 and concentrated to afford 458 mg of triazole 501 as
colorless oil in a yield of 94%. MS (ESI): 267.0 (100%)
(M+Na).sup.+.
Synthesis of Triazole 504
[0456] To a solution of triazole 501 (458 mg, 1.88 mmol) in
CH.sub.2Cl.sub.2 (10 mL) and MeOH (2 mL) was added 4 mL of HCl
solution (4.0 M in dioxane). After stirring at room temperature for
2 h, the reaction was concentrated to dryness. The residue was
dissolved in DMF (7 mL) and then chloride 90 (377 mg, 1 mmol) and
Hunig's base (diisopropylethylamine, 0.8 mL, 4.6 mmol) were added.
The solution was heated at 70.degree. C. for 3 h. The DMF was
removed in vacuo, and the residue was dissolved in a mixed solvent
of THF (10 mL) and water (2 mL). K.sub.2CO.sub.3 (414 mg, 3 mmol)
and di-tert-butyl dicarbonate (545 mg, 2.5 mmol) were then added,
and the reaction was stirred at room temperature for 12 h. The THF
was removed in vacuo, 50 mL of EtOAc was added, and the solution
was washed with water, dried over MgSO.sub.4 and concentrated. The
crude product was purified by preparative thin layer chromatography
(15:1:0.1 CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 192 mg
of triazole 504 in a yield of 33%. MS (ESI): 485.1 (100%), 607.2
(M+Na).sup.+.
Synthesis of Compound 5001
[0457] To a solution of triazole 504 (192 mg, 0.33 mmol) in
CH.sub.2Cl.sub.2 (10 mL) and MeOH (2 mL) was added 4 mL of HCl
solution (4.0 M in dioxane). After stirring at room temperature for
12 h, the reaction was concentrated and washed with EtOAc/MeOH to
give 150 mg of triazole 5001 in a yield of 94%. MS (ESI): 485.1
(100%) (M+H).sup.+, 507.2 (M+Na).sup.+.
Example 75
Synthesis of Triazole 5002
[0458] Scheme 51 depicts the synthesis of triazole 5002.
##STR00660##
Synthesis of Triazole 505
[0459] A mixture of 1H-1,2,3-triazole-5-thiol sodium salt 502 (246
mg, 2 mmol) and 2-(BOC-amino)propyl bromide 506 (476 mg, 2 mmol) in
DMF (2 mL) was stirred at room temperature for 1 h. 50 mL of EtOAc
was added and the solution was washed with water, dried over
MgSO.sub.4 and concentrated to afford 508 mg of triazole 505 as
colorless oil in a yield of 98%. MS (ESI): 281.1 (100%,
(M+Na).sup.+).
Synthesis of Triazole 507
[0460] To a solution of triazole 505 (365 mg, 1.36 mmol) in
CH.sub.2Cl.sub.2 (10 mL) and MeOH (2 mL) was added 4 mL of HCl
solution (4.0 M in dioxane). After stirring at room temperature for
2 h, the reaction was concentrated to dryness. The residue was
dissolved in DMF (5 mL) and then chloride 90 (377 mg, 1 mmol) and
Hunig's base (diisopropylethylamine, 0.52 mL, 3 mmol) were added.
The solution was heated at 50.degree. C. for 10 h. The DMF was
removed in vacuo and the residue was purified by preparative thin
layer chromatography (10:1:0.1
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 230 mg of crude
triazole 5002 (90% pure, MS (ESI): 499.1 (100%) (M+H).sup.+).
[0461] The free base of 5002 was dissolved in a mixed solvent of
THF (10 mL) and water (2 mL), and K.sub.2CO.sub.3 (138 mg, 1 mmol)
and di-tert-butyl dicarbonate (207 mg, 0.95 mmol) were then added.
The reaction was stirred at room temperature for 12 h. The THF was
removed in vacuo. 50 mL of EtOAc was added and the solution was
washed with water, dried over MgSO.sub.4 and concentrated. The
crude product was purified by preparative thin layer chromatography
(15:1:0.05 CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 220
mg of triazole 507 in a yield of 37%. MS (ESI): 499.3 (100%), 621.1
(M+Na).sup.+.
Synthesis of Compound 5002
[0462] To a solution of 507 (98 mg, 0.16 mmol) in CH.sub.2Cl.sub.2
(5 mL) and MeOH (1 mL) was added 2 mL of HCl solution (4.0 M in
dioxane). After stirring at room temperature for 12 h, the reaction
was concentrated and washed with EtOAc/MeOH to give 78 mg of
compound 5002 in a yield of 95%. MS (ESI): 499.1 (100%,
(M+H).sup.+).
Example 76
Synthesis of Triazole 5007
[0463] Scheme 52 depicts the synthesis of triazole 5007.
##STR00661##
[0464] To a solution of triazole 501 (488 mg, 2 mmol) in
CH.sub.2Cl.sub.2 (10 mL) and MeOH (2 mL) was added 4 mL of HCl
solution (4.0 M in dioxane). After stirring at room temperature for
2 h, the reaction was concentrated to dryness. The residue was
dissolved in DMF (5 mL) and then chloride 123 (541 mg, 1.4 mmol)
and diisopropylethylamine (0.7 mL, 4 mmol) were added. The solution
was heated at 50.degree. C. for 18 h. The DMF was removed in vacuo
and the residue was purified by preparative thin layer
chromatography (10:1:0.15 CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O)
to afford 250 mg of compound 5007 in a yield of 36%. MS (ESI):
495.0 (100%) (M+H).sup.+.
[0465] The free base of compound 5007 was dissolved in
CH.sub.2Cl.sub.2 (5 mL) and MeOH (5 mL). 2 mL of HCl solution (4.0
M in dioxane) was added at 0.degree. C. After stirring at room
temperature for 1 h, the reaction was concentrated, washed with
EtOAc/MeOH to give 260 mg of the HCl salt compound 5007 in a yield
of 97%. MS (ESI): 495.1 (100%) (M+H).sup.+.
Example 77
Synthesis of Triazole 5005
[0466] Scheme 53 depicts the synthesis of triazole 5005.
##STR00662##
Synthesis of Triazole 508
[0467] To a solution of 1H-1,2,4-triazole-3-thiol 509 (202 mg, 2
mmol) and 2-(BOC-amino)ethyl bromide 503 (448 mg, 2 mmol) in THF (5
mL) and MeOH (2 mL) was added a solution of NaOMe in MeOH (25% wt.,
432 mg, 2 mmol). After stirring at room temperature for 2 h, 50 mL
of EtOAc was added, and the solution was washed with water, dried
over MgSO.sub.4 and concentrated to afford 464 mg of triazole 508
as colorless oil in a yield of 95%. MS (ESI): 266.8 (100%)
(M+Na).sup.+.
Synthesis of Triazole 510
[0468] To a solution of triazole 508 (366 mg, 1.5 mmol) in
CH.sub.2Cl.sub.2 (10 mL) and MeOH (2 mL) was added 4 mL of HCl
solution (4.0 M in dioxane). After stirring at room temperature for
3 h, the reaction was concentrated to dryness. The residue was
dissolved in DMF (5 mL) and then chloride 90 (377 mg, 1 mmol) and
Hunig's base (diisopropylethylamine, 0.7 mL, 4 mmol) were added.
The solution was heated at 50.degree. C. for 12 h. The DMF was
removed in vacuo and the residue was purified by preparative thin
layer chromatography (10:1:0.15
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 250 mg of crude
compound 5005 (85% pure, MS (ESI): 485.1 (100%) (M+H).sup.+)).
[0469] The crude 5005 was dissolved in a mixed solvent of THF (10
mL) and water (2 mL), and then K.sub.2CO.sub.3 (276 mg, 2 mmol) and
di-tert-butyl dicarbonate (218 mg, 1 mmol) were added. The reaction
was stirred at room temperature for 12 h. The THF was removed in
vacuo. 50 mL of EtOAc was added and the solution was washed with
water, dried over MgSO.sub.4 and concentrated. The crude product
was purified by preparative thin layer chromatography (15:1:0.1
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 150 mg of 510 in
a yield of 26%. MS (ESI): 485.1 (100%), 607.1 (M+Na).sup.+.
Synthesis of Compound 5005
[0470] To a solution of triazole 510 (150 mg, 0.26 mmol) in
CH.sub.2Cl.sub.2 (10 mL) and MeOH (2 mL) was added 2 mL of HCl
solution (4.0 M in dioxane). After stirring at room temperature for
12 h, the reaction was concentrated and washed with EtOAc/MeOH to
give 120 mg of compound 5005 in a yield of 89%. MS (ESI): 485.1
(100%, (M+H).sup.+), 507.0 (M+Na).sup.+.
Example 78
Synthesis of 5011
[0471] Scheme 54 depicts the synthesis of triazole 5011.
##STR00663##
Synthesis of Compound 511
[0472] A mixture of amine 54 (714 mg, 2 mmol), 2R-(-)-glycidyl
tosylate 512 (456 mg, 2 mmol), N,N-diisopropylethylamine (0.44 mL,
2.5 mmol) and potassium iodide (33 mg, 0.2 mmol) in DMF (5 mL) was
heated at 70.degree. C. for 1 h. The reaction was diluted with 50
mL of EtOAc. The solution was washed with water, dried over
MgSO.sub.4 and concentrated. The crude product was purified by
preparative thin layer chromatography (10:1:0.1
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 350 mg of
compound 511 in a yield of 42%. MS (ESI): 414.1 (100%), 436.0
(M+Na).sup.+.
Synthesis of Compound 513
[0473] To a solution of compound 511 (160 mg, 0.39 mmol) in THF (10
mL) and DMF (1 mL) was added di-tert-butyl dicarbonate (138 mg,
0.63 mmol), triethylamine (0.2 mL, 1.4 mmol) and
N,N-dimethylaminopyridine. The reaction was stirred at room
temperature for 1 h, and THF was removed in vacuo. 40 mL of EtOAc
was added and the solution was washed with water, dried over
MgSO.sub.4 and concentrated. The crude product was purified by
preparative thin layer chromatography (15:1:0.1
CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O) to afford 138 mg of
compound 513 in a yield of 70%. MS (ESI): 514.1 (100%) (M+H).sup.+,
536.1 (M+Na).sup.+.
Synthesis of Compound 514
[0474] To a solution of compound 513 (120 mg, 0.23 mmol) and
LiClO.sub.4 (27 mg, 0.25 mmol) in acetonitrile (2 mL) was added
1H-1,2,4-triazole-3-thiol 509 (24 mg, 0.23 mmol). The reaction was
heated at 100.degree. C. for 6 days and concentrated to dryness.
The crude product was purified by preparative thin layer
chromatography (15:1:0.1 CH.sub.2Cl.sub.2/MeOH/NH.sub.3.H.sub.2O)
to afford 75 mg of compound 514 in a yield of 53%. MS (ESI): 515.1
(100%), 615.1 (M+H).sup.+.
Synthesis of Compound 5011
[0475] To a solution of compound 514 (75 mg, 0.12 mmol) in
CH.sub.2Cl.sub.2 (5 mL) and MeOH (1 mL) was added 1 mL of HCl
solution (4.0 M in dioxane). After stirring at room temperature for
24 h, the reaction was concentrated and washed with EtOAc/MeOH to
give 62 mg of 5011 in a yield of 94%. MS (ESI): 515.1 (100%)
(M+H).sup.+.
INCORPORATION BY REFERENCE
[0476] The entire disclosure of each of the patent documents and
scientific articles referred to herein is incorporated by reference
for all purposes.
EQUIVALENTS
[0477] The invention may be embodied in other specific forms
without departing from the spirit or essential characteristics
thereof. The foregoing embodiments are therefore to be considered
in all respects illustrative rather than limiting on the invention
described herein. Scope of the invention is thus indicated by the
appended claims rather than by the foregoing description, and all
changes that come within the meaning and range of equivalency of
the claims are intended to be embraced therein.
* * * * *